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Abstract
Connecting dynamics to structural data from an array of diverse yet complementary experimental sources,
all-atom molecular dynamics (MD) simulations permit the exploration of biological phenomena in unparal-
leled detail. We employed MD simulations and molecular modeling to investigate the dynamic properties of
virus capsids, to determine the atomic structure of highly-flexible capsid domains, which could not be solved
using a single experimental method, and to unravel the molecular mechanisms of host-pathogen interactions.
Furthermore, we have recently integrated MD simulation into a de novo antibody design program to assess
the binding and thermal stabilities of the designed antibodies and to identify antibodies with high binding
a nity.
We first investigated a retrovirus capsid in its immature, non-infectious state. For a retrovirus to be
infectious, the immature retrovirus has to undergo maturation where the immature capsid proteins, also
known as Gag, are cleaved proteolytically and then rearranged to form a mature capsid. Obtaining an
atomic structure of the immature capsid has been elusive for many years. Recent advances in cryo-electron
microscopy have yielded high resolution density maps and therefore enabled accurate computational mod-
elings and simulations. We report the first atomic model of an immature Gag lattice, using Rous sarcoma
virus (RSV) as the model system. The model includes an atomic model of a flexible domain called spacer
peptide. The immature Gag lattice model was obtained using homology modeling and microsecond-long
MD simulations and was tested via mutagenesis experiments in vitro. Upon obtaining the atomic structure
of immature RSV lattice, we characterized the roles of key charged residues of RSV by simulating the wild
type and mutant structures. We discovered a novel allosteric pathway that could explain how a mutation
could suppress the detrimental e↵ect of another mutation despite being 20 A˚ apart.
The human body has two types of immune systems to prevent and combat viral infection: innate and
adaptive immune systems. Lung surfactant proteins are part of the innate immune system, and they act at
the front-end of the host defense. Surfactant proteins A (SP-A) and D (SP-D) protect humans from bacterial
infection and influenza A virus, respectively. Using structural information from X-ray crystallography, we
probe the interactions between SP-D and influenza A virus at the atomic level. Our simulation results show
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that a double mutant of SP-D binds stronger to influenza A virus using a di↵erent binding loop than the
wild type SP-D. Additionally, the lipid binding properties of SP-A were probed using MD simulations and
mutational studies. We found a non-canonical lipid binding site with several critical binding features that
involve cation-⇡ interactions. Steered MD simulations also revealed that SP-A binds to bacterial lipid more
tightly than lung surfactant. These results suggest that SP-A may transfer from surfactant to bacterial
membranes to initiate its host defense functions.
Antibodies are secreted by a type of white blood cell called B lymphocytes, which is an important com-
ponent of the adaptive immune system. Antibodies identify and neutralize pathogens such as bacteria and
viruses. Developing antibodies using solely experimental methods is a time-consuming process. Therefore,
computational methods have been developed to design antibodies. However, most of these computational
methods lack dynamic information during the design process as only static structures are considered. To gen-
erate antibodies with high binding a nity, we incorporated MD simulation into the antibody design workflow
to account for the dynamic nature of the antigen-antibody interaction. The antibody design program with
the improved workflow has successfully designed high-a nity antibodies to target a small, 12-residue-long
peptide antigen, and the program is currently being used to design antibodies targeting a larger antigen,
namely the Ebola glycoprotein.
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Chapter 1
Introduction
A virus is an infectious agent that can replicate only inside a living cell. Viruses represent a serious public
health threat, and millions of people die every year from viral diseases. Viruses were first discovered by
Martinus Beijerinck, a Dutch microbiologist, in 1898. Beijerinck filtered the sap of diseased plants through
porcelain, a microporous material known to block the passage of cellular organisms such as bacteria. Through
a series of filtration experiments, Beijerinck showed that tobacco mosaic disease is caused by an infectious
agent smaller than any known bacterium. As the infective agent is too small to be seen using a light
microscope, it was not until development of the electron microscope in the 1930s that the morphology of
virus particles was first observed. The successful crystallization of tobacco mosaic virus by Wendell Stanley
in 1935, for which he earned the 1946 Nobel Prize in Chemistry, eventually lead to visualization of the virus
structure at atomic resolution by X-ray crystallography.
There are two general types of viruses: enveloped and non-enveloped viruses. Non-enveloped viruses
like tobacco mosaic virus and poliovirus do not have a lipid envelope and only have a capsid coat made of
proteins. Enveloped viruses like human immunodeficiency virus (HIV), influenza A virus and Ebola virus,
have two structural components that are of great pharmaceutical interest: envelope and capsid proteins.
Envelope proteins form a membrane envelope protecting the capsid inside. The envelope proteins on the
surface of the envelope are often glycoproteins which serve to identify and bind to receptor sites on the
host’s membrane. These viral surface proteins could be targeted with antibodies and drugs to prevent viral
adhesion, cell entry, and release of progeny virons [1]. Virus capsids, made of protein, are shells that encase
and protect the viral genome. To obtain the structure of virus capsids, X-ray crystallography and cryo-
electron microscopy (cryo-EM) are often used. To generate dynamics information from the static structures
from X-ray and cryo-EM, MD simulations were performed to monitor detailed dynamics of capsid protein
assemblies in their native environments [2, 3]. Subsequently, interesting events like allostery and global
structural changes of viral proteins could be gleaned from analyzing their structure and dynamics [4, 5].
It is important to note that regardless of whether structural data are obtained by cryo-EM, X-ray
crystallography, or NMR spectroscopy, inherent molecular flexibility often means a biological structure
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cannot be fully resolved. The corresponding lack of structural segments is evident in many structures
deposited in the PDB that have missing coordinates for inserted loops and chain termini, which represent
the most higly disordered regions of a protein. In silico structure prediction tools can be utilized to rebuild
missing structural features, providing complete initial input models for further structural refinement and
MD simulations [6].
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Figure 1.1: The biological systems that have been studied in this dissertation. (A) The hexamer-of-hexamer
lattice model of the immature Rous sarcoma virus [2]. The lattice consists of a short peptide called p10,
N-terminal and C-terminal domains, which are colored in cyan, beige and dark blue, respectively. (B)
Antibody binding to Ebola glycoprotein. The Ebola glycoprotein consists of GP1 and GP2, shown in dark
and light blue surfaces. The antibody is represented as orange ribbon. (C) Lung surfactant protein D binds
to hemagglutinin of influenza A virus. Hemagglutinin consists of two domains, namely HA1 and HA2, which
are shown as cyan and light gray surfaces. Surfactant protein (green ribbon) binds to the glycan chain of
HA (orange/red licorice) using its calcium ions (orange spheres) [1].
To fight against the invasion of viruses, the human body has two types of immune systems: innate and
adaptive immune systems. Innate immunity is a collection of non-specific defense mechanisms that come
into play immediately or within hours of an antigen’s appearance in the body. These mechanisms include
physical barriers such as skin, chemicals in the blood, and certain proteins like lung surfactant proteins [1, 7]
at the air-liquid interface in the lungs. The innate immune response is activated by chemical properties of the
antigen, like glycosylation of the envelope proteins of influenza A virus [1]. Adaptive immunity, on the other
hand, is an antigen-specific immune system. The adaptive immune response is more complex than the innate
2
and therefore it takes longer to develop. The antigen first must be processed and recognized. Once an antigen
has been recognized, the adaptive immune system creates an army of immune cells specifically designed to
attack that antigen. There are two types of adaptive immune responses: humoral immunity, mediated by
antibodies produced by B lymphocytes, and cell-mediated immunity, mediated by T lymphocytes. Adaptive
immunity also includes a “memory” that makes future responses against a specific antigen more e cient.
Since developing antibodies is a time-consuming process, computational antibody design tools combined
with MD simulation are developed to generate antibodies with high binding a nity and specificity [8].
This dissertation presents the results of MD simulations that were employed to investigate the structure,
dynamics and function of three biological systems: the immature capsid of Rous sarcoma virus [2, 4], lung
surfactant proteins which provide innate immune response against inhaled pathogens [1, 7], and antibodies
targeting Ebola glycoproteins [8]. Figure 1.1 shows the three biological systems that are discussed in this
dissertation. As important as it is to perform the simulations and to analyze the results, it is worth noting
that visualization has become an indispensable tool to facilitate scientific discovery and to deliver scientific
impact to a broader community [9, 10, 11].
1.1 The immature capsid of Rous sarcoma virus
After infecting a cell, a retrovirus like HIV will replicate its viral genome and produce thousands of copies
of identical Gag polyproteins. These polyproteins will subsequently oligomerize themselves into a hexameric
lattice commonly referred as the immature Gag lattice. Once budded from the cell surface, the immature
virus will undergo maturation by proteolytic cleavage of Gag. Gag consists of matrix protein (MA), capsid
protein (CA), nucleocapsid protein (NC), and other smaller peptides. For Rous sarcoma virus (RSV) and
HIV, a short spacer peptide (SP) is present in between CA and NC. The SP domain plays an important
role in immature retroviral assembly and acts as a molecular switch in stabilizing the immature retroviral
lattice. Recent experimental e↵orts have greatly increased our understanding of the structure of SP, but
the structural information of SP at the atomic level remains incomplete. Furthermore, obtaining an atomic
structure of the immature Gag lattice has been elusive for many years. Recent advances in cryo-electron
microscopy have yielded high resolution density maps and therefore enabled accurate computational modeling
and simulations.
We report the first atomic model of the Gag lattice, using RSV as the model system. RSV is an
ideal candidate for such modeling e↵ort because of the available X-ray crystallography data, along with
extensive genetic, biochemical studies on the MA, SP and NC subdomains that are implicated in Gag
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assembly [12, 13, 14, 15, 16]. Based on the cryo-EM density map of M-PMV [17], together with structural
data from X-ray crystallography and nuclear magnetic resonance (NMR) of RSV, an all-atom model of the
immature RSV Gag lattice has been computationally derived (Figure 1.1A). The validity of the lattice model
is tested by all-atom molecular dynamics simulations [3] and biochemical experiments. We find that the
Gag lattice containing only the NTD and CTD layers of CA, is not stable, however the Gag lattice that
incorporates additional upstream and downstream components achieves stability. The results support the
importance of p10-CA interactions in the formation of stable NTD hexamers and identify in particular the
key stabilizing role of a collar of charged residues present in the 6HB for Gag assembly and stability. In light
of our results, we discuss the electron micrograph of the immature capsid of RSV, which was published two
months after our work. The results on immature RSV capsid are described in Chapter 2 and were published
in Ref. [2].
The CA monomer comprises two predominantly alpha-helical domains, a 7-helix N-terminal domain
(NTD) and a 4-helix C-terminal domain (CTD). The helical folds of the two domains are largely identical
in both the mature and immature capsid forms with the major distinguishing feature being the  -hairpin
structure that precedes the first-helix of the mature NTD. This  -hairpin forms only after CA is cleaved
from the upstream Gag domain, namely MA. In the NTD, helices ↵1 – ↵4 and the last helix form a tight
bundle, while the loops and short helices between ↵4 and the last helix comprise a surface-exposed flexible
loop (FL) region that is the least conserved region in the CA sequence and exhibits considerable structural
variation across retroviral families [18, 19, 20, 21, 22].
With the atomic model of the immature RSV capsid determined, we have examined the contributions
of specific FL residues in the assembly of infectious RSV particles in order to provide important functional
data needed for the assessment of the evolving models for alpha-retrovirus assembly. Teaming up with
biochemists in the Craven lab at Pennslyvania State University, mutations were designed in the FL region,
targeting predominantly charged residues, and their e↵ects on the overall electrostatic potential and allosteric
communication of the lattice virus were assessed. By analyzing the dynamics of the capsid proteins in
simulation trajectories, we discovered a novel allosteric pathway that could explain how a mutation could
suppress the detrimental e↵ect of another mutation despite being 20 A˚ apart [4]. The results on the e↵ect
of mutations to the virus functions are described in Chapter 3 and were submitted for publication [4].
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1.2 Lung surfactant proteins and their innate immune properties
Lung surfactant is produced in mammalian lungs and serves a dual role of maintaining normal breathing
and shielding the organism from inhaled pathogens. Lung surfactant is a complex mixture of 90 % lipid
and 10 % protein. The most abundant component in surfactant is dipalmitoylphosphatidylcholine (DPPC)
lipid, which accounts for 40% of the total mass of lung surfactant. DPPC is essential to forming an air-liquid
interface in the lung, and minimizing the contact between hydrophobic region (air) and water molecules,
thereby lowering the lung surface tension and preventing lung collapse [23].
A 
B 
Figure 1.2: X-ray structures of lung surfactant pro-
teins. SP-A (A) adopts a ‘T’-shape conformation
while SP-D (B) adopts a ‘Y’-shape conformation.
Surfactant proteins are shown as cartoon represen-
tations in blue, red, gray colors. Calcium ions at the
lectin site are represented as orange spheres.
Surfactant proteins A (SP-A) and D (SP-D) are
hydrophilic proteins that belong to the collectin
(collagen-containing C-type lectin) protein family,
and have antiviral and antimicrobial properties. C-
type lectins are carbohydrate-binding proteins that
bind to the sugar molecules on pathogenic surfaces
using calcium ions. As both SP-A and D use calcium
ions to bind sugar molecules, we will refer to the C-
type lectin binding site as simply the lectin site. Fig-
ure 1.2 shows the slight di↵erence in the overall shapes
of SP-A and SP-D. Owing to its ‘T’-shape conforma-
tion, SP-A binds well to flat surfaces like the lipid
membrane, making SP-A primarily an antimicrobial
protein. On the contrary, SP-D is an antiviral protein,
partly due to the more extended ‘Y’-shape conforma-
tion.
SP-A and SP-D are directly related to the innate
host defense of the lung where they recognize, bind
and eliminate pathogens using their lectin sites [24].
SP-A and SP-D support the host’s immune system,
but in contrast to the adaptive immune system that
establishes a learnt response to pathogens, the lung
surfactant system acts at the front-end of the host defense, without adaptation. It relies on an a priori
recognition, namely a recognition of sugar molecules that is covalently linked to proteins at the surface of
pathogens, in particular, also to the influenza virus.
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By teaming up with crystallography experts from the Seaton lab at Boston University, we have used
X-ray crystallography, molecular modeling and large-scale molecular dynamics to probe the interactions
between SP-D and influenza A virus (IAV) at the atomic level. Our studies target the hemagglutinin (HA)
from the A/Aichi/68/H3N2 strain of IAV (also known as X31). This HA has only one N-linked glycan on
the head domain, at residue 165, an important glycosylation site location for H3N2 strains [25], as lack of
this residue is associated with collectin-resistance [26]. We demonstrate that native SP-D possesses antiviral
activity against the Aichi strain, indicating that the 165 N-glycan is su cient for SP-D recognition of IAV.
The present studies o↵er the first computational investigation involving a complex of a full HA trimer
and a trimeric neck and carbohydrate recognition domain (NCRD) of SP-D (Figure 1.1C). Additionally,
the binding a nity between the HA glycan and SP-D has been studied and compared with experimental
data. Comparisons between wild type and mutant SP-D NCRDs allow the linking of viral neutralization
to molecular properties underlying SP-D/HA binding. The results on SP-D/HA are described in Chapter 4
and were published in Ref. [1].
SP-A plays two integral roles in the lung surfactant: aggregate the lipid, particularly DPPC, in lung
surfactant to form lamellar bodies and tubular myelin, and protect the lungs from infection by recognizing
the lipid component (lipid A) on gram negative bacterial surfaces [27]. To unravel the dual role of SP-A,
we performed crystallographic and mutational analyses as well as all-atom MD simulations. In previous
crystallographic studies of SP-A [28, 29], we studied a construct containing the entire CRD and neck domain
(NCRD), which recapitulates many of the binding properties of the intact protein. In the initial report [28],
we observed that the tyrosine-rich CRD surface included three surface-exposed tyrosine residues (Y164,
Y208, and Y192) arranged in part as a box-like structure, and a proximal basic cluster containing two
arginines (R216 and R222). These residues were hypothesized to form part of a phosphocholine binding
site via an apparent ⇡-cation interaction and hydrogen bonds. The validity of the phosphocholine site were
further tested using mutagenesis and binding assays. Finally, we extended these studies to investigate SP-
A/lipid A complexes, for which there are no crystallographic data, utilizing large-scale molecular dynamics
simulations to investigate DPPC and lipid A binding in a membrane milieu. These combined studies present
a cohesive view of the molecular interactions, on an atomic level, of SP-A and two of its major lipid ligands
as occur in the presence of membranes. The results on SP-A/lipid membrane are described in Chapter 4
and were submitted for publication [7].
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1.3 De novo design of antibodies targeting Ebola glycoproteins
Over 28,000 cases of Ebola virus (EBOV) disease have been reported since the outbreak began in December
2013. As EBOV uses the glycoproteins (GP) on the viral surface to mediate host cell entry, finding an
antibody to bind with EBOV GP is crucial for both diagnostic and post-infection treatment purposes. The
EBOV GP is a trimeric structure that comprises a 334-residue-long GP1 and a shorter 131-residue GP2 per
monomer (Figure 1.1B). GP1 recognizes and attaches on the human cell surface; upon attachment, GP1 and
GP2 undergo structural transformation where the transformed GP2 faciliates membrane fusion to complete
the cell entry. Targetting the attachment and membrane fusion processes using antibody is key to prevent
infection and neutralize the functions of EBOV.
Developing antibodies using solely experimental methods is a time-consuming process. Therefore, com-
putational methods have been developed to design antibodies. There are several antibody design programs
such as RosettaAntibody [30], ROSIE [31], OptCDR [32] and OptMAVEn [33]. OptMAVEn, which was
developed by our collaborators in the Maranas lab at Pennsylvania State University, performs antibody
design in two general phases: antibody generation (phase A) and antibody maturation (phase B). Phase A
involves generating antibodies from a library of antibody fragments, docking the generated antibodies to the
target antigen, and score the resulting antigen-antibody complexes by their interaction energies. Phase B
mimics the natural evolution of an antibody in vivo by mutating the amino acid residues of the antibody to
enhance the interaction of the antigen-antibody complexes generated from phase A. The goal is to increase
the binding constant between antibody and the given antigen by introducing computationally mutations into
the antibody. The resulting antigen-antibody complexes are then scored computationally according to their
antigen binding energies. Typically, around 5-10 complexes with the lowest interaction energies are selected
for experimental validation. At this point starts the costly experimental phase of the project. The compu-
tationally determined antibodies are manufactured and exposed to the antigen. Dissociation constants, Kd,
of the antibodies are measured using biolayer interferometry; smaller Kd corresponds to a higher binding
a nity.
The success rate of computationally-designed antibodies, unfortunately, is very low. The calamity can
partly be attributed to the lack of dynamic information during the design process as only static structures are
considered. To generate antibodies of high quality, MD simulations are incorporated into the design workflow
of OptMAVEn to account for the dynamic nature of the antigen-antibody interaction. MD simulations have
previously been applied to investigate antibody-antigen interactions [34, 35]. However, these simulations are
often short (5 ns) and therefore insu cient to assess the binding stability of the antibody. For this purpose the
antigen-antibody complexes generated from phase A of OptMAVEn are subjected to MD simulations. The
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antigen-antibody complexes are each simulated independently starting in a way typical for MD simulations:
the complexes are energy minimized and then thermally annealed ending at physiological temperature. The
resulting solvated system is then subjected to a 100 ns of equilibrium simulation. The outcomes of the MD
simulations are the structures reached at the ends of the equilibration runs. The outcomes are categorized
into consistent binding, altered binding, partial binding and unbinding cases depending on if the antigen
remained, at the end of the 100 ns simulations, completely bound to the same binding pocket, relocated to a
new binding pocket, partially bound, or completely unbound. The designs with the antibody unbound from
the antigen were discarded from the design workflow. The simulated structures of the designs with bound or
partially-bound antibody are used as input structures for phase B of OptMAVEn. After phase B, additional
MD simulations could be performed to further assess the stability and refine the binding interface. The
iteration between OptMAVEn and MD could be performed several times to obtain a good and converged
antibody design. The top antibody designs, ranked by their antigen-antibody interaction energies, are then
selected for experimental validation.
For the purpose of developing and testing the MD-incorporated OptMAVEn, also known as OptMAVEn-
MD, we first develop antibodies for a model antigen, a 12-residue peptide (dodecapeptide) antigen. This
antigen was chosen since a native, i.e., highly evolved, antibody existed already, namely 2D10. Several novel
antibody designs were predicted computationally to bind strongly the antigen, and they were subsequently
validated experimentally to bind to the antigen with a nities comparable to those of 2D10 [8]. With the new
method in hand, we are currently employing OptMAVEn-MD to design antibodies that target the EBOV
GP. Since the Ebola glycoprotein is almost a hundred times larger in size than the dodecapeptide, it presents
a new set of challenges for de novo antibody design where a number of modeling and design methodologies
have to be developed to overcome these challenges. The results on antibody design are described in Chapter 5
and were submitted for publication [8].
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1.4 Methodology
The computational techniques employed in our work presented in this dissertation are molecular dynamics
(MD) and steered molecular dynamics (SMD) simulations. This section will provide a background of these
methods.
1.4.1 MD simulations
MD simulation is a popular sampling technique where the motion of the molecules is governed by Newtonian
mechanics. It computes the spatio-temporal evolution of all interacting particles of a molecular system by
solving Newton’s equations of motion (Eq. 1.1)
mi
d2
 !
R i
dt2
=  r !
R i
UMD( !r 1, !r 2, . . .) =  r !R iUMD(
 !
R i), (1.1)
bond 
dihedral 
angle 
Figure 1.3: Bonded potential energy terms in MD
force fileds illustrated with a peptide bond.
Heremi is the mass of particle i, Ri is its position, and UMD
is the total potential energy that is a function of all parti-
cle positions and, thereby, couples the motion of particles.
Physical properties of the molecular system can be derived
by analyzing the position and momentum of particles from
the simulation trajectory. In an all-atom MD simulation,
each atom is modeled as a single particle which has a set
of parameters, such as charge and radius, to describe the
intrinsic properties of the atom in simulations. The param-
eters depend sensitively on the chemical structure context
in which the atom arises, such that carbon atoms, for ex-
ample, are presented through hundreds of di↵erent parameter sets, depending on the chemical context.
All-atom MD simulations employ force fields to describe the total potential energy (UMD) of atomic
systems as a function of the spatial arrangement of all atoms (Ri). The force acting on every atom can be
determined by the total potential energy function with respect to the rest of the system. A common form
of the function is
UMD(
 !
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X
bond
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Here the first three terms account for bonded interactions, as illustrated in Fig. 1.3. In Eq. 1.2, the bond
term accounts for covalent bonds, representing the stretching motion of each pair of bonded atoms; the angle
term accounts for angles between each pair of covalent bonds that share the same atom, representing the
bending motion of each pair of connected bonds; the dihedral term accounts for the spatial relationship of
a group of four atoms separated by exactly three covalent bonds with the central bond subject to a torsion
angle  . The last two terms account for non-bonded interactions including the van der Waal’s potential as
the fourth term and the pairwise electrostatic potential as the last term. The force fields parameters are
predetermined and available in a very large database (commonly referred to as “the force field”) to account
for every type of chemical context of the interactions among atoms in MD simulations [36].
All MD simulations in this paper were performed using NAMD [37], a highly scalable MD simulation
package that has been developed over the past two decades in the Schulten lab. Modeling and analysis
employed the program VMD [38] from the same lab.
1.4.2 SMD simulations
The SMD method [39] is a technique to mechanically manipulate the biomolecular system, for example
through stretching and twisting, using a user-defined potential during all-atom MD simulations. In NAMD,
there are two ways to manipulate the system: constant force pulling and constant velocity pulling. SMD
simulations that use the constant force pulling method apply a constant force to a selection of atoms in a
defined direction.
For the constant velocity pulling method, the center of mass of selected atoms is attached to a dummy
atom via a virtual spring with force constant k. This dummy atom is moved at constant velocity  !v in
the direction  !n and the force between the center of mass and dummy atom  !F SMD is measured using
Equations 1.3 and 1.4
 !
F SMD( !r 1, !r 2, . . . , t) =  r !R iUSMD(
 !r 1, !r 2, . . . , t) (1.3)
USMD( !r 1, !r 2, . . . , t) = 12k
⇥ !v it  ( !Rd(t)  !Ri(t)) · !n ⇤2, (1.4)
where
 !
Rd(t) and
 !
Ri(t) are the positions of the dummy atom and the center of mass of the selected atoms,
respectively.  !r 1, !r 2, . . . are the positions of the selected atoms, and t is time. In the case of constant
velocity pulling SMD simulations, a force-extension curve can be extracted from the simulations.
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Chapter 2
Retrovirus Modeling and Simulations
Reproduced in part with permission from Boon Chong Goh, Juan R. Perilla, Matthew R. England, Katrina J.
Heyrana, Rebecca C. Craven, and Klaus Schulten. Atomic modeling of an immature retroviral lattice using
molecular dynamics and mutagenesis. Structure, 23:1414–1425, 2015 (Copyright 2015 Elsevier).
2.1 Introduction to retroviruses and immature retroviral lattice
A retrovirus is a single-stranded RNA enveloped virus that replicate in a host cell through reverse tran-
scription. During reverse transcription, the double-stranded viral DNA is generated from the viral RNA
with an DNA intermediate. The viral DNA is then integrated into the host cell DNA to hijack the cell’s
machinery [40]. The hijacked cell encodes a viral polyproteins known as Gag that contain subdomains cor-
responding to the matrix (MA), capsid (CA), nucleocapsid proteins (NC), as well as other smaller peptides.
In the infected cell, thousands of Gag proteins oligomerize into an immature retroviral lattice at the plasma
membrane, driving the assembly and budding of the virus particle [41, 42]. Once budded from the cell
surface, the immature virus undergoes maturation triggered by proteolytic cleavage of Gag, and marked by
structural rearrangement of the internal constituents of the virion, formation of a mature capsid structure
composed of CA, and activation of virion infectivity [43, 44, 45].
The Gag lattices from viruses of the Orthoretrovirinae subfamily share similar morphologies in vivo,
that is, a nearly spherical but incomplete shell [46, 47, 48]. The MA proteins are arranged at the outer
most layer of the Gag lattice with the N-termini bound to the viral membrane; they are followed by the
CA proteins, and subsequently by the NC proteins that are located at the inner most layer, closest to the
viral genome (Figure 2.1). The CA proteins from the orthoretrovirus genera all share a common domain
organization with two primarily alpha-helical parts (the NTD or N-terminal domain and CTD or C-terminal
domain) [49, 50, 51, 52, 53, 54]. These two domains provide the majority of the intermolecular interactions
that determine the short- and long-range packing geometry of Gag in the immature virion and of CA in the
mature capsid [51, 55].
11
Whereas the two CA domains can make all interactions needed to build a mature capsid and CA protein
alone is su cient to build capsid-like structures in vitro [56, 57, 58, 59, 54], the assembly of a Gag lattice
requires the contributions of additional components of Gag, both upstream and downstream of CA [15, 47,
60, 14, 61]. The Gag proteins of both the Rous sarcoma virus (RSV) and human immunodeficiency virus
type 1 (HIV-1) contain, immediately following the CA CTD, a short spacer peptide subdomain called SP (12
amino acid residues in RSV) or SP1 (14 residues in HIV-1) separating CA from NC. While the SP subdomain
is absent in the Mason-Pfizer monkey virus (M-PMV), this subdomain is a necessary component for Gag
assembly of both RSV and HIV-1 [62, 63, 61, 64] as it provides crucial lateral stabilization of hexameric
Gag complexes [65, 66, 67]. Mutations or deletions of SP/SP1 residues interfere with Gag-Gag interactions
in vitro [15, 14, 68, 64, 69] and cause in vivo phenotypes ranging from mild to severe disturbances of virion
morphology and even to the total blockage of virus assembly [63, 70, 71].
Recent cryo-electron tomography studies of RSV, HIV-1, and M-PMV - members of the alpha-, lenti-,
and beta- retrovirus genera, respectively - have provided comparative analyses of the organization of the
Gag lattice at resolutions that now exceed subnanometer detail for the two latter viruses [47, 17, 72, 48],
in particular showing that the packing of CA CTDs is highly conserved among the three viruses. Also, for
RSV and HIV-1, a spacer peptide bundle region has been observed in cryo-electron tomograms [47]. The
high resolution density maps of HIV-1 suggest the existence of a 6-helix bundle (6HB) composed of the
SP1 regions belonging to six hexamerically related Gag proteins [72, 48]. Similarly, the SP of RSV has
also been suggested to form a 6HB by hydrophobic interactions at the SP-NC subdomains [14, 47]. Note
however, that although the HIV-1 density maps are 8-9 A˚ in resolution, the density corresponding to the
SP1 subdomain is not well resolved. Furthermore, solid-state NMR measurements of HIV’s CA-SP1 show
that the region corresponding to SP1 is in a random coil conformation and dynamically disordered [73], in
contrast to solution NMR studies which show a helical propensity of SP1 [74, 75]. Additionally, the SP-NC
subdomains of HIV-1 have been investigated computationally by means of coarse-grained simulations [76] and
replica exchange molecular dynamics simulations [64]. Although these studies provided valuable information
in describing the interactions of Gag proteins in a lattice environment, neither e↵ort could determine the
atomic structure of the oligomerized SP-NC. Therefore, there is no clear model to date that elucidates the
atomic details of the CA-SP1 complex.
In RSV, an upstream segment of Gag contributes additional stabilizing contacts to the lattice. A
25-residue long peptide, located upstream of the NTD of CA, p10, is essential to the assembly of Gag
[77, 12, 13, 78, 16]. The complete sequence of p10 contains 64 residues, but only the last 25 residues have
been structurally determined and identified as an important component of the Gag lattice [77, 12]. Fur-
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thermore, in vitro assembly experiments [13] suggest a key role for the shorter p10 peptide by providing
intermolecular interactions between Gag molecules in the immature lattice via p10-CA interactions as pre-
dicted via crystallography. However, the experimental data could not di↵erentiate whether the cross-linked
p10-CA molecules form a hexamer, as suggested by Phillips et al. [13], or form a trimer of dimers. Unfor-
tunately, the cryo-electron tomograms of RSV have yet to reach the resolution to confirm this structural
feature.
In this study, we present an atomic model of the Gag lattice, using RSV as the model system. RSV
is an ideal candidate for such modeling e↵ort because of the available X-ray crystallography data, along
with extensive genetic, biochemical studies on the p10, SP and NC subdomains that are implicated in Gag
assembly [12, 13, 14, 15, 16]. Based on the cryo-EM density map of M-PMV [17], together with structural
data from X-ray crystallography and nuclear magnetic resonance (NMR) of RSV, an all-atom model of the
immature RSV Gag lattice has been computationally derived. The validity of the lattice model is tested
by all-atom molecular dynamics simulations [3] and biochemical experiments. We find that the Gag lattice
containing only the NTD and CTD layers of CA, is not stable, however the Gag lattice that incorporates
additional upstream and downstream components achieves stability. The results support the importance of
p10-CA interactions in the formation of stable NTD hexamers and identify in particular the key stabilizing
role of a collar of charged residues present in the 6HB for Gag assembly and stability.
Our model was validated by the Briggs lab two months after this work has been published. Using cryo-
electron tomography and subtomogram averaging, the Briggs lab determined the structure of the immature
p10-CA lattice at a resolution of ⇠ 8 A˚[79]. They also observed a density below CA that is consistent with
the presence of SP forming a six-helix bundle. However, the local resolution of the SP density is too low to
model an atomic structure of the 6HB for the comparison with our 6HB model.
2.2 Results
The roles played by both p10 and SP-NC in the stability of the Gag lattice were investigated by extensive MD
simulations (Table 2.1). Additionally, the interactions predicted by the model were tested by mutagenesis
experiments in vitro.
2.2.1 Modeling of the RSV Gag lattice
The building process of the Gag lattice of RSV (Figure 2.2) involves several docking procedures. First,
to obtain the RSV CA dimer (Figure 2.2B), RSV’s NTD (PDB 1P7N) [12] and CTD (PDB 1D1D) [50]
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Figure 2.1: Schematic diagram of the full-length Gag protein of RSV. The shaded rectangles illustrate the
Gag construct used in the MD simulations (Table 2.1). The simulated construct includes the entire CA-SP
region plus flanking residues belonging to p10 and NC.
Table 2.1: List of simulations performed for the present study employing molecular dynamics (MD) and
replica exchange molecular dynamics (REMD) simulations. The full-length Gag construct is shown in
Figure 2.1 for reference.
Simulation Description Residues Time
(ns)
Method System size
(atoms)
PCALres p10-CA lattice with restraints 211 to 469 100 MD 1,820,000
PCAL p10-CA lattice without restraints 211 to 469 100 MD 1,820,000
CAL CA lattice without restraints 240 to 469 100 MD 1,800,000
BCAL  -CA lattice without restraints 240 to 469 100 MD 1,710,000
PCAD p10-CA dimer of RSV 211 to 469 110 MD 87,000
CAD CA dimer of RSV 240 to 469 110 MD 81,000
BHBR Bush 6-helix bundle [14] 469 to 496 3,750 REMD 19,000
RHBR Refined 6-helix bundle 469 to 496 3,750 REMD 18,000
RHBA Refined 6-helix bundle with 4-alanine
mutation
469 to 496 200 MD 17,000
PCALB p10-CA lattice with Bush 6-helix
bundle
211 to 496 100 MD 637,000
PCALRR p10-CA lattice with refined 6-helix
bundle
211 to 496 5,000 REMD 624,000
monomers were individually docked into their correspoding regions of the cryo-EM density map of the M-
PMV CA dimer (EMDB 2090) [17] (Figure 2.2A). Then, to obtain a hexamer of dimers (Figure 2.2C), each
RSV CA dimer was subsequently docked into the cryo-EM density map of the M-PMV hexameric lattice
(EMDB 2089) [17]. Additional components, namely p10 and SP-NC (Figure 2.2C), were independently
modeled and sequentially added to the CA lattice to complete the central hexamer of the Gag lattice. The
hexamer of hexamers belonging to the Gag lattice model (Figure 2.2D) was then obtained by docking the
central hexamer as the basis unit, to the surrounding density map. All docking steps were performed using
Situs rigid body docking [80, 81].
2.2.2 Role of upstream CA layer in stabilizing the RSV Gag lattice
Structural and disulfide cross-linking experiments suggest that the p10 that is connected to a CA monomer
interacts with the NTD of an adjacent CA subunit [12, 13]. Such intermolecular interaction between p10
and adjacent NTD was ascertained by the antiparallel p10-NTD homodimer configuration in the crystal
structure (PDB 1P7N). To incorporate p10 in the CA lattice, p10 and NTD from conjugate monomers were
14
Cryo-EM density map 
of a M-PMV CANC tube  
NTD 
CTD 
90o 
Amphipathic 
6HB 
NTD 
p10 
p10 with a 
neighboring NTD 
A 
B 
C D 
Figure 2.2: Summary of the Gag lattice model building process. (A) Cryo-EM density map of the M-PMV
Gag lattice. (B) Atomic structure of RSV CA (NTD in green and CTD in red) docked to the density in (A).
(C) Atomic models of p10 (blue) and SP-NC (orange) modeled into the Gag lattice. (D) Resulting model
of the RSV Gag lattice in tubular form.
extracted from the crystal structure (Figure 2.2C). Then, the p10-NTD heterodimer from the previous step
was aligned to each of the CA monomers in the lattice using the NTD as reference. Lastly, the connecting
loop between p10 and its corresponding NTD, residues 240 to 249, was modeled using VMD and refined
using Modeller [82]. The resulting model of the lattice shows that the corresponding p10 of one CA monomer
cross-links in a counter-clockwise manner to the NTD of the adjacent subunit within a hexamer (Figure 2.3),
similar to the model previously proposed by Phillips et al. [13].
To evaluate the key residues that provide stabilization to the p10-CA lattice, the system was simulated
for 100 ns (simulation PCALres in Table 2.1) with positional restraints at the boundary of the NTD lattice
and at all helices of CTD. The boundary restraints were applied to replicate the spatial confinement on
the lattice present in a fully assembled Gag lattice; the CTD helices were held in position to mimic the
stabilizing e↵ect provided by the missing domains downstream, namely SP-NC. In all cases, the restraints
were applied such that the average displacement is within 1.0 A˚ from the initial configuration. For the MD
simulations, the p10-CA lattice was solvated in a su ciently large water box (Figure 2.4).
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Figure 2.3: The p10 peptides cross-link adjacent CAs in a counter-clockwise manner to stabilize the NTD
hexamer. The p10 and NTD domains are shown as helices and tubes, respectively, with each p10-CA
monomer colored di↵erently. Only the NTDs are shown for clarity. Inset: Residues L229, V225, W222, I258,
L295, and V298 form a intra-hexameric hydrophobic core. p10 and the NTD of the adjacent CA monomer
are represented in blue and olive, respectively. Such intra-hexameric interaction is absent if immature HIV-1
lattice is used as a modeling template.
Simulation PCALres shows that the central hexamer remains largely unchanged, with a root mean squared
deviation (RMSD) of below 4.0 A˚. The p10-NTDs of the central hexamer were then analyzed to identify key
stabilizing residues at the interfaces. The respective residues are summarized as part of Table 2.2. The p10-
CA lattice model also provides novel information regarding the trimeric interface of the NTD layer. Due to
the all-atom nature of MD simulations, the e↵ects of ions and water can be directly addressed. Particularly,
it is observed that residues K346 coordinate chloride ions at the trimeric interface (Figure 2.9C). Similarly,
the model shows that D310 plays a complementary role at the same interface by coordinating sodium ions
(Figure 2.9D).
To simulate the commencement of maturation upon cleavage of p10 and SP-NC from Gag, the p10-CA,
CA,  -CA lattices were simulated for 100 ns without any restraints (simulations PCAL, CAL and BCAL in
Table 2.1). The  -hairpin (residues 241 to 250) in the  -CA lattice can only be formed once p10 has been
cleaved. It is therefore a characteristic of the mature capsid. The  -hairpin was modeled into the CA lattice
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Figure 2.4: System overview of the corresponding Gag constructs used in each simulated system. (A) RSV
Gag lattice in simulations PCALres, CALres, BCALres, PCAL, CAL, and BCAL. (B) Reduced Gag lattice in
simulations PCALB and PCALRR. The RSV Gag lattices, consist of p10 (blue), NTD (green), CTD (red)
and SP-NC (orange) subdomains. The simulation box containing water is shown in shaded blue (ions not
shown).
based on the PDB 1EM9 [52] using the same protocol as the one described for p10.
The NTDs of the p10-CA lattice were significantly more stable than the NTDs of the CA and  -CA
lattices as measured by root mean squared fluctuation calculations (RMSF) and quantified in Figure 2.5.
Furthermore, the NTD hexamers at the circumference of the  -CA lattice were su ciently distorted such
that one of the 6 surrounding hexamers was dissociated from the lattice (Figure 2.5), suggesting that the
presence of  -hairpin at the upstream of CA could accelerate the distortion and disassembly of the Gag
lattice. The e↵ect of  -hairpin in the dissociation of  -CA lattice is consistent with an experimental study
that showed modifying the N-terminus of CA could a↵ect Gag assembly and capsid maturation [83].
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Figure 2.5: NTD hexamers in the Gag lattice stabilized by p10. The degree of fluctuation of each Gag
residue is measured in the course of simulations by root mean squared fluctuation (RMSF). Residues in red
map to regions with large fluctuation (⇠ 7 A˚), while those colored blue map to regions with relatively small
fluctuation (⇠ 2 A˚). The red arrow highlights the breaking of an NTD hexamer at the circumference of the
 -CA lattice. Only NTDs are shown for clarity.
2.2.3 Role of the SP-NC subdomains in stabilizing the Gag lattice
Although the NTD hexamers of the p10-CA lattice are more stable than that of the CA and  -CA lattices
(Figure 2.5), the distortions at the CTD region were prominent in all three cases (Figure 2.6; Figure 2.10B).
Such fragile CTD lattices led us to predict that the residues downstream of CA are essential to maintain the
integrity of the immature CTD hexamers. To further test this prediction, an all-atom model of the SP-NC
region was constructed.
It has been previously proposed that SP-NC of RSV arranges in a 6-helix bundle (6HB) [61] and an initial
model of such arrangement was recently proposed by Bush et al. [14]. The Bush 6HB model was derived
via homology modeling, using a de-novo designed ion channel (PDB 3R47) as the template [84]. To assess
the structural integrity of the Bush 6HB model we ran 3.75 µs of replica exchange MD (REMD) simulations
(simulation BHBR). Out of the 75 tempered replicas >50% of the Bush 6HB model collapsed radially inward
due to the large amount of hydrophobic residues at the inner surface of the bundle (Figure 2.7B) even with
the presence of positional restraints at the N-terminus of the 6HB (see Methods). To test the stability of
those replicas which did not collapse, the replica with lowest RMSD value (2.4 A˚) from the initial 6HB
model was extracted from simulation BHBR and simulated for another 60 ns at 310K, which resulted in
disrupted bundles (Figure 2.8A). To illustrate the distortion of the Bush 6HB model is not due to an artifact
of the positional restraints applied, the uncollapsed replica was incorporated into the p10-CA lattice and
simulated for 100 ns (simulation PCALB). The 6HB collapsed within 20 ns (Figure 2.8B) and exhibited
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Figure 2.6: The stability of the CTD hexamers and CA dimer of RSV. The CTD hexamer in the Gag lattice
is severely disintegrated without its downstream flanking regions. The CTD hexamers in all three lattices
showed significant distortions compared to the initial, undistorted CTD lattice. Particularly, the lattice
distortion observed is indicative of a dimeric disassembly during the maturation process. The dimers in
the distorted lattice are circled in red. The stabilities of the lattices are quantified by measuring RMSF.
High RMSF (red) reflects an unstable region, similarly low RMSF (blue) identifies stable regions of the
lattice. The RMSF values for simulations PCALres , CALres, and BCALres were calculated from the 100 ns
unrestrained equilibrium simulation.
similar characteristics as observed in simlation BHBR.
To improve the 6HB structure, the Bush model was adjusted in search of an energetically favorable
conformation. Conformational search was performed by helically shifting one to three residues in all six
helices of the bundle. Shifting by one or three residues, results in energetically unfavorable conformations.
Shifting by two-residues - which results in an e↵ective ⇠ 180 degree clockwise rotation along its helical axis
from the original model - places residues R493 and E494 within distance to potentially form salt bridges at
the outer circumference. After 3.75 µs of REMD (simulation RHBR) a 6HB model was selected based on
the results from the partitioning around medoids (PAM) [85] clustering scheme described in Experimental
Procedures. The improved 6HB model which shows an inter-helical hydrophobic interface (Figure 2.7D) and
a complex salt bridge network at the C-terminus region (Figure 2.7E and 2.7F) will be referred henceforth
as the refined 6HB model.
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Figure 2.7: Complex salt bridge network stabilizing the refined 6-helix bundle model (6HB). The sequence
of the 28-residue-long CA-SP-8NC construct is shown at the top panel, with the key residues for assembly
highlighted in blue [14]. The same residues are highlighted in panels A-D in licorice representation, with
hydrophobic and polar residues colored in white and green, respectively. (A) 6HB proposed by Bush et
al. (colored in cyan). (B) The Bush 6HB model collapses after 3.75 µs of MD simulation, forming a
hydrophobic core at the center of the bundle. (C) 6HB is remodeled (shown as orange cartoon), such that
the hydrophobic residues are not pointing directly inward towards the bundle as in (A), but towards the
inter-helical interface. (D) After ⇠ 9 µs of REMD simulation, the inter-helical interactions in the 6HB model
are further refined and the tertiary structure remains intact (D). (E,F) A salt bridge network stabilizes the
bottom of the equilibrated 6HB model. The charged residues involved in forming this network are shown in
licorice representation (carbon in cyan, oxygen in red, nitrogen in blue); salt bridges are shown as red lines.
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To complete the model of the Gag lattice, the refined 6HB was then incorporated into the p10-CA lattice
using VMD [38]. Additionally, the connecting loops between the 6HB and the CTDs of the lattice were built
using Modeller [82]. To avoid involvement of the carboxyl terminus in the salt bridge network, the C-terminal
residue D496 was left uncharged. The Gag lattice was then simulated for 5 µs using REMD (simulation
PCALRR) in order to refine the entire model and test its stability. Because refining the CTD-6HB interface
does not require simulating the whole lattice, only the central hexamer and its neighboring Gag proteins
were included in the REMD simulation (Figure 2.4B). The REMD replicas were swapped at high frequency
(every 48 fs) and high e ciency (⇠ 65%) (Figure 2.11B) characteristic of optimal REMD simulations [86].
The representative model of the Gag hexamer was selected using the Gromos algorithm [87] as described
in Methods and the pdb of the Gag hexamer model can be found in the Supplemental Information section.
In the presence of the refined 6HB model, the CTD hexameric lattice remained stable throughout the 5 µs
REMD simulation (Figure 2.10c,d); without the 6HB, the hexameric lattice was significantly distorted within
100 ns of simulation (simulation CAL) (Figure 2.10A,B).
2.2.4 Properties of the refined 6HB model
After a cumulative simulation time of almost 9 µs (simulations RHBR and PCALRR), the refined 6HB model
exhibits both a salt-bridge network as well as hydrophobic contacts between adjacent helices. Several of the
hydrophobic residues at the SP, previously identified to be important in Gag assembly [14], are involved in
stabilizing 6HB by forming hydrophobic contacts between helices (Figure 2.7D). Additionally, an electrostatic
network is formed by the last 4 charged residues of the 6HB (R493, E494, R495, D496) (Figure 2.7E,F). The
importance of the electrostatic network is particularly evident when simulation RHBA shows the collapse of
the refined 6HB collapsed within 200 ns of simulation after the 4 charged residues at C-terminus of the 6HB
were mutated to alanine residues (Figure 2.8C).
As residues R493 and E494 are facing outwards from the 6HB center and could be important for
Gag assembly, three charge-swap mutagenesis experiments were proposed, namely R493E, E494R, and
R493E/E494R. Reversing the charge of residue 493 (R493E) results in impaired assembly of Gag in vitro.
However, assembly was restored by a secondary charge reversal of residue 494 (R493E/E494R) [2].
Table 2.2 summarizes the key residues involved in intermolecular and intramolecular interactions, the
selection criteria of such residues is outlined in the Methods section, and their location is shown in Fig-
ure 2.9B. The model reveals several novel interactions. For instance, D464 at the CTD and R472 at the 6HB
form intra-hexameric salt bridges that stabilize the N-terminus of the 6HB. Residues corresponding to these
salt bridges and other untested interactions listed in Table 2.2 provide a roadmap to future experiments.
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Furthermore, another attribute of the refined 6HB model is the kink present at the middle of the SP-NC
helix due to the presence of a helix-breaking proline (P485). Noteworthy, while the refined 6HB is stable and
maintains its hexameric shape, the relative orientation of the entire 6HB with respect to the CA hexamer
fluctuates over time (Figure 2.11A).
Table 2.2: Summary of the key interactions identified in the Gag lattice with the relevant experiments
reported for reference.
Interaction Residues involved Domain Relevant experiments
Intra-hexameric
W222 V225 L229
p10-NTD X-ray [12],mutagenesis [13, 16, 78]
I258 L295 V298
E228 – K256
T220/W222 – D291
E280 – R380/R384 NTD Not testedR464/K466 – D472 CTD
L470 I475 A477 M479
A482 I483 P485 I487 SP Mutagenesis [14]
M488 A489
R493 – E494 NC Mutagenesis [69, 68]R495 – D496
Trimeric
R297 – D310
NTD Not testedD310, K346
R339 – D350
Inter-hexameric R271 / R384 – D418 NTD-CTD Not testedW392 L419 A423 CTD X-ray [54]
Intramolecular
E401 – R409 CTD
X-ray [54],
mutagenesis [89]
F403 F406 F432 CTD X-ray [54], NMR [50, 52],mutagenesis [89]
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Figure 2.8: The relative stability of the refined and Bush 6HB models and the collapse of the mutated 6HB.
(A) The refined 6HB model exhibits higher stability than the 6HB model previously proposed by Bush et al.
as measured by RMSD. The refined 6HB model stays within 1.5 A˚ of the initial structure, compared to more
than 2.5 A˚ for 2 Bush models selected from simulations BHBR. (B) The Bush 6HB model was distorted
when incorporated into the p10-CA lattice. The Bush 6HB (cyan cartoon) collapsed inwards despite the
presence of p10-CA lattice. (C) Refined 6HB model collapses in the absence of the salt-bridge network.
With the 4 charged residues at the C-terminus of the 6HB mutated into alanine residues, the mutated 6HB
(pink) collapsed within 200 ns. The four alanine residues were explicitly shown in licorice representation.
23
C 
D 
K346
D310
90o 
K346
D310
E 
p10 
N-terminal 
α1 
α3 
α2 α4 
α5 
α10 
α8 
α9 
α7 
α6 
α11 
C-terminal 
E280 
R380 
R384 
R384 
D418 
R384 
D418 
A B 
F G H 
Figure 2.9: The relative positions of the key residues invovled in intra- and inter-molecular interactions. (A)
Helix naming scheme for a p10-CA monomer. (B) The identified key residues are highlighted. The Cbeta of
the key residues identified in Table 2.2 are shown in spheres. They are colored according to their interac-
tions, namely intra-hexameric (cyan), trimeric (black), inter-hexameric (gray), and intramolecular (purple),
respectively. (C,D,E) Trimeric interface of the Gag lattice stabilized by salt bridges. High occupancy of
chloride (lime surface in C) and sodium ions (yellow surface in D) were consistently observed near K346 and
D310, respectively, at the trimeric interface. (E) Relative positions of K346 and D310 in the NTD trimeric
interface, with only helices ↵4 and ↵5 shown for clarity. CA monomers, shown in cartoon representation, are
distinguished by di↵erent color. The occupancy map was generated using the VolMap plugin of VMD [38].
(F,G) Comparison of the salt bridge formed between residues D418 and R384 in the mature and immature
CA-lattices. (F) D418-R384 links adjacent hexamers in the immature lattice of RSV; (G) D418-R384 links
the NTD and CTD in a mature hexamer of RSV (PDB 3TIR) [53]. (H) Salt bridges formed between helices
↵2 and ↵7 stabilize the inter-hexameric interface. Residue E280 (helix ↵2) is able to form salt bridges with
either R380 or R384 (helix ↵7) of the conjugate monomer (shown in licorice representation).
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Figure 2.10: SP and the first 8 residues of NC stabilizing the CTD hexameric lattice. Only the CTDs and
SP-NC are shown for clarity. (A) Initial CA hexameric lattice. (B) Lattice in (A) dissociated after 100 ns
simulation. (C) Starting model of the CA lattice in presence of refined 6HB. (D) Structure in (C) remains
intact after 5 µs of REMD simulation.
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Figure 2.11: The flexibility of the 6HB relative to the CA lattice. (A) Average occupancy of the 80 most
representative structures from the REMD simulation PCALRR. The structures were extracted from the
largest cluster using g cluster. The 6HB region is of lower occupancy due to the inherent flexibility of the
6HB, however the overall shape of such region is clearly in the form of a hollow tube. The occupancies were
calculated using the VolMap plugin in VMD, and the image was rendered using Chimera [88]. (B) Uniform
temperature mixing observed in the replica exchange molecular dynamics (REMD) simulation PCALRR.
All replicas perform random walks in temperature space, reaching high temperatures (red color) and low
temperatures (blue color). REMD was performed for temperatures between 305 - 375 K, using 113 replicas.
The total cumulative time is 5 µs.
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2.3 Discussion
There has been an increasing interest in the structure of the Gag lattice as it is considered an unexploited
therapeutic target [90, 91]. With this report we present what is, to our knowledge, the first atomic model
and the first all-atom MD simulation of a Gag lattice that consists of CA together with the upstream and
downstream subdomains of p10, SP and NC that are known to provide critical stabilization. Between the two
available paradigms for Gag domain packing (HIV-1 and M-PMV), the presented work provides a strong
argument for the M-PMV model to describe RSV structure as well as for the p10-NTD interaction first
illustrated by crystallography. The computationally derived model clearly identifies essential residues at the
CA, p10, and SP-NC subdomains of Gag, elucidating the domains’ role in stabilizing the immature RSV
Gag lattice. The Gag lattice model provides the structure of immature particles of retroviruses in atomic
detail; the model provides also a novel template to investigate the assembly/disassembly and maturation
processes of retroviruses like HIV-1 and may assist in the development of new drugs.
2.3.1 Gag exhibits multiple packings for di↵erent retroviruses
B A 
α1 α1 
Figure 2.12: The NTD of the HIV-1 immature capsid is not a good template for RSV. (A) The positions
of p10 resulted in inter-hexameric interactions with the neighboring NTDs, rather than intra-hexameric as
suggested by Phillips et al. [13]. (B) Packing of HIV’s NTD is unable to accommodate p10 due to severe
steric clashes. The NTDs of HIV are represented as transparent tubes, colored blue for the central hexamer
and red for the surrounding hexamers. The p10 subdomains are shown in cartoon representation in solid
blue and red, for the central and surrounding hexamers, respectively.
The comparative analysis of a variety of retroviruses has historically provided important insights into
the mechanism of virus assembly, crucial for understanding the human virus, namely HIV-1. Cryo-electron
tomography studies of HIV-1 and M-MPV Gag lattices have recently revealed structural information at
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subnanometer resolution about the arrangement of the CTDs and its downstream sequence, namely SP1 [17,
72, 48]; such lattices also exhibit the same CTD packing for both HIV-1 and M-MPV [17, 48], suggesting
that CTD packing might be a common motif across most retroviruses [72] as previously suggested by lower
resolution studies [47]. On the other hand, the quaternary structure of the NTDs of the HIV-1 Gag lattice is
significantly di↵erent from that of M-PMV [17, 48]. During the building process of the RSV Gag lattice model
of this study, both the HIV-1 and M-PMV lattices were considered as starting points. However, upon docking
of p10-NTD into the density map of the HIV-1 Gag lattice [48], severe steric clashes between p10 and helix ↵1
of the adjacent NTD were observed (Figure 2.12). Furthermore, the relative orientation of p10 with respect
to the adjacent NTD only allows for the formation of inter-hexameric p10-NTD interactions (Figure 2.12),
rather than intra-hexameric interactions as predicted by biochemical experiments [13]. Therefore, the Gag
lattice of M-PMV [17] emerged as the template of choice, both for NTDs and CTDs, to construct and
investigate the RSV Gag lattice (Figure 2.2). The resulting Gag lattice model not only is consistent with
a large body of published genetic, biochemical and structural data on RSV, as listed in Table 2.2, but the
model also pointed out several new interactions for future investigations.
2.3.2 Structural architecture of the RSV Gag lattice
The tertiary structure of the capsid protein is highly conserved across all retroviruses [92], in particular the
CA of RSV contains 7 helices (↵1 - ↵7) at the NTD, and 4 helices (↵8 - ↵11) at the CTD (Figure 2.9A).
The quaternary arrangement of the NTDs in the RSV Gag lattice is similar to the packing observed in
the M-PMV Gag lattice and di↵erent from the one observed in HIV-1 particles. Particulary, the resulting
arrangement of the NTDs accomodates p10 in such a way that the p10 helix forms a three-helix bundle with
helices ↵1 and ↵3 of the adjacent NTD (Figure 2.3) stabilized by contacts between hydrophobic residues. The
resulting interactions between p10 and helices ↵1/3 are similar to the ones proposed in a previous study [13];
the hydrophobic interactions at the p10-NTD interface (Figure 2.3) are consistent with several experimental
studies [12, 16, 13]. Such p10-NTD interaction is the primary intra-hexameric interaction in which p10
bridges the NTDs that are scarcely interacting within a single hexamer [13]. The NTDs instead contribute
to a large dimeric interface that serves to hold together adjacent hexamers in the lattice. Specifically, helices
↵2 and ↵7 of conjugate NTDs are held together by the formation of salt bridges (Figure 2.9H). At the
interaction site of three hexamers, namely at the trimeric interface, helices ↵4 and ↵5 come together by
coordinating ions via residues K346 and D310 (Figure 2.9C,D,E).
The quaternary packing of the CTDs in the RSV Gag lattice largely resembles the CTD packing of
M-PMV and HIV-1 Gag lattices (Figure 2.13B) [17, 72, 48, 47]. The main contact point is between helices
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↵9 at the inter-hexameric interface, however the CTDs scarcely interact with each other intra-hexamerically.
As such, the CTD hexameric ring is stabilized by the downstream subdomains (SP and part of NC) rather
than by adjacent CTDs.
In our study, the minimal region which confers stability to the CTD hexamers spans the last 7 residues
of CA, the entire SP and the first 8 residues of NC arranged in an amphipathic six-helix bundle, consistent
with studies from the Vogt lab [15, 13, 69, 14]. The structure of the 6HB was computationally derived and
refined based on the Bush model, and remained stable in microsecond-long simulations. SP residues critical
for assembly, as identified by mutagenesis experiments [14], served as validation of the inter-helix interface
in the refined 6HB (Figure 2.7C,D). The resulting model also reveals a series of inter-helical hydrophobic
contacts as well as a collar of electrostatic interactions around the circumference of the bundle. Thus,
the e↵ects of mutations on the integrity of the lattice were investigated via mutagenesis experiments [2] .
Since each helix of the SP-NC complex is connected to the C-terminus of the CTD by a flexible loop, the
6HB is inherently flexible (Figure 2.11A). Such flexibility has been previously observed in NMR studies of
monomeric RSV CA-SP [52] and HIV-1 CTD-SP1 [74, 75, 73] constructs.
A B 
Figure 2.13: The complete hexamer model to form a stable RSV Gag lattice. (A) The hexamer with the
refined 6HB model derived from REMD shown in orange cartoon. The p10, NTD, and CTD are shown in
cartoon representations in blue, green and red, respectively. (B) The CTD and 6HB of RSV docked into
HIV-1 Gag density map for comparison.
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2.3.3 Hexameric Gag is stabilized by a network of salt-bridges
At the C-terminus of the refined 6HB model there is a network of salt bridges formed by the last four
residues of the CA-SP-8NC construct. The salt bridges formed between R493 and E494 are of particular
interest due to their location at the outer circumference of the refined 6HB, in contrast to the Bush model
which locates such residues at the inner circumference [14]. In the Gag assembly experiments, the ability of
E494R to correct the assembly defect caused by R493E, provides strong support for the importance of such
electrostatic interactions [2]. Additionally, removal of the salt-bridge network through alanine mutations
resulted in a collapsed bundle in a 200 ns MD simulation (Figure 2.8C). Importantly, the refined 6HB model
is consistent with the findings that removal of charge by mutations R493A and R495A disrupts Gag assembly
in vitro [69] and that the addition of the first 8 NC residues to purified CA-SP shifts its assembly mode
from mature, or CA-like, to a more Gag-like behavior [68]. Such a charged motif has been proposed to assist
in the formation of helical bundles in the murine leukemia virus (MLV) via directed charged surfaces [93].
Interestingly, the deletion experiments showed that the charged motif of MLV can tolerate minor charge
imbalances without a↵ecting particle production [93]. Therefore, it might not be surprising that the E494R
mutation in RSV did not a↵ect Gag assembly. The robust assembly of the single charge reversal, namely
E494R, might stem from the inherent flexibility observed in the 6HB. Moreover, the lack of the remaining
NC residues and RNA could prevent a full accounting of all possible electrostatic interactions in our model.
Overall, the experimental studies support a role for a salt bridge network involving charged residues of NC
at the end of the 6HB in stabilizing the Gag hexamer.
Using our model of 6HB as reference and based on the distribution of polar and hydrophobic residues
at the SP1 and NC subdomains of HIV-1 [74], we suggest that the SP1-NC domain of HIV-1 could form
an amphipathic 6HB similar to the one derived for RSV. Despite the smaller hydrophobic face of each helix
in the bundle of HIV-1 compared to that of RSV, the 6HB of HIV could still form hydrophobic contacts
at the inter-helical interface. Similarly, we speculate that the polar and charged residues of HIV-1 could
form intra-hexameric hydrogen bonds to stabilize such 6HB. The presence of a motif similar to such 6HB
in immature virions of HIV-1 has been recently observed [72, 48]. Noteworthy, the cryo-EM density of such
bundle overlaps well with the model derived in this study, but only at the top half of 6HB (Figure 2.13B);
a density corresponding to the lower half of the bundle may be absent for two reasons: 1) flexibility of the
bundle that results in a washed out density, or 2) an inherently shorter 6HB of HIV-1 compared to RSV [47].
29
2.3.4 Stabilizing interactions extracted from MD simulations
The NTD layer of the p10-CA lattice remained stable while the CTD layer was distorted during the unre-
strained simulation (Figure 2.3; Figure 2.6). Therefore, our model suggests that the p10-NTD and CTD-
SP-NC interaction layers contribute independently to the stability of Gag hexamers in the lattice, consistent
with current structural models for HIV-1 and M-PMV [17, 72, 48] and with the need for the PR domain
to cleave within both regions to allow the CA protein to rearrange into a capsid. In addition our model
clearly identifies a set of intermolecular NTD-CTD interactions present in the RSV Gag lattice. Particu-
larly, residue D418 forms inter-hexameric salt bridges with either R384 or R271 of the adjacent subunit.
Conversely, the same residue (D418) is known to make an intramolecular contact with R384 in a mature
RSV capsid [53]. The di↵erent interaction modes between D418 and R384 between immature and mature
lattices (Figure 2.9F,G) implies that D418 might play a key role in regulating the maturation process. The
need for D418 to switch from an intermolecular to an intramolecular interaction could explain the ability to
trigger in vitro assembly of CA protein into apparently identical capsid-like particles by either exposure to
low pH which protonates a nearby residue D418 [53, 54] or high phosphate condition which can shield the
cluster of basic residues at the NTD [94] thereby encouraging D418 to break its intermolecular salt bridge.
A B
C D
Figure 2.14: Di↵erence in organization of the immature and mature RSV lattices. (A,B) Side and Top views
of the immature RSV lattice derived in this study. (C,D) Side and Top views of the mature RSV capsid
obtained via X-ray crystallography [53].
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Relative orientations of the individual domains of CA are significantly di↵erent between the mature
and immature forms of the capsid (Figure 2.14A-D) [61, 53]. In particular, the arrangement of CA in
the immature lattice results in an unstable structure, as shown in simulation CAL, where a significant
distortion of the CA domain was evident (Figure 2.5; Figure 2.6). Such distortion of the CA domain
was also observed in the all-atom simulation of an isolated immature CA hexamer model of HIV-1 [76].
Furthermore, according to our simulations, CAs of an immature lattice require the presence of both the
p10 and SP-NC subdomains for stability, unlike oligomers of CAs in the mature capsid which are known
to remain stable in silico [56]. Furthermore, the dissociation pattern observed for both NTDs and CTDs
(Figure 2.5 and Figure 2.6) suggests that upon cleavage of p10 and SP-NC, the lattice breaks down into
dimers belonging to conjugate Gag hexamers as early intermediates of the disassembly process. Such dimers
are stable for over 100 ns (Figure 2.15A,B), and are held together by interactions at the NTD (residue E280
of helix ↵2 and residues R380, R384 of helix ↵7), in contrast to the dimers found in the mature capsid,
where the dimerization interface is part of the CTD. Overall our findings support the idea of a di↵usion
driven disassembly-reassembly maturation pathway [95, 94, 17, 96] over the non-di↵usive displacive transition
hypothesis for retroviruses [97, 98].
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Figure 2.15: Isolated immature dimers of p10-CA and CA remain associated for over 100 ns. (A) Immature
CA dimer after 110 ns of MD simulation. (B) The NTD of the immature p10-CA and CA dimers stay
associated (center of mass (C.O.M.) distances between the NTD dimers equilibrate at ⇠ 22 A˚) during the
simulation.
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2.4 Conclusion
The atomic model of a Gag lattice presented here, containing segments both upstream and downstream
of CA, identifies several important interactions that are shown to contribute to the lattice’s stability. The
refined 6HB model presented in this study – derived from microsecond-long replica exchange MD simulations
– provides a refined atomic template to study the properties of the SP-NC subdomains and enables the
modeling of atomic structures of 6HB for the SP-NC subdomain of several other retroviruses, including
HIV-1. Furthermore, extensive simulations of the Gag lattice reveal novel mechanistic aspects of Gag related
to assembly, stability, and maturation. Altogether, we expect that the model derived in this study extends
beyond RSV, o↵ering an unique glimpse into the maturation process of retroviral particles, and constituting
a new platform for drug targets hopefully useful in the development of novel antiretroviral therapies.
2.5 Methods
2.5.1 All-atom molecular dynamics simulation
Systems were prepared using VMD [38] and simulations were performed using NAMD2.9 [37] with the
CHARMM36 force field [99]. The protein assemblies (Table 2.1) were simulated in a su ciently large water
box such that the minimal distance between solute and box boundary is 20 A˚ along all three axes. The
solvated systems were neutralized and the salinity of the solvent being set to 100 mM NaCl. 100 mM
NaCl was also used in the assembly experiments [14]. The ionized systems were then minimized for 20,000
steps and subsequently thermalized to 310 K within 4 ps. All equilibrium simulations were performed in
the NPT ensemble. Simulations PCALres, CALres and BCALres were performed for 100 ns with positional
restraints applied to the backbone atoms of the lattice boundary and CTDs. The lattice boundary is defined
as the residues that are beyond 60 A˚ from the central hexamer. Simulations PCAL, CAL and BCAL were
performed without restraints. For simulation PCALRR and PCALB, only the central hexamer along with
its neighboring monomers were included in the simulation in order to limit the system size.
For simulation PCALres, the positional restraints were applied to the backbone atoms of the residues
60 A˚ away from the central hexamer. Additionally, the backbone of the CTD helices were restrained to
mimic the stabilizing e↵ect of downstream of CA. For simulations PCAL, CAL and BCAL, no positional
restraints was applied and the entire lattice assumes full degree of freedom.
Simulations BHBR and RHBR were subjected to REMD simulations to increase the conformational
sampling. The first 4 ↵-carbon atoms (C↵) at the N-terminus of the two 6HB models, L470 to Q473, were
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restrained to mimic the presence of CTD hexamer. For simulations PCALB and PCALRR, no restraint
was applied to the 6HB, but the backbone atoms 10 A˚ away from the central hexamer were restrained to
simulate the boundary conditions of a fully assembled lattice. All restraints were applied at 1 kcal mol 1
A˚ 2.
The temperatures (in K) used in simulations BHBR and RHBR are
(275.00 276.40 290.07 292.63 294.91 297.02 299.01 300.90 302.73 304.49 306.22
307.90 309.56 311.19 312.79 314.38 315.95 317.51 319.05 320.59 322.12 323.64
325.16 326.67 328.18 329.69 331.21 332.72 334.23 335.74 337.26 338.78 340.31
341.85 343.39 344.93 346.49 348.05 349.63 351.21 352.81 354.42 356.04 357.68
359.33 361.00 362.68 364.39 366.11 367.85 369.62 371.41 373.23 375.07 376.94
378.85 380.78 382.75 384.76 386.80 388.89 391.03 393.22 395.45 397.75 400.11
402.54 405.03 407.61 410.28 413.03 415.89 418.86 421.94 425.14)
whereas the temperatures (in K) used in simulation PCALRR are
(305.00 305.55 306.10 306.65 307.21 307.76 308.32 308.87 309.43 309.99 310.55
311.11 311.68 312.24 312.80 313.37 313.94 314.51 315.08 315.65 316.22 316.79
317.37 317.94 318.52 319.10 319.68 320.26 320.84 321.43 322.01 322.60 323.18
323.77 324.36 324.95 325.55 326.14 326.73 327.33 327.93 328.53 329.13 329.73
330.33 330.94 331.54 332.15 332.76 333.37 333.98 334.59 335.21 335.82 336.44
337.06 337.68 338.30 338.92 339.54 340.17 340.79 341.42 342.05 342.68 343.31
343.95 344.58 345.22 345.86 346.50 347.14 347.78 348.42 349.07 349.72 350.36
351.01 351.66 352.32 352.97 353.63 354.28 354.94 355.60 356.26 356.93 357.59
358.26 358.92 359.59 360.26 360.94 361.61 362.29 362.96 363.64 364.32 365.00
365.68 366.37 367.06 367.74 368.43 369.12 369.81 370.51 371.20 371.90 372.60
373.30 374.00 374.70)
Simulations were performed using NAMD 2.9 [37] with the CHARMM36 force field for the protein [99]
and the TIP3P model [100] for water molecules. Periodic boundary conditions were assumed, and the
particle mesh Ewald summation method was employed for the evaluation of Coulomb forces. The van der
Waals energy was calculated using a cuto↵ of 12 A˚. The temperature and pressure were maintained at 310 K
and 1 atm, respectively, using a Langevin thermostat with a damping constant of 1 ps 1 and Nose´-Hoover
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Langevin piston methods. The integration time step was 2 fs. The non bonded interactions were evaluated
for every 2 fs, and electrostatics were evaluated for every 6 fs.
2.5.2 Replica exchange molecular dynamics (REMD) Simulations
Temperature replica exchange molecular dynamics as implemented in NAMD 2.9 [37] was used to sample the
conformational space of the 6HB [101]. Simulations BHBR and RHBR employed a total of 75 replicas with
temperature ranges from 275 K to 425 K with a target exchange ratio [102] of 0.5, and exchanges between
replicas attempted every 2 ps. For simulation RHBR the 6HB model that corresponds to the medoid of
the largest cluster was selected using the partion around medoids (PAM) algorithm [85, 103] and was then
incorporated into the Gag lattice. The details of the PAM algorithm can be found in the Supplementary
Information.
For simulation PCALRR, 113 replicas were simulated with temperature ranges from 305 K to 375 K with
a target exchange ratio of 0.25. The frequency of exchange was enhanced by attempting an exchange every
48 fs [104]. The list of temperatures used for each of the REMD simulations can be found in Supplementary
Information. The program g cluster from GROMACS [105] was used to cluster the final snapshots from the
113 replicas corresponding to simulation PCALRR, into 12 di↵erent clusters using the Gromos algorithm [87].
The structure corresponding to the centroid of the largest cluster - which contains 80 of the 113 replicas -
was selected as the final lattice model.
Clustering methods Dissimilarity matrices for the ensemble of structures at T=310K in simulations
BHBR and RHBR were constructured using RMSD as the similarity criterion. The RMSD between structures
was calculated using the Kabsh algorithm [106]. Structures were then divided into clusters using the partion
around medoids (PAM) algorithm [85, 103]. In order to assess the quality of clustering as a function of the
number of clusters, the Silhouette criteria [107] was employed, as illustrated in Figure 2.16. For simulation
RHBR two major clusters are identified, with the medoid of the largest cluster selected as the final structure.
2.5.3 Selection criteria for key interacting residues
The key interacting residues listed in Table 2.2 were selected from the replica that corresponds to temperature
T=310 K in simulation PCALRR and filtered according to the criteria outlined below. Each of the six
monomers in the central hexamer were examined individually, and the results were averaged over the entire
set. Residues that form intermolecular hydrogen bonds were identified by the Hbonds plugin in VMD [38],
and identified as key residues if the average occupancies were above 50%. Residues in a hydrophobic core were
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Figure 2.16: Two distinct clusters were observed for the refined 6HB model (gray circles) using PAM
clustering, as described in the Methods section. The gray arrow pinpoints the optimal number of clusters
identified by the Silhouette criteria. Conversely, by the same criteria, there is not an optimal number of
clusters for the Bush 6HB model (black circles).
identified as key contacts if the contact area between the hydrophobic side-chains was above 100 A˚2. Some
of the intramolecular interactions are included in Table 2.2 due to their relevance in several experimental
studies listed in the same table.
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Chapter 3
E↵ect of Mutations on the Functions
of a Retrovirus
Reproduced in part with permission from Katrina J. Heyrana, Boon Chong Goh, Juan R. Perilla, Tam-
Linh N. Nguyen, Matthew R. England, Maria C. Bewley, Klaus Schulten, and Rebecca C. Craven. Con-
tributions of Charged Residues in Structurally Dynamic Capsid Surface Loops to Rous Sarcoma Virus
Assembly. Journal of Virology, In Press (Copyright 2016 American Society for Microbiology),
3.1 Introduction
As described in the last chapter, the Gag polyprotein in immature Rous sarcoma virus (RSV) is composed of
subdomains corresponding to the matrix (MA), capsid (CA), spacer peptide (SP) and nucleocapsid proteins
(NC). CA provides the protein-protein interactions that organize both the immature Gag lattice and the
capsid structure of the mature core, thereby determining the size, shape, and functionality of both struc-
tures. The tertiary structure of CA is highly conserved despite considerable CA sequence variation across the
orthoretroviruses families including human immunodeficiency virus (HIV, a lentivirus), RSV (an alpharetro-
viruses), murine leukemia virus (MLV, a gammaretrovirus) and Mason-Pfizer monkey virus (M-PMV, a
betaretrovirus).
The CA monomer comprises two predominantly alpha-helical domains, a 7 helix N-terminal domain
(NTD) and a 4-helix C-terminal domain (CTD). The helical folds of the two domains are largely identical
in both the mature and immature capsid forms with the major distinguishing feature being the  -hairpin
structure that precedes the first-helix of the mature NTD. This  -hairpin forms only after CA is cleaved
from the upstream Gag domain, namely MA. In the NTD, helices ↵1 – ↵4 and the last helix form a tight
bundle, while the loops and short helices between ↵4 and the last helix comprise a surface-exposed flexible
loop (FL) region that is the least conserved region in the CA sequence and exhibits considerable structural
variation across retroviral families [18, 19, 20, 21, 22].
The sequence diversity in the FL region across virus families has been driven in part by species-specific
interactions between the viruses and their hosts, since the region is displayed on the outer capsid surface
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and exposed to the cytosol after entry into a new cell [58, 108] . At least three cellular proteins are known
to bind the HIV-1 FL region: cyclophilin A, tripartite motif 5 (TRIM5), and cleavage and polyadenylation
specific factor 6 (CPSF6) [109, 110, 111, 112, 113, 114, 115]. The MLV CA interacts with the cellular Friend
virus susceptibility factor 1 (Fv1) [116]. Binding of these proteins to capsids in the cytosol a↵ects several
post-entry events [109, 110, 116, 117, 118], suggesting that the FL serves both structural and regulatory
roles in the establishment of a new infection. As yet, no CA-binding host proteins have been identified in
the alpharetroviruses.
Diversity in the FL sequences is also likely related to the unique structural roles that the region plays
in the Gag lattices of evolutionarily distant viruses. The immature structures are comprised of Gag protein
hexamers with the CA NTD and CTD of each molecule vertically stacked and both interhexameric and
intrahexameric contacts mediated horizontally (i.e. NTD-NTD and CTD-CTD) [61, 47, 46]. Recent high-
resolution studies of immature virions of M-PMV and HIV allowed unequivocal positioning of the alpha
helices of the two domains. The packing of CTDs in the inner CA layer is highly conserved across virus
families [47, 17, 48] and provides for the critical role of the CTD and immediately downstream spacer peptide
in creating the interhexameric contacts that form the Gag lattice. In contrast, NTD packing is strikingly
di↵erent between the two viruses. Two new models of the RSV Gag lattice developed by all-atom molecular
dynamics modeling and by cryo-electron tomography, respectively, now indicate that the RSV lattice bears
more similarity to the M-PMV Gag model than to that of HIV [2, 79].
Genetic studies in RSV and other retroviruses support the dominant role of the CTD and adjacent SP
in driving Gag assembly [97, 119, 120, 15]. However, biological evidence from several labs has also suggested
a contribution of the FL in the assembly of functional virions, consistent with the recent structural studies.
Deletions within the FL region of a protease-deficient RSV Gag yielded particles of highly heterogeneous
size [78]. Similarly, in MLV and HIV, various point mutations, deletions, or insertions involving the FL
region resulted in ine cient particle release or products of heterogeneous size [65, 121]. In another RSV
study, FL point mutations emerged spontaneously as second-site suppressors of  -hairpin lesions, suggesting
a role of the FL residues either during Gag assembly or maturational rearrangements [122].
In this current study, we have examined the contributions of specific FL residues in the assembly of infec-
tious RSV particles in order to provide important functional data needed for the assessment of the evolving
models for alpharetrovirus assembly. We designed mutations in the FL region, targeting predominantly
charged residues, and assessed their e↵ects on the overall electrostatic potential and allosteric communi-
cation of the lattice virus, which are related to virus replication and particle assembly. The results are
consistent with a role for the FL region in the NTD-NTD interface to form a well-ordered Gag lattice. Be-
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cause of the need for such contacts to separate upon proteolytic processing during maturation, the orderly
rearrangements that create the functional core structure are also expected to require proper management of
surface charges.
3.2 Results
This study was initiated to provide functional data about the contributions of NTD residues in the formation
of immature virions to complement the emerging structural models of immature retrovirions. Our attention
was directed to the FL region by a prior study in which compromising mutations in the  -hairpin region
of RSV CA were partially suppressed by compensating mutations at R86 and N104 in the FL region [122].
Several mutations on R86, D87, R89, and E99 were tested in in vitro and in vivo experiments. Virus
infectivity and particle assembly were found to be severely crippled when the charge was removed or replaced
by an opposite charge [4].
3.2.1 Structural consequences of D87 mutations.
MD simulations employing the recent computational model [2] for the wild type (WT) Gag lattice revealed
a number of intermolecular electrostatic and hydrogen bond interactions contributed by the FL residues
(Table 3.1), many of which had been predicted by the p10-CA dimer crystal structure [12] and/or the recent
cryo-tomography model [79]. Nonetheless a number of novel interactions were observed by all-atom MD
simulations. One such interaction was the transient intra-hexameric bonding between a cluster of charged
FL residues (R86, D87, and R89) and several residues in the CA N-terminus that form the  -hairpin upon
proteolytic processing (Figure 3.1A, Table 3.1).
Besides intermolecular interactions, D87 also forms a prominent intramolecular salt bridge with R89
(Figure 3.1A) in the same monomer at 84% likelihood as determined by structural clustering. In addition,
residue E99 in the large loop forms intramolecular interaction with R125 at a 50% likelihood which may
help to stabilize the region by anchoring the loop to helix ↵7.
The D87E, D87A, D87R, E99A, and E99Q changes were introduced into the Gag lattice model in silico
and e↵ects on the surface charge distribution and the network of interactions were examined (Figures 3.1C
and 3.2; Table 3.1). Removal of a negative charge at position 87 or 99 resulted in a noticeable accumulation of
positive charges at the interhexameric interfaces of the lattice. In addition, the D87A substitution caused an
approximately two-fold increase in flexibility of the CA monomer in the large loop (residues 90-95) compared
to the WT protein (Figure 3.1B). No similar alterations in flexibility were observed with the other mutants.
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Figure 3.1: Mutations at residues 87 and 99 modify several properties of the immature lattice. (A) D87A
alters the conformations adopted by R89 and its network of interactions. Hydrogen bonds are shown as
black lines. (B) The flexibility of a part of FL large loop was significantly increased as reflected by RMSF
upon D87A mutation. (C) Electrostatic potential maps show that the removal of negative charges by D87A
or E99Q resulted in an accumulation of positively-charged regions at the inter-hexameric interface, indicated
by black arrows. Only the NTD of the lattice was shown for clarity. (D) Di↵erent electrostatic interactions
observed at the NTD dimer interface between WT and D87E mutant. E41 favors forming hydrogen bonds
(black lines) with R141 and R145 in WT but favors interacting with Q138 and R145 in D87E. Helices ↵2
and ↵7 are shown in solid ribbons and the remaining of the NTD are shown in translucent ribbons.
The three mutations introduced at position 87 (D87E, D87A and D87R) each caused unique e↵ects on
the intramolecular interaction between D87 and R89 in silico. The D87A and D87R mutations e↵ectively
reduced the frequency of D87-R89 bonding from 84% to 22% and 0%, respectively. Furthermore, when R89
39
Table 3.1: A selected list of intermolecular hydrogen bonds involving p10 (residues -28 to -1) and NTD
observed in the simulated WT and mutant Gag lattices. Both inter-hexameric and intra-hexameric interac-
tions are considered. Residue numbering follows conventions used in the crystal structure for the p10-CA
NTD (PDB: 1P7N [12]) with residue 0 denoting the Met residue at the p10-CA cleavage site. Donor and
acceptor residues are labeled as D and A, respectively.
Residue
name
D Residue
name
A WT D87E D87A D87R E99A E99Q A134V D87E-
A134V
K107D
THR -19 ASP 52 79.57 60.03 73.93 62.23 82.47 84.03 85.40 63.50 62.90
TRP -17 ASP 52 81.10 82.53 80.40 83.87 84.80 90.67 88.93 79.33 84.03
VAL 2 ASN 55 17.82 16.80 13.08 22.95 15.48 19.02 20.67 21.55 15.07
LEU 14 THR -19 31.53 28.30 34.13 37.17 41.30 30.47 31.07 36.13 28.87
LYS 17 GLU -11 44.57 77.67 75.47 65.83 71.77 66.03 63.23 54.83 48.70
THR 20 GLU -11 12.93 7.73 7.87 16.63 6.23 13.80 8.77 8.60 11.20
ASN 55 TRP -17 14.80 14.23 9.70 16.80 12.37 11.47 15.20 15.00 13.37
ASN 55 VAL 2 17.48 11.22 13.60 16.07 13.17 19.08 16.67 21.13 15.53
ARG 58 MET 0 10.63 6.95 4.30 4.77 7.37 9.83 4.20 5.48 1.70
ARG 58 ASP 71 37.92 39.00 11.50 30.88 38.08 26.82 16.33 27.83 69.50
ARG 58 GLU 142 35.08 25.62 16.50 18.27 28.65 17.62 10.42 40.28 12.27
ARG 86 ILE 4 5.90 2.68 8.93 13.33 12.18 6.35 15.78 17.10 12.60
ARG 86 LYS 5 10.05 3.68 8.65 6.28 8.28 4.88 11.40 11.97 8.75
ARG 86 GLU 7 18.42 20.67 15.70 12.77 16.73 18.30 16.42 29.00 24.80
ARG 86 GLY 8 11.43 7.63 9.45 3.47 13.72 4.20 7.58 14.77 18.92
ARG 86 PRO 9 4.25 2.10 4.88 2.48 11.73 0.83 3.72 0.70 6.02
ASP 87 GLU 7 0.00 0.00 0.00 11.80 0.00 0.00 0.00 0.00 0.00
ASP 87 GLY 8 0.00 0.00 0.00 7.38 0.00 0.00 0.00 0.00 0.00
ASP 87 PRO 9 0.00 0.00 0.00 7.70 0.00 0.00 0.00 0.00 0.00
ARG 89 GLU 99 0.40 0.00 7.23 0.13 0.00 0.67 1.85 0.72 0.67
ARG 100 ASP 111 20.48 25.95 26.83 26.78 27.78 27.98 28.50 38.23 17.25
ASN 102 ASP 111 16.72 19.87 17.63 5.77 21.87 19.52 17.80 9.97 13.77
ARG 105 ASP 111 16.92 12.42 10.52 0.33 8.52 3.80 13.37 12.70 7.92
GLN 138 GLU 41 17.45 33.65 25.88 21.38 28.52 31.72 27.40 15.10 21.95
ARG 141 GLU 41 34.60 11.77 23.40 31.32 33.72 31.58 20.50 44.52 47.73
ARG 141 GLN 138 1.90 11.27 8.42 6.38 2.62 6.17 8.68 8.42 7.25
ARG 145 GLU 41 39.67 61.22 45.38 29.23 36.57 47.98 48.03 26.27 50.20
was freed from its interaction with D87 by the D87A substitution, it gained the ability to adopt alternate
conformations, forming intramolecular and intermolecular interactions with nearby polar residues that were
not seen in the WT lattice (Figure 3.1A and Table 3.1). Additionally, introduction of D87R enables residue
87 to interact with neighboring N-terminal CA residues such as E7, G8, and P9 (Table 3.1). Thus, D87A
and D87R both disturb the network of interaction observed in WT and result in an accumulation of positive
charges at the interhexameric interface (Figure 3.1A, 3.1C, and Figure 3.2 – the 9 electrostatic maps).
The conservative D87E change, which in vivo allowed the production of abundant amounts of normal
appearing but poorly infectious particles, slightly increased the likelihood of interaction with R89 from 84%
(WT) to 93%. More striking, however, were long-distance e↵ects of D87E on CA-CA interactions. In the
WT lattice, E41 on helix ↵2 interacts prominently with residues Q138, R141 and R145 in a polar cluster on
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the lower half of helix ↵7, which make the primary point of NTD-NTD contact across the dimer interface
(Figure 3.1D). The D87E substitution shifted the frequency of E41 interactions to favor contact with Q138
and R145 rather than R141 (Figure 3.1E and Table 3.1).
WT D87E D87A
D87R E99A E99Q
-100 mV
+100 mV
K107D
Figure 3.2: Electrostatic potential surface maps show that point mutations at D87 and E99 lead to accumu-
lation of basic charges at interhexameric interfaces.
3.2.2 A second-site suppressor of D87E.
Spontaneously arising second-site suppressors have proven to be a powerful and unbiased means to reveal
functional relationships between residues in RSV CA [123, 124, 125]. An experimental study put D87E
mutant virus through a serial passaging protocol to encourage outgrowth of new genetic variants, where
viruses that showed improved infectivity were isolated and sequenced [4]. Although many variants reverted
to the WT aspartate, some viruses independently acquired a second mutation, an alanine to valine change
at position 134 on helix ↵7 (A134V). It was later shown that the addition of A134V to a D87E virus
dramatically improved virus infectivity compared to D87E alone. The double-mutant virus infects chicken
cells at a rate 54% that of the WT compared to 16% for the D87E virus, confirming A134V as a partial
suppressor of the D87E lesion.
3.2.3 The top and bottom of the NTD are dynamically coupled.
With D87 and A134 are approximately 20 A˚ apart, how A134V suppress the detrimental e↵ect caused by
D87E mutation? If infectivity and assembly defects in the D87E virus are related to the altered intermolecular
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interactions seen with MD modeling of the mutant lattice (Figure 3.1E), we predicted that the addition of
the second site suppressor A134V to the lattice simulation may correct the changes in these interactions.
This e↵ect is indeed evident in D87E-A134V model (Table 3.1). MD simulations that include the second-
site suppressor A134V showed shifts in the frequencies of intermolecular interactions involving residues E41,
Q138, R141 and R145 at the point of NTD-NTD contact in the immature lattice, restoring the contacts that
were disturbed by D87E (as noted above) to a more WT pattern. In the double mutant, A134V reduces
the frequency of the E41-R145 interaction while increasing the E41-R141 contact (Figure 3.1E, Table 3.1).
Presence of the A134V mutation also increases the buried surface area in this region of the dimer interface
by an average of 15 A˚2 per monomer compared to the WT lattice.
The reversal of the core stability and infectivity deficits in D87E virions by the A134V compensatory
change suggests that long-range communication occurs between the FL and helix ↵7. Therefore, we applied
dynamical network analysis to our MD models to identify dimer interface residues whose motions are highly
correlated [126]. This approach identified a route of communication between D87 and R145 along an optimal
pathway that in the WT lattice includes residues D87, A83 and V80 near the top of helix ↵4 and residues
S135, Q138, R141 and R145 in the lower part of helix ↵7 in the same NTD (Figure 3.3A and B).
We employed “dynamic coupling” as a relative measure of the strength of communication, inversely
related to the degree to which the motion of a pair of residues is coupled. Figure 3.3C presents the dynamic
coupling between D87 and helix 7 residues in the WT lattice (blue bars). The low values for Q138, 141 and
145, as well as their interacting partner E41, indicate a strong correlation between these residues and D87
that is not seen for two residues (V2 and I4 near the CA N-terminus) that are not part of the observed
pathway.
Analyses of the D87E and D87E-A134V lattices predict e↵ects of the mutations that correlate with the
phenotypes in vivo. The primary route of communication was not altered by D87E (Figure 3.4). However,
the D87E crippling mutation reduced the strength of the dynamic coupling between D87 and each of four
residues in the pathway (E41, Q138, R141 and R145) as indicated by the higher average values compared to
the WT (Figure 3.3, red bars). Also, the high standard deviations observed at points all along the pathway
argue that there is increased heterogeneity in the available pathways in this mutant. The latter is evidenced
by the appearance of residues V40 to L48 from the neighboring monomer in the ensemble of pathways
(Figure 3.4B). Importantly, the A134V compensatory mutation, which is located at the point of cross-over
along the ↵4-↵7 communication path, restored the strength of dynamic coupling that was compromised by
D87E (Figure 3.3C, cyan bars). In contrast, three residues that are not part of the communication pathway
(V2 and I4 in the same monomer and R145 of the adjacent monomer) failed to show similar responses to the
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Figure 3.3: Allosteric pathway in the NTD from D87 residue. Residues 87 and 145 are connected via an
allosteric pathway in the monomeric CA NTD (gray). (A) A pathway for WT with an average dynamic
coupling involve a number of residues to bridge helix ↵4 and helix ↵7. Helix ↵7 of NTD is colored in
yellow while other helices are in light gray. (B) Histogram of the WT residues involved in the allosteric
pathways connecting D87 and R145. L77, V80, A83, S135, A139 were consistently observed as the most
connected residues. (C) The average dynamic coupling between residue 87 with E41, Q138, R141, R145,
V2, and I4 were listed for WT, D87E, A134V, and D87E-A134V mutants. Dynamic coupling is a measure
of the computed path length between two nodes (as described in Sethi et al., ref. [126]) along the optimal
communication path. * indicates coupling across the dimer interface, i.e., between D87 of monomer 1 and
R145 of monomer 2.
D87E and A134V mutations. In total, these findings suggest that A134V suppresses the D87E maturation
defect by correcting defects in long-distance communication caused by mutation in the FL.
43
3.3 Discussion
The flexible loop region, like many parts of CA, plays distinctly di↵erent structural and functional roles
in immature particles versus the mature infectious virions. In the immature particle, the FL is contained
within a larger portion of the NTD region that forms closely packed NTD-NTD contacts [2, 79]. In contrast,
the FL is displayed on the outer capsid surface in the mature virus and does not appear to form direct
protein-protein contacts (Figure 3.5). With this study, we sought to assess the contributions of individual
FL residues to the assembly pathway and thereby provide important functional data in the context of the
RSV structure. Residue D87 at the beginning of the FL (Figure 3.5A) was found to play a dual role,
namely, making important contributions to the functional Gag lattice and controlling core maturation via
long-distance communication with the distal half of helix ↵7.
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Figure 3.4: Histogram of the connecting residues in the accumulated suboptimal paths. L77, V80, A83,
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Figure 3.5: Positions of the key residues at the immature and mature hexamers. The key residues are shown
in spheres (D87 in blue, E99 in red, K107 in yellow, A134 in green, R145 in black). Residues 87 and 134
reside at the NTD dimer interface of the immature lattice (A) while none of the key residues forms any
intermolecular interaction in the mature hexamer (B). Only the NTD and CTD are shown for clarity.
All-atom MD simulations provide both a high-resolution look at the extensive NTD-NTD interfaces of
the RSV Gag lattice and rationale for the assembly-disruptive e↵ects of mutations at key positions. The
major NTD-NTD inter-hexameric dimer interface involves much of the FL with additional contributions
from helices ↵2 and ↵7 (Figure reffl:bothA). In addition, the loop between helices ↵5 and ↵6 participates in
trimeric interactions between NTD hexamers. Throughout this region the R86, D87, R89, E99, and K107
residues participate in an extensive network of electrostatic and hydrogen bonds across NTD-NTD interfaces
as well as intra-molecular interactions within the FL.
D87 sits within a cluster of charged residues (R86-D87-R89) at the end of helix ↵4 and the beginning
of the large ↵4-↵5 loop and is involved in hydrogen and electrostatic interactions both within and between
monomers (Figures 3.1 and 3.2). Disruption of the interactions of D87 with R89, as well as its contacts
with the CA N-terminus, may explain the suboptimal particle release and disordered morphology in vivo as
well as the a ggregation of the mutant Gag proteins upon purification observed with the D87A and D87R
45
mutations [4]. Specifically, loss of the intramolecular D87-R89 salt bridge due to D87A increases flexibility
within the large loop (residues 95-100, see Figure 3.1B) and also allows R89, which is normally constrained
in the WT particle by its interaction with D87, to make rogue inter- and intra-molecular interactions with
nearby residues (Table 3.1). Second-site suppressor analysis had previously suggested a biologically impor-
tant interaction of this N-terminal region with the flexible loop [122].
Similarly positioned D83 and R85 residues occur in the MLV CA and an X-ray crystal structure for an
MLV CA hexameric lattice showed that these make salt bridge interactions around a 3-fold inter-hexameric
interface. Although this arrangement has not been confirmed in immature virions, charge-neutralizing
mutations in this region of the MLV Gag protein led to its accumulation at the cell membrane and destroyed
particle release, consistent with the RSV mutant phenotypes described here [22].
Playing a distinctly di↵erent role than that of D87, K107 lies at the beginning of the ↵5-↵6 loop and,
in the MD model of an assembled Gag particle, at the point of 3-fold lattice symmetry where the three
lysines coordinate a chloride ion [2]. The alanine substitution may introduce variability into hexamer pack-
ing by preventing these local electrostatic interactions, thereby dysregulating normal lattice curvature and
producing the particle heterogeneity observed in K107A by EM and gradient analysis.
3.3.1 Role of the FL in host factor interactions?
The above analyses do not preclude possible e↵ects of some FL mutations on other aspects of the virus
life cycle. It is possible that infectivity defects in some FL mutants, most notably those with mutations
involving the E99, may be due in part to disturbance of interactions between CA and an unknown cytosolic
protein or proteins. E99 lies within the large ↵4 – ↵5 loop in RSV CA which is among the most mobile
regions in monomeric CA (78, 81). This is reflected by the considerable structural heterogeneity of these
loops at various positions in the lattice model (not illustrated here) and the prominent peak in the RMSF
plot centered around residue 97 (Figure 3.1B). E99 interacts with R125 (about 50% of the time in the MD
simulations, see Table 3.1), which anchors the loop to helix ↵7 and potentially provides stability to the
region. However, the assembly of the RSV E99 mutants appears normal. The E99A Gag assembly behavior
was largely una↵ected in vivo and in vitro as were CA assembly and capsid stability [4]. We note that
the structurally analogous loops in HIV and MLV have been implicated in binding of the restriction factors
TRIM5↵ and Fv-1, respectively, and cyclophilin A in HIV [114, 127]. Thus, it is possible that some or all
of the infectivity deficits seen in the E99A and E99Q viruses reflect altered interactions with as yet to be
discovered host factors.
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3.3.2 Contribution of D87 to mature core formation.
The phenotype associated with the charge-conserving D87E mutation indicates a strong influence of this
region on core formation during maturation. Gag function was normal in D87E virus as indicated by both in
vivo analyses and in vitro Gag assembly. However, the released particle cores exhibited a detergent-sensitive
phenotype comparable to that caused by potent maturation-preventing CTD mutations in RSV [4, 89, 123].
Soluble D87E CA protein CA showed no deficit in assembly activity in vitro consistent with the location of
the D87 in the capsid model (Figure 3.5B). Instead, the in vivo core maturation defect is more likely due
to a failure of the Gag interfaces to properly separate upon PR cleavage or otherwise rearrange properly to
allow capsid formation. This is strongly supported by the properties of the spontaneous A134V suppressor,
which corrected both the infectivity and core stability defects caused by D87E and in in silico simulations
counteracted long-range disturbances of inter-molecular bonds involving the lower half of helix ↵7 (Table 3.1).
Such long-range e↵ects of core-maturation suppressors have been a recurring theme in studies of RSV
assembly. Alterations of highly conserved residues in the CTD major homology region sequence compromise
the ability of mature CA to form the CTD-CTD dimer interface. This e↵ect can be suppressed by any one
of several secondary mutations scattered across the CA sequence, including the NTD [123, 128]. Also, a
crippling  -hairpin substitution K5R was optimally suppressed by a combination of two mutations, R86C
and C192R, in the FL and the CTD dimer interface, respectively [122]. In this study, network analysis of the
MD Gag lattice model identified a pathway of communication connecting the beginning of the FL with the
lower half of helix ↵7. The strength of the dynamic coupling between these opposite faces of the NTD was
modulated by the D87E and A134V substitutions in a fashion that correlated with their e↵ects on infectivity
and stable core formation arguing for relevance to the maturation pathway.
D87 contributes to a local network of electrostatic interactions that includes residues near the N-terminus
of CA (Figure 3.1A and refs [2, 79]). Schur and co-authors suggested that cleavages upstream of CA help
to regulate maturation by disrupting the interaction of p10 with the CA NTD [79]. The analyses presented
here suggest an additional possibility for future consideration: that cleavage at the p10-CA junction and/or
folding of the  -hairpin can trigger capsid formation via allosteric signaling across the NTD, promoting the
switching of interactions involving the C-terminal half of helix ↵7 that was previously noted by Goh et al.
[2]. Similarly, dynamic allostery has been observed in assembled complexes of HIV CA, which demonstrate
distal structural alterations when CypA binds [129].
47
3.4 Conclusion
Overall, this study supports a role for FL residues in allowing appropriate NTD packing, leading to the
release of well-formed immature virions, and in the proper management of the many possible electrostatic
interactions that are critical during maturation to allow the CA domains to separate, rearrange and transition
to the final, infectious retroviral capsid. Evolution has selected for an appropriate balance of charge across
the surface of CA and the capsid that permits the competing functions in Gag assembly, core maturation
and the early post-entry events to be accommodated in support of e↵ective virus replication.
3.5 Simulation methods and analyses
Wild-type (WT) model and eight models incorporating the mutations (D87A/E/R, E99A/Q, K107D, A134V
and D87E/A134V) were prepared using VMD [38] based on a previously published structure [2]. Each model
was solvated in a su ciently large water box with salinity set to 150 mM NaCl. All-atom MD simulations
were performed using NAMD 2.10 [37] for 100 ns with positional restraints applied to the lattice boundary
and CTDs. The number and frequency of all intermolecular electrostatic and hydrogen bonds involving
the NTD were calculated and listed in Table 3.1 for the WT and all mutant lattices. For each lattice, the
occupancy of bonding between each pair of residues was averaged over 6 monomers in the central hexamer.
For ease of reading, the prominent interactions (those that occur with > 30% frequency in either the WT or
one of the mutant models) were highlighted. Flexibility of the protein was measured by means of the root-
mean-square fluctuations (RMSF). Additionally, VMD was used to estimate interaction strengths between
subunits using the number of hydrogen bonds between monomers as a surrogate measure [38]. Electrostatic
potentials for the average coordinates of the heavy atoms over the last 50 ns of simulation were determined at
300 K and 150 mM of NaCl, using the PDB2PQR/APBS v2.0.0 suite of programs [130, 131]. The partition-
around-medoids (PAM) algorithm was employed to cluster the structural ensembles from the simulations, the
root-mean-square di↵erence (RMSD) between structures was employed as the criteria for similarity [2]. PAM
identified representative conformations and quantified the relative population between multiple conformers
present during simulation.
Network analysis was performed to quantify the dynamic coupling between residue D87 and the residues
at the NTD-NTD dimer interface [126]. The value of the dynamic coupling is inversely proportional to the
correlation between residues, and it is employed as a measurement of the allosteric communication between
distal residues. Correlation between residues for the central hexamer in the Gag lattice was calculated from
the last 50 ns of simulation using CARMA [132]. Subsequently, optimal communication pathways, with
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their respective dynamic coupling, between residues of interest were calculated employing the subopt feature
available in NetworkTools (http://www.scs.illinois.edu/schulten/software/networkTools/). Additionally, a
total of 1,000 suboptimal paths between D87 and R145 of each NTD dimer in the central hexamer were
identified using Weighted Implementation of Suboptimal Paths (WISP) [133]. Therefore, a total of 6,000
shortest paths were collected for each RSV mutant (Figure 3.4).
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Chapter 4
Host-Pathogen Interactions
Reproduced in part with permission from Boon Chong Goh, Michael J. Rynkiewicz, Tanya R. Cafarella,
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Klaus Schulten and Barbara A. Seaton Molecular Mechanisms of Inhibition of Influenza by Surfactant
Protein D Revealed by Large-scale Molecular Dynamics Simulation. Biochemistry, 52:8527–8538, 2013
(Copyright 2013 American Chemical Society).
4.1 Pulmonary surfactant and lung surfactant proteins
Pulmonary surfactant is a mixture of lipids and proteins which is secreted into the alveoli of the lung.
The two main functions of surfactant is to lower the surface tension at the air-liquid interface thereby
preventing lung collapse during breathing [23, 134] and to provide first line of immune defense against
inhaled pathogens [1, 7].
Surfactant is composed of approximately 90% lipids and 10% proteins. The most abundant lipid
constituent of the surfactant in all mammalian species is phosphatidylcholine (PC) at 80% citeVELD98.
Amongst the PC, approximately 60% is in the dipalmitoylated form, which is also knowon as dipalmi-
toylphosphatidylcholine (DPPC). Phosphatidylglycerol (PG) comprises approximately 10% of the surfac-
tant lipid composition and small amounts of phosphatidic acid (PA), phosphatidylinositol (PI) and phos-
phatidylethanolamine (PE) are found [134]. DPPC lipid is known for generating a near-zero surface tension
at the air-lung interface during compression [23] [13]. The two saturated acyl chains enable the lipid to form
a tightly packed monolayer which can generate these low surface tension values without collapsing. Other
functions of DPPC in intracellular events, such as formation of lamellar body and tubular myelin [135],
transport or secretion, have been suggested but have yet to be conclusively proven [134, 136].
There are six types of surfactant proteins: surfactant protein A (SP-A), SP-B, SP-C, SP-D, and the
recently discovered SP-G [137] and SP-H [138]. These proteins can be divided into two groups, SP-B, SP-C,
SP-G, and SP-H are small hydrophobic proteins that found embeded in lipid membranes [23], whereas SP-A
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and SP-D are large hydrophilic proteins that provide innate immune response against inhaled pathogens [24].
The hydrophobic surfactant proteins are important to maintain the respiratory function of the lungs [138,
134]. However, since SP-B, SP-C, SP-G, and SP-H do not play a role in providing innate immunity, they
will not be further discussed in this chapter.
SP-A and SP-D belong to the collectin (collagen-containing C-type lectin) protein family. C-type lectins
are carbohydrate-binding proteins that bind to the sugar molecules on pathogenic surfaces using calcium
ions. The collectin binding site is therefore referred as the lectin site. SP-A and D are directly related to
the innate host defense of the lung where they recognize, bind and eliminate pathogens using their lectin
sites [24, 1]. SP-A and SP-D act as support roles for the host’s immune system, but in contrast to the
immune system that establishes a learnt response to pathogens the lung surfactant system acts at the very
front-end of the host defense. It relies on an a priori recognition, namely a recognition of sugar molecules
often covalently linked to proteins at the surface of pathogens, in particular, also to the influenza virus.
4.2 Mechanism of Influenza Inhibition by SP-D
4.2.1 Introduction
Influenza A virus (IAV) poses a major global biothreat to humans and animals. Newly emerging viral strains
and viruses from animal reservoirs are responsible for IAV outbreaks that cause widespread illness before
vaccines can be developed. Initial host defense is provided by the innate immune system, which can neutralize
novel viral strains without prior recognition. One of the hosts innate strategies against influenza relies on
collagenous lectins (collectins), which are present in respiratory lining fluids where they participate in front-
line defense against pathogens. Pulmonary collectins, including surfactant protein D (SP-D), are calcium-
dependent (C-type) mammalian lectins that are involved in a wide range of immune functions [139, 140]
SP-D, a pattern recognition receptor present in mucosal secretions, targets glycoproteins on viruses, bacteria,
fungi, yeast and allergens [141] SP-D mediates a wide range of anti-influenza activities [26, 25, 142, 143],
including inhibition of hemagglutination, viral aggregation and neutralization. The major IAV target for
SP-D is the viral glycoprotein hemagglutinin (HA), a major virulence factor which packs densely on the viral
surface. HA plays a central role in influenza infection. It is responsible, through its sialic acid receptor site,
for attaching IAV to sialylated glycoproteins on host cells and facilitating entry of the viral genome. HA on
its own surface expresses high-mannose glycans, particularly a highly-branched nonamannose (Man9), which
are recognized by SP-D through lectin activity. There is accumulating evidence that increased virulence of
HA strains is correlated with evasion of SP-D innate surveillance through loss of HA glycosylation [26, 144].
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Collectins are secreted multi-domain C-type (calcium-dependent) lectins with a short N-terminal do-
main, a collagen-like domain, an alpha-helical neck domain, and a carbohydrate recognition domain (CRD),
which contains the lectin site. Recombinant production of the neck and carbohydrate recognition domain
(NCRD) yields a trimeric unit with lectin activity, capable of binding saccharides and pathogens. Interest-
ingly, whereas wild-type human SP-D NCRD (WT) binds saccharides and HA but exhibits poor antiviral
activity [145, 146], gain-of-function NCRD mutants can be engineered to perform such activities at levels
approaching or exceeding those of native collectins [146]. These mutants are able to aggregate IAV particles,
which is surprising given that they lack the N-terminal and collagen domains of SP-D which are associ-
ated with oligomeric assembly, increased avidity, and the neutralizing and aggregating activity of native
SP-D [146]. This attribute of these mutants was unexpected and up to now unexplained. The mutants have
provided a valuable probe into correlations between HA interactions and antiviral activity in vitro and in
vivo. For example, we have reported that unlike WT, D325A+R343V inhibits seasonal and poorly glycosy-
lated pandemic strains of IAV and protects against influenza infection when administered intra-tracheally
to mice [146].
Molecular recognition between viral glycoproteins and lectins involved in the innate immune response
is poorly understood; little is known beyond the basic knowledge that carbohydrate targets are involved.
Although dozens of crystal structures of HA and of several complexes with antibody Fab fragments have been
reported [147, 148], no protein-HA complexes with innate host defense proteins have been studied at atomic
level detail. Previous computational studies of lectins with anti-influenza activity, namely of SP-D [149, 150]
mannan-binding lectin [151] and galectins [152], have focused on complexes with isolated carbohydrate
ligands rather than with viral glycoproteins. Similarly, computational studies on hemagglutinins [150, 153]
have not addressed binding to lectins; a major barrier has been the large size of the system, necessitating
advanced computational approaches.
In the present studies, we have used X-ray crystallography, molecular modeling and large-scale molecular
dynamics to probe the interactions between SP-D and HA at the atomic level. Our studies target HA from
the A/Aichi/68/H3N2 strain of IAV (also known as X31). This HA has only one N-linked glycan on the head
domain, at residue 165, an important glycosylation site location for H3N2 strains [25], as lack of this residue
is associated with collectin-resistance [26]. We demonstrate that native SP-D possesses antiviral activity
against the Aichi strain, indicating that the 165 N-glycan is su cient for SP-D recognition of IAV. We have
shown previously that SP-D does not inhibit PR-8 (A/Puerto Rico/8/1934/H1N1), an IAV strain that has
no HA head glycans, and that SP-D strongly inhibits Phil82 (A/Philippines/1982/H3N2), which has over
90% sequence identity with Aichi and contains the 165 N-linked glycan among other head glycans [26].
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The present studies o↵er the first computational investigation involving a complex of a full hemagglutinin
trimer and a trimeric NCRD of SP-D. Additionally, the binding a nity between the HA glycan and SP-D
has been studied and compared with experimental data. Comparisons between WT and D325A+R343V
SP-D NCRDs allow the linking of viral neutralization to molecular properties underlying HA/SP-D binding,
thereby promoting a greater understanding of the recognition of IAV by innate host defense molecules.
4.2.2 Results
Comparison of Wild-type and Mutant SP-Ds using MD Simulations
Table 4.1: Simulations performed in this study.
Simulation Description Time (ns) Number of runs
WTS Wild type, equilibration of WT/HA com-
plex with Man9 chain
100 3
DMS Double mutant, equilibration of
D325A+R343V/HA complex with Man9
chain
100 3
WTNS Wild type without sugar, equilibration of
WT/HA complex without Man9 chain
100 1
DMNS Double mutant without sugar, equilibra-
tion of D325A+R343V/HA complex with-
out Man9 chain
100 1
SMS Single mutant, equilibration of R343V/HA
with Man9 chain
100 1
The crystal structure of the D325A+R343V was solved unliganded at 2.1 A˚ resolution and in complex
with Man9 at 3.2 A˚ resolution (PDB identifiers 3G83 and 3G84) [1]. Along with the available structures of
HA and WT SP-D [145, 154], these crystal structures provided the starting structures and positions for the
MD simulations (Figure 4.1).
In simulations WTS and DMS (Table 4.1), both WT and D325A+R343V are found to be stably bound
to HA (Figure 4.1). Furthermore, both SP-D proteins are seen to block the sialic acid binding site of HA
(Figure 4.2). To quantify the inhibition of the sialic acid binding site by SP-D, the sialic acid (SA) accessible
surface area (ASA) was calculated using the rolling ball algorithm [155]. Instead of using the radius of a
water molecule, i.e., 1.4 A˚ for the rolling probe, we used the radius of gyration of sialic acid, i.e. 3.0 A˚, to
evaluate the ASA. As shown in Figure 4.3, both WT and D325A+R343V resulted in similar SA ASA values
of approximately 150 A˚2 at the end of either simulation, carrying out in each case an average over three
independent trajectories. At the beginning of the simulation, the SA binding site was only partially blocked
by SP-D as reflected in an SA ASA value of 200 A˚2. The decrease of SA ASA over time, implying that the
SA binding site becomes less accessible to SA in the course of the simulation. Given that the SA ASA for
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Figure 4.1: View of the entire simulated system. Hemagglutinin (HA) is shown in cartoon and transparent
surface representation in cyan and lung surfactant protein-D (SP-D) is shown in cartoon and transparent
surface representation in green. HA and SP-D are connected non-covalently through a Man9 chain, shown
enlarged in the insert with the sialic acid binding site shown in surface representation in pink, and the
calcium ions of SP-D as orange spheres. Water molecules and ions are not shown.
a fully exposed SA binding site is approximately 450 A˚2, it is apparent that both WT and D325A+R343V
SP-D fully block the SA binding site at the end of the simulations.
The interaction energies between SP-D and HA residues were also monitored. The average total inter-
action energies between SP-D with HA and the Man9 chain are -123 ± 8 kcal/mol (WT) and -142 ± 14
kcal/mol (D325A+R343V); the interaction energies between SP-D and the Man9 chain alone are -87 ± 7
kcal/mol and -97 ± 5 kcal/mol for WT and D325A+R343V, respectively. Table 4.2 shows that the mannose
residue, which is directly bound to the SP-D lectin calcium ion, accounts for about half of the total interac-
tion energy of the protein complex. Such a significant contribution to this interaction underscores that the
sugar-calcium ion interaction at the lectin site is essential for SP-D binding to saccharide ligands.
Two key loop regions were seen in the simulations to inhibit the sialic acid binding site of HA. Table 4.3
lists interaction energies for di↵erent residues of SP-D. Residues 300 to 304 in the short loop (residues 297 –
304) show lower interaction energies for D325A+R343V, while residues 324 to 329 in the long loop (residues
307 – 331) indicate lower energies for WT. Residues 300 to 304 of D325A+R343V are observed to inhibit
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Figure 4.2: Inhibition of the sialic acid binding site. The binding site, located on HA, is shown as a pink
surface; the remainder of HA is shown in cartoon and transparent surface representation in cyan; the Man-9
chain linked to HA is shown in licorice representation in red-orange. (A) HA bound to WT, the latter
shown in cartoon and transparent surface representation in green. (B) HA bound to D325A+R343V, the
latter shown in cartoon and transparent surface representation in purple. Two loop regions of both WT and
D325A+R343V, colored in tan and blue, are seen to cover and thereby inhibit the sialic acid binding site.
Figure 4.3: Accessible surface area of the HA sialic acid binding site. Shown is the time evolution of the
average sialic acid binding site accessible surface area for WT (black) and D325A+R343V (grey) bound to
HA.
the SA binding site while residues 324 to 329 of WT inhibit this site. Residues 300 to 304 and 324 to 329
are highlighted in blue and tan, respectively, in Figure 4.2.
In the simulations the binding of HA with D325A+R343V, but not with WT, reveals involvement of
hydrophobic interactions. Figure 4.4A illustrates the di↵erence in average hydrophobic interaction between
SP-D and HA for WT and D325A+R343V. As shown in Figure 4.4B, Ala325 of D325A+R343V is observed to
interact with another hydrophobic residue of HA, Trp222. Additionally, Pro319 of D325A+R343V interacts
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Table 4.2: Average interaction energies by residues between SP-D and mannose-9 chain only in simulations
WTS and DMS. The three mannose residues nearest to the calcium ion interact strongly with SP-D. The
mannose residue that directly interacts with the calcium ion of the SP-D is labeled with *.
Residue Name
(WT / D325A+R343V)
Average Energy for
WT (kcal/mol)
Average Energy
for D325A+R343V
(kcal/mol)
Di↵erence
(kcal/mol)
MAN503A -1.9 ± 1.4 -5.1 ± 0.7 3.2 ± 2.0
MAN505A / MAN504A* -69.0 ± 0.5 -69.6 ± 0.4 0.5 ± 0.9
MAN504A / MAN505A -11.2 ± 5.1 -14.8 ± 1.8 3.7 ± 6.9
Remaining residues in
Man9 chain
-4.9 ± 1.9 -7.7 ± 5.5 2.8 ± 7.4
Table 4.3: Average interaction energies by residues between SP-D and HA + Man9 chain in simulations WTS
and DMS. Positive values in the di↵erence column indicate that the corresponding residues of D325A+R343V
contribute more towards the overall stability than they do for WT. The interaction energies are averages
over three independent simulations.
Residue Name
(WT / D325A+R343V)
Average Energy for
WT (kcal/mol)
Average Energy
for D325A+R343V
(kcal/mol)
Di↵erence
(kcal/mol)
Label
THR300 -1.2 ± 0.3 -2.9 ± 2.1 1.7 ± 2.4
Short loop
GLU301 -5.1 ± 1.8 -6.8 ± 4.0 1.7 ± 5.8
GLY302 -1.6 ± 1.2 -4.0 ± 0.7 2.7 ± 1.9
LYS303 -1.6 ± 1.1 -3.8 ± 0.2 2.2 ± 1.3
PHE304 -0.3 ± 0.1 -1.8 ± 1.1 1.5 ± 1.2
Residues 300 to 304 -9.8 ± 4.0 -19.3 ± 5.1 9.5 ± 9.1
ASP324 -4.5 ± 3.4 -2.4 ± 1.2 -2.0 ± 4.6
Long loop
ASP325/ALA325 -9.4 ± 2.5 -4.2 ± 0.3 -5.2 ± 2.8
GLY326 -4.1 ± 0.8 -1.5 ± 0.1 -2.6 ± 0.9
GLY327 -4.2 ± 2.1 -0.5 ± 0.1 -3.7 ± 2.2
SER328 -1.6 ± 0.8 -0.3 ± 0.0 -1.3 ± 0.8
GLU329 -12.4 ± 0.9 -7.6 ± 0.2 -4.8 ± 1.1
Residues 324 to 329 -36.1 ± 4.8 -16.5 ± 1.5 -19.6 ± 6.3
GLU333 0.4 ± 1.3 -14.6 ± 0.4 15.0 ± 1.7
ARG343/VAL343 -10.7 ± 4.5 -0.8 ± 0.1 -9.9 ± 4.6
with Ala138 of HA throughout the entire trajectory. It is evident that the Asp-to-Ala mutation of residue 325
increases the hydrophobic interaction between D325A+R343V and HA, and provides additional stabilization
to the complex. This hydrophobic interaction may provide a basis for the enhanced HA binding by the
D325A+R343V mutant compared with the HA binding by the R343V mutant.
As shown in Figure 4.6, the charged residues Arg343 and Asp325 in WT stabilize Man9 chain binding
through formation of hydrogen bonds. As a result of the two mutations, the Man9 chain becomes engaged
in a strong hydrogen bond formed between Glu333 and MAN505A. Despite the stability of the SP-D/HA
complexes in the presence of Man9, SP-D is seen to di↵use away from the SA binding site within the first
40 ns in the absence of the glycan as shown in Figure 4.5, though D325A+R343V without glycan is observed
to di↵use back to its starting location. These results justify the timescale of the simulations, i.e., if an
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Figure 4.4: Hydrophobic interaction formed between SP-D and HA. (A) Shown is the time evolution of the
average hydrophobic contact area between HA and WT (black) or D325A+R343V (grey) in the simulations
WTS and DMS, respectively (B) HA and D325A+R343V are shown in cartoon and transparent surface
representation in cyan and purple, respectively. Hydrophobic interactions arise mainly between Ala325 and
Pro319 of D325A+R343V (labeled green) with Trp222 and Ala138 of HA (labeled dark orange).
SP-D/HA complex is not stably bound together, the SP-D has su cient time in our simulations to leave the
SA binding site by di↵usion.
4.2.3 Discussion
We have undertaken a crystallographically-informed MD approach to investigating SP-D interaction with
HA glycans and its influence on antiviral activity. NMR and MD approaches [156], together with statistical
analyses [157, 158], show that despite the inherent flexibility of glycosidic linkages, branched high-mannose
glycans such as those found on viral surfaces have a limited number of overall conformations. These structures
can be recognized by pattern recognition receptors such as C-type lectins of the innate immune system.
Binding of mannosyl oligosaccharides has been explored structurally for several C-type lectins, including SP-
D [145, 159], mannose binding protein [160, 161], dendritic cell surface receptor DC-SIGN and endothelial cell
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Figure 4.5: Role of mannose-9 chain in stabilizing the complex between SP-D and HA. A comparison of
simulations DMS, DMNS, and WTNS demonstrates the role of the sugar in stabilizing the complex between
SP-D and HA. Shown is the time evolution of the RMSD of SP-D relative to HA for WT (black) and
D325A+R343V (grey) without the mannose-9 chain and for D325A+R343V with Man9 chain.
receptor DC-SIGNR [162, 163], all of which recognize N-linked glycans on viral pathogens such as influenza
and HIV. The crystallographic complexes are similar overall in that the major point of contact between
sugar and protein is at the lectin site; significant contacts with other lectin residues are sparse. Nonetheless,
nearby residues, e.g. Asp325 and Arg343 in SP-D [145, 159], influence spatial accessibility for portions of
the branched oligosaccharide chains, thereby imposing a degree of selectivity. Our previous studies of SP-D
have shown that mutating these residues greatly influences antiviral activities, with D325A+R343V gaining
significant functional capabilities compared with WT. Therefore our studies focus on the dynamic properties
of both WT and mutant SP-D with respect to N-glycan binding and HA inhibition.
Figure 4.6: R343V mutation alters the Man9 binding mode. Figure shows the di↵erence in hydrogen bond
networks for Man9 chain binding for WT (left) and D325A+R343V (right). The red arrows point to the
hydrogen bonds, which are represented as black solid lines. WT and D325A+R343V are shown in transparent
cartoon representation in green and purple, respectively; D325A+R343V calcium ions are shown as orange
spheres; mannose residues are shown in licorice representation with oxygen red, carbon orange and hydrogen
white; protein residues are shown in licorice representation with oxygen red, carbon cyan, nitrogen blue and
hydrogen white.
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Our computational studies of SP-D binding to Aichi HA show excellent agreement with experimental data
for SP-D binding to HA from Phil82, another H3N2 strain containing glycan 165. The critical importance of
the lectin activity in the interaction is underscored in two sets of simulations, WTNS and DMNS, in which
both WT/HA and D325A+R343V/HA complexes exhibit significant fluctuation and drifting in 100ns when
the Man9 chain is absent (Figure 4.5). Similar results were obtained in simulations with porcine SP-D [149].
In prior SPR experiments with Phil82 HA, D325A+R343V was found to bind more tightly than WT, with
mean apparent Kd values of 0.04 nM versus 0.231 nM, respectively [146]. The computational results with
Aichi HA are consistent with the experimental Phil82 HA data in that while WT and D325A+R343V both
bind to the viral glycoprotein, D325A+R343V binds with higher a nity (Table 4.3). The computational
results further suggest that the greater HA binding by D325A+R343V may be due, in part, to higher
glycan binding a nity. Table 4.2 shows that compared with WT, D325A+R343V binds more strongly to
the Man9 chain by approximately 10 kcal/mol. These results are consistent with carbohydrate microarray
experiments in which R343V, which shares the same arginine mutation as D325A+R343V, binds more
strongly to branched mannose oligosaccharides than does WT [145].
The nature of the mutations appears to play a role in the di↵erences between WT and D325A+R343V
in binding Man9. Table 4.2 shows a di↵erence in interaction energies for two neighboring mannose residues,
namely MAN505A/MAN503A for D325A+R343V, and MAN504A/MAN503A for WT. These data suggest
that an increase in interaction energy at MAN505A is due to the Arg343 to Val mutation, consistent with
structural evidence [145]. Detailed hydrogen bond searching allows determination of the key residue that in-
teracts most strongly with the extended glycan chain. Formation of hydrogen bonds between Glu333/Arg349
and MAN505 (labeled in Figure 4.6) is potentiated by the Arg343 to Val mutation, which removes the steric
hindrance caused by Arg343. MD simulations are able to reproduce this feature and suggest that a hydrogen
bond between MAN505 and Glu333 is more likely to form than between MAN505 and Arg349. A decrease
in interaction energy at MAN503A suggests that the Asp325 to Ala mutation stabilizes the binding of the
Man9 chain on SP-D. Ala325 is in close proximity to MAN503A suggesting loss of a steric constraint due
to the Asp325 to Ala mutation. However, simulation SMS with the single mutant R343V does not support
this hypothesis as it shows that Asp325 interacts strongly with MAN503A due to the formation of hydrogen
bonds. Further, crystallographic data regarding the role of Asp325 are obscured by this residues involvement
in crystal contacts [159]. Therefore, the underlying molecular mechanism of the e↵ect of the Asp325 to Ala
mutation on Man9 binding remains unclear.
Mannose interactions are not the only component of D325A+R343V binding to HA. From the interaction
energies calculated from simulations WTS and DMS, D325A+R343V binds more strongly than WT to HA
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by approximately 19 kcal/mol. After subtracting the interactions between SP-D and the Man9 chain, it
is observed that D325A+R343V still interacts more strongly with HA by an average of 9 kcal/mol. This
di↵erence may be explained by protein-protein interactions, particularly hydrogen bonds that form between
the short and long loops of SP-D and the HA surface. It is important to note that the interaction energies do
not account for hydrophobic contributions and that D325A+R343V/HA has higher interaction energy than
WT/HA if one takes only electrostatic interactions into account. As shown in Figure 4.3, D325A+R343V
forms hydrophobic contacts with HA, but WT does not. As a result, D325A+R343V binds more strongly
to HA than does WT by more than 19kcal/mol. The observation of hydrophobic interactions in the DMS
simulation is novel in that protein-protein interactions in mammalian lectins have not been widely described.
The key loop interactions with the SA binding site of HA are di↵erent for WT and D325A+R343V. As
seen in Figure 4.2, Table 4.3, and the interaction energies between SP-D and HA calculated for simulations
WTS and DMS and shown in Figure 4.3, residues 324-329 form the primary, long loop for WT that interacts
with HA and inhibits its SA binding site. Interestingly, for pig SP-D, there is an insertion of three amino
acid residues between residues 328 and 329 [149]. The elongation increases the flexibility of the loop and
may give rise to the enhanced inhibition of pig SP-D activity against IAV [149, 164, 165]. However, in
contrast to WT and pig SP-D, the long loop of D325A+R343V contributes less to the overall stabilization
of the complex; instead, in the D325A+R343V complex, short loop residues 300-304 interact primarily with
HA at the SA binding site. Although the interaction energies for residues on the short loop fluctuate, the
importance of the short loop for D325A+R343V could still be harnessed by averaging the energies over three
independent trajectories.
In addition to using di↵erent loops, WT and D325A+R343V exhibit di↵erent modes of glycan binding
that impact their interactions with the HA trimer. In crystallographic studies of ↵-1,2-dimannose complexes
with WT or R343V, a reversed mode of dimannose binding is observed between the two proteins [145]. In
WT, the non-reducing end of mannose (MAN505A) is bound to the lectin site. In the mutant, MAN505A
occupies space vacated by the mutation and the reducing end mannose (MAN504A) is bound in the lectin
site, where it makes similar interactions as does MAN505A in the WT complex. MAN504A in R343V is
rotated 180  such that its O3 and O4 atoms are swapped compared to MAN505A in WT (Figure 4.6). In
the present liganded D325A+R343V crystal structure, the double mutant binds to the dimannose moiety
of Man9 in a manner similar to the binding of dimannose to R343V, providing further evidence that the
Arg343 to Val mutation is responsible for the altered binding mode [1]. Figure 4.7 shows how these di↵erent
binding modes alter the overall orientation of the modeled HA-SP-D complexes.
We have proposed previously that in D325A+R343V, viral aggregation can be achieved by SP-D-mediated
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cross-linking of HA on neighboring viral particles. Experimental evidence from that study shows that
trimeric D325A+R343V NCRD is nearly as e↵ective at aggregating IAV as is native dodecameric SP-D,
whereas the WT NCRD trimer does not aggregate or neutralize the virus [146]. These observations suggest
that D325A+R343V is able to utilize a mechanism that circumvents the need for an extended oligomer to
aggregate viral particles. Significant di↵erences in spatial orientation adopted by WT and D325A+R343V,
such as those seen in Figure 4.7, could provide such a mechanism by altering the ability to cross-link HA
and promoting viral aggregation and neutralization.
A! B!
Figure 4.7: Di↵erences in orientation in HA complexes with WT (A) or D325A+R343V (B). The end points
of three repeated simulations are overlapped for simulations WTS and DMS, respectively. Calcium ions are
represented in VDW representation in orange, red and white; WT and D325A+R343V are in transparent
cartoon representation in green and purple, respectively; HA is shown in cartoon representation in cyan.
In summary, simulation of entire SP-D/HA complexes has allowed us to investigate the detailed molecular
interactions between SP-D and IAV HA. Using modeling and MD approaches, we have determined that SP-D
not only binds to the glycan chains on HA, but additionally blocks the SA binding site upon binding to the
glycan chains for the H3N2 strain that we studied. To test our hypotheses, site-directed mutants will be
made in the short and long loops to evaluate the in vitro and in silico properties of individual residues, e.g.,
systematic mutation of Ala325 to residues that vary in charge and size should alter interactions with Trp222
from HA. Based on experimental and computational evidence, we speculate that altered binding orientation
and increased viral aggregation, perhaps coupled with the increased binding to HA by the mutant, enhance
the ability of D325A+R343V to neutralize IAV. Viral aggregation studies of novel mutants should address
this speculation. These studies thus shed light on how factors associated with HA binding correlate with
antiviral activities of SP-D.
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4.2.4 Method
Molecular Modeling of SP-D/HA complex
To create the starting model for molecular dynamics calculations, coordinates from three crystal structures
were assembled to form an initial HA-Man9-SPD complex. The model employed the HA crystal structure
from the A/Aichi/68/H3N2 strain (PDB code 1HGE) [154]. This structure was selected because it has only
one glycan on the HA head at N165. The first three sugars of this N-linked glycan (residues NAG500,
NAG501, and BMA502 in Figure 4.8) are visible in the HA crystal structure, while MAN505A, MAN504A
and MAN503A are observed in the SP-D crystal structure. These two sugar chains are connected using the
Man8 chain from an Fab-Man9 crystallographic complex (PDB code 3TV3 [166]) as a structural template
such that the relative position of SP-D to HA is determined. Figure 4.8 shows the resulting model of the
Man9 component of the D325A+R343V/HA complex. This model was the only one consistent with the
crystallographic data and favorable glycosidic linkages.
Figure 4.8: Schematic diagram (left) and structure (right) of the Man9 glycan of HA. Left: Mannose (MAN)
residues are represented as circles and N-Acetylglucosamine (NAG) as squares. MAN504 and MAN505
interact with calcium ions in D325A+R343V and WT and are di↵erentiated in order to specify in the text
which sugar residue actually contacts the ions directly. NAG residues connect Man9 to Asn165 of HA.
Right: MAN505A (conformation as used in this work) binds to the lectin calcium ion of WT, shown as an
orange sphere. Man9 and NAG are represented in licorice with oxygen red, carbon orange, nitrogen blue,
and hydrogen white.
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Since the objective of the molecular dynamics (MD) simulations is to compare the WT/HA and D325A+
R343V/HA complexes, the starting coordinates of both models need to be chosen as similar as possible. In
wild-type or mutant SP-D crystal structures, residues at positions 325 and 343 do not interact in any
way, nor is there any evidence that the side chains contribute to the overall conformation of the lectin
site [145, 146, 159]. Therefore, we used the coordinates of the D325A+R343V/HA complex as a template
to obtain the starting model for WT. We restored the WT structure by mutating Ala325 and Val343 back
to Asp325 and Arg343, respectively. These mutations were made using VMD [38]. Additionally, the Man9
chain had to be remodeled because WT binds to the reducing end of the mannose-9 (Man9) chain (circle in
vertical stripes), while D325A+R343V binds to the non-reducing end (circle in horizontal stripes) as shown
in the schematic diagram of Figure 4.8.
To model the Man9 chain in the WT/HA model, two mannose residues (MAN504A and MAN505A),
which interact with the lectin site of SP-D, were replaced by two corresponding mannose residues found in
the WT/dimannose complex (PDB ID 3G83, [145]) The latter two residues were manually connected to the
remaining 7 mannose residues, resulting in a long bond connecting MAN503A and MAN504A. To correct
this long bond, energy minimization was performed for 10,000 steps on the Man9 chain while restraining the
coordinates of MAN504A, MAN505A and the protein complex. All mannose residues in the minimized com-
plex were found in our calculations to be in the stable chair conformation, indicating that the rearrangement
of the Man9 chain did not introduce large steric and torsional strains onto the chain.
Molecular Dynamics (MD) Simulations
Figure 4.1 shows the protein system that was simulated for the present study: the HA trimer glycosylated
with one Man9 and complexed with one trimer of SP-D (either WT or D325A+R343V) with bound calcium
ions. Table 4.1 lists timescale of the simulations carried out in the present study. Each complex was solvated
in a water box chosen large enough, so that the minimum distance between the complex and the boundary
of the water box is 15 A˚ along all three axes. The system was neutralized with 150 mM NaCl to match
the optimum salt concentration present in in vitro experiments [167]. The final simulated systems contain
approximately 320,000 atoms, including proteins, water molecules and ions.
The systems described were subjected to conjugate gradient minimization for 50,000 steps and subse-
quently heated to 310 K in a time less than 4 ps. The procedure was followed by 0.5 ns equilibration with
all protein and sugar atoms fixed under an NPT ensemble, and 2 ns equilibration under an NVT ensem-
ble. Finally, 100 ns production simulations under an NVT ensemble were performed. To ensure that the
starting structures retain the key interactions, the hydrogen bond network and other non-covalent inter-
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actions between O3, O4 of the calcium-bound mannose residue and the SP-D protein were maintained by
imposing virtual springs to constrain their distances. The constants of these virtual springs were set to
50 kcal mol 1 A˚ 2 during minimization, to 20 kcal mol 1 A˚ 2 during NPT ensemble equilibration and to
10 kcal mol 1 A˚ 2 during NVT ensemble equilibration. The constraints were removed in the final 100 ns
simulation.
All coordinated ligands of the calcium ion were restrained to circumvent potential force field limitations
and preserve the bidentate property of calcium-bound mannose. All 8 coordinated ligands were constrained
with a harmonic potential of the form where k was 1000 kcal mol 1 A˚ 1 and xref was set to 2.41 A˚ [168]
throughout minimization, heating, equilibration and final 100 ns simulations. The constraint is a reasonable
approach given the sub-microsecond timescale of our simulations. Unbinding rates of calcium-bound ligands
are measured experimentally to be on the order of seconds to minutes [169] such that unbinding, impossible
with the constraints impose, is expected to be very rare.
Simulations were performed using the program NAMD 2.9 [37] assuming the CHARMM27 force field
with CMAP corrections [170] for the protein and assuming the TIP3P model for water molecules [100]. The
CHARMM36 force field was used for the sugars [171]. Periodic boundary conditions were assumed, and the
particle-mesh-Ewald summation method was employed for the evaluation of Coulomb forces. The van der
Waals energy was calculated using a cuto↵ of 12 A˚. Temperature and pressure were maintained at 310K and
1 atm using a Langevin thermostat with a damping constant of 1 ps-1 and Nose´-Hoover Langevin piston
methods [172]. The integration time step was 1 fs.
Residue-based interaction energies between SP-D and HA were calculated using a modified generalized-
Born (GB) model [173]. This model considers van der Waals interaction, electrostatics, and a solvation energy
component that takes solvent-polarization into account. The solvent model did not include hydrophobic
interactions, unlike the GB-molecular surface area approach [155]. However, the GB model is a su ciently
good approach to quantify the interaction energies since the interactions between SP-D with HA and man9
involve mostly polar residues.
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4.3 Elucidation of Lipid Binding Sites on SP-A
Surfactant protein A (SP-A), a collagenous C-type lectin, is the most abundant of the surfactant-associated
proteins. SP-A is known to rapidly associate with secreted lamellar bodies and to occupy the corners of
the unfolding phospholipid membranes that ultimately constitute tubular myelin [174, 175], the lattice-like
structure that serves as the reservoir for replenishment of the surfactant monolayer. The critical role of
SP-A in the structure of surfactant aggregates became apparent when it was found that Sftpa-/- mice,
which are deficient in SP-A, lacked tubular myelin [176]. Surprisingly, these animals did not have obvious
alterations in surfactant function, content or secretion that had been predicted by more than a decade
of in vitro experiments, but were found to have defects in host defense when challenged with infectious
microorganisms [177, 178]. Data collected from studying these animals and other experiments suggests
that the association of SP-A with surfactant phospholipids primarily functions to position the protein at
the air-liquid interface as the first line of defense against inhaled pathogens [174, 179, 24, 180, 181]. It is
therefore important to understand the molecular interactions that determine di↵erential binding of SP-A to
phospholipid and microbial surfaces.
Studies of SP-A binding to phospholipids [182, 183] have shown that SP-A binds to phosphatidylcholine
(PC), but not to phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylethanolamine (PE) or
phosphatidylserine (PS), demonstrating that the polar head group influences binding. The protein binds
most avidly to dipalmitoylphosphatidylcholine (DPPC), the major lipid component of surfactant, but not to
other dipalmitoylglycerophospholipids such as dipalmitoylphosphatidylglycerol (DPPG) or dipalmitoylphos-
phatidylethanolamine (DPPE). The length and saturation state of the fatty acid groups in the sn-1 and
sn-2 positions also influences binding; SP-A binds avidly to distearoylphosphatidylcholine but not dimyris-
toylphosphatidylcholine, and fails to bind to l-palmitoyl-2-linoleoyl-dilinoleoylphosphatidylcholine or lysoPC.
The binding of SP-A to phospholipids typically requires calcium. In addition to its key role in the structure
of tubular myelin, binding of SP-A to surfactant membranes has been reported to enhance the resistance
of surfactant to foreign protein-mediated inhibition of its surface tension lowering properties, and to the
recycling of surfactant into type II cells [184].
SP-A also recognizes pathogen-associated molecular patterns (PAMPs) such as the lipid A portion of
lipopolysaccharide of gram-negative bacteria [27]. This interaction is required for the key roles of the SP-
A-mediated immune response against these microorganisms, which includes direct antimicrobial activity,
agglutination, and opsonization. SP-A-sensitive PAMPs typically contain polar domains and hydrophobic
microbial components, such as are found in lipid A [141]. The binding sites on SP-A for DPPC, lipid A
or other lipids are unknown, but the structural features of lipid ligands suggest that lectin-type activity is
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not involved. In the alveoli, SP-A must alternately interact with surfactant membrane interfaces and with
hydrophobic PAMPs. The extent of physical overlap between these ligand binding sites is a major knowledge
gap. Multiple lines of evidence have shown that the carbohydrate recognition domain (CRD) of SP-A is
capable of binding to lipid [185, 186, 187, 188]. Earlier mapping studies using chimeric SP-A proteins that
contained homologous regions from surfactant protein D implicated broad domains in PC binding [189]. The
objective of the current work is to refine our molecular understanding of SP-A/lipid interactions and how
these features influence SP-A function.
In previous crystallographic studies of SP-A [28, 29], we studied a construct containing the entire CRD
and neck domain (NCRD), which recapitulates many of the binding properties of the intact protein. In the
initial report [28], we observed that the tyrosine-rich CRD surface included three surface-exposed tyrosine
residues (Y164, Y208, and Y192) arranged in part as a box-like structure, and a proximal basic cluster
containing two arginines (R216 and R222). Our proposal that these two features together form part of a
PC binding site was supported by the nearby presence of a bound MES (2-(N morpholino)ethanesulfonic
acid) bu↵er molecule, a close structural mimetic of phosphocholine, the hydrophilic component of PC. In
the crystal structure, the MES binding site was not contiguous with the lectin calcium-binding site, and
therefore was inconsistent with a lectin-mediated binding mechanism. The MES site was notable for binding
of the positively charged morpholino group to Y164, one of the aforementioned tyrosines, via an apparent ⇡-
cation interaction. We postulated that for PC, the choline group would associate primarily with the tyrosine
box and that the phosphoryl group would bind to the basic cluster. Unfortunately, analysis of binding
of other ligand molecules to this region was precluded by the presence of crystal contacts and the use of
sulfate salts in the crystallization medium, as the sulfate bound strongly to the basic cluster. We therefore
sought to crystallize an SP-A NCRD/phosphocholine complex in the absence of sulfate, and these results
are reported herein. We further tested the validity of the phosphocholine site using mutagenesis and binding
assays. Finally, we extended these studies to investigate lipid A/SP-A complexes, for which there are no
crystallographic data, utilizing large-scale molecular dynamics simulations to investigate DPPC and lipid A
binding in a membrane milieu. These combined studies present a cohesive view of the molecular interactions,
on an atomic level, of SP-A and two of its major lipid ligands as occur in the presence of membranes.
4.3.1 Result
To obtain both atomic-level description and the dynamical properties of the membrane binding events, a
series of MD simulations were performed on two systems, namely, SP-A on DPPC membrane and SP-A
on lipid A membrane (Table 4.4). SP-A, initially placed 15 A˚ above the membrane, binds firmly to both
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Table 4.4: MD simulations performed in this study
Simulation Description Time (ns) No. of runs
EPC Equilibrium simulation of SP-A on DPPC membrane 200 2
ELA Equilibrium simulation of SP-A on lipid A membrane 200 2
SPC SMD simulation of SP-A on DPPC membrane 41 2
SLA SMD simulation of SP-A on lipid A membrane 53-68 2
membranes after 200 ns of MD simulations, respectively (Figure 4.9).
Figure 4.9: Lipid membrane binding by SP-A simulated using MD simulations. SP-A (ribbon representation
in magenta) di↵uses and binds firmly to the membrane bilayer within 100ns and stayed bound for another
100ns.
The tyrosine residues bind to choline of DPPC lipid via cation-⇡ interaction.
Cation-⇡ interaction, although not being calculated explicitly in a classical force field, is present. Despite
classical force field underestimation of the cation-⇡ interaction [190], we consistently observed binding events
of choline by several tyrosine residues. Therefore, we employed a geometry criterion to count the interaction
in a more qualitative approach [191].
Four tyrosine residues (Y164, Y192, Y208, and Y221) bind frequently to the choline of DPPC (Fig-
ure 4.10B), especially after 100 ns of simulation where all three chains of the SP-A trimer are bound to the
membrane. To estimate the relative strengths of the tyrosine-choline interactions between di↵erent tyrosine
residues, durations of the binding events were calculated and only the events that lasted for more than 5
ns were presented (Figure 4.10C). In simulations EPC, the tyrosine residues (Y164, Y192, Y208) that form
the tyrosine box bind to choline substantially longer than does an isolated tyrosine residue (Y221). The
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isolated Y221 never binds to a choline for more than 10 ns while Y208, the center of the tyrosine box,
showed a binding duration of 30 ns, two times longer than the reported cation-⇡ duration of arginine and
tryptophan [192]. Since the only way Y208 can bind to choline is in the tyrosine box (Figure 4.10A), we
suspect the box-like arrangement of tyrosine molecules amplifies the cation-⇡ interaction.
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Figure 4.10: Tyrosine box amplifies the cation-⇡ interaction. (A, B) Three tyrosine residues form a box-like
conformation to bind with choline, part of the DPPC lipid head group. Occupancy plot (C) and histogram
(D) show the frequency and duration of a choline bound to the key tyrosine residues of SP-A in simulation
ELPC, respectively. SP-A is represented in transparent magenta ribbon, calcium ion is shown as orange
sphere, and DPPC lipid, which comprises nitrogen (blue), oxygen (red), carbon (cyan), and phosphorus
(tan) atoms, is shown in ball-and-stick representation.
Comparison of lipid A and DPPC interfacial binding surfaces in SP-A.
MD simulations also estimate the e↵ect of SP-A binding to multiple lipid molecules. Trimeric SP-A interacts
with more lipid A molecules (13.9 ± 2.0) than with DPPC molecules (9.8 ± 4.4), as measured from the
number of lipid molecules forming hydrogen bonds with SP-A in the last 10 ns of the MD simulations.
SP-A also forms more hydrogen bonds with lipid A (Figure 4.11) than with DPPC because SP-A can
bind not only to phosphate groups of lipid A, but also to the hydroxyl groups of its carbohydrate rings.
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Table 4.5: Evaluation of the strength of interaction between SP-A and lipid membrane. Important SP-A
residues were identified by calculating their average interaction energies with DPPC or lipid A membranes
for the last 50 ns of the simulations. R216, Y221 and R222 form the most consistent hydrogen bonds with
the lipid molecules. Only residues that have the highest hydrogen bond occupancy among the three SP-
A monomers are listed. The occupancy values (in percentage) were calculated for the last 100 ns of the
simulations. For some residues, occupancy of > 100% was observed because two residues can form more
than one bond simultaneously.
Residue of Average interaction energies Hydrogen bond occupancy
SP-A (kcal/mol) (%)
SP-A/DPPC SP-A/lipid A SP-A/DPPC SP-A/lipid A
N162 -6.4 ± 4.8 -6.6 ± 3.7 20 41
N163 -3.3 ± 1.6 -2.8 ± 1.6 3 9
Y164 -5.3 ± 5.9 -7.5 ± 4.2 43 78
Y192 -7.8 ± 6.9 -4.2 ± 2.9 47 65
R197 -21.4 ± 16.1 -21.4 ± 12.5 84 112
K201 -6.1 ± 10.9 -30.3 ± 12.4 40 148
Y208 -2.9 ± 3.0 -2.8 ± 2.4 19 63
R216 -30.0 ± 16.9 -27.1 ± 7.7 82 172
Q220 -14.0 ± 7.6 -10.4 ± 2.9 57 93
Y221 -9.4 ± 7.0 -10.0 ± 2.9 67 96
R222 -22.6 ± 10.6 -22.3 ± 6.2 81 177
Calcium -11.7 ± 7.9 -8.9 ± 2.2 - -
Additionally, hydrogen bonds that involve the basic residues (particularly R216 and R222) and Y221 are
the most consistently formed. The occupancy values for most of the residues listed in Table 4.5 are larger in
simulations ELA (Table 4.4), indicating that SP-A forms more consistent hydrogen bonds on lipid A. Some
basic residues at certain chains have unusually low hydrogen bond occupancy (< 10%) due to lack of access
to the hydroxyl or the phosphate groups of the lipids.
Figure 4.11: Hydrogen bonding plays a more important role for SP-A binding to lipid A than to DPPC. The
hydrogen bonds curves plotted are the average hydrogen bond numbers of the two independent simulations
ELA (black curve) and simulations EPC (gray curve), respectively. See Table 4.4.
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The basic residues contribute the majority of the interaction energies for the protein-lipid interfaces of
both DPPC and lipid A membranes (Table 4.5). K201 plays an important role in forming strong hydrogen
bonds with lipid A, although less so with DPPC. Q220 and Y221 also form hydrogen bonds with the lipid
A phosphate group. Not as prominent as the other basic residues, the hydrogen bonds formed by these two
polar residues are not negligible. Based on the hydrogen bond occupancy, trajectory plots and interaction
energy analysis, SP-A forms stronger interactions, including more hydrogen bonds, more consistently with
lipid A than with DPPC, suggesting that SP-A binds stronger to lipid A than to DPPC.
Di↵erences in the properties of lipid A and DPPC.
Figure 4.12 shows that the vertical (perpendicular to the membrane surface) fluctuation amplitude of DPPC
is almost twice as large as that of lipid A. When SP-A binds to the DPPC membrane, the higher vertical
fluctuation of DPPC increases the frequency of bond breaking and may e↵ectively weaken the binding of
SP-A and DPPC. Evidently, the SP-A DPPC interaction is more intermittent than that with lipid A. SP-A
moves from one DPPC lipid to another throughout the 200 ns simulation, whereas such movement was rarely
observed in SP-A/lipid A binding.
Figure 4.12: The lipid head groups of DPPC have larger vertical fluctuations than lipid A. The normalized
histograms and their corresponding fitted Gaussian curves show that the fluctuation amplitude of DPPC
lipid (gray) is almost twice of that of lipid A (black).
Although lipid A is negatively charged and DPPC is neutral, the electrostatic potentials of both mem-
brane surfaces are similar because the sodium ions from bulk water screens the negative charges of the
phosphate group of lipid A. Figure 4.13 shows that the electrostatic potentials of both lipid membrane
70
surfaces are nearly indistinguishable.
Figure 4.13: Electrostatic potential maps of DPPC and lipid A membranes. The membranes are colored
according to their electrostatic potentials. The positions of SP-A are outlined through thick black lines.
Estimation of relative lipid binding strength of SP-A via Steered Molecular Dynamics
simulations.
To compare the binding strengths of SP-A on DPPC and lipid A membranes, steered molecular dynamics
(SMD) simulations were performed to pull SP-A away from the membrane with constant velocity. The speed
of pulling was chosen to be identical for both systems. The force-extension curves are plotted in Figure 4.14.
The pulling forces of SP-A are consistently larger for lipid A than for DPPC.
Despite the long durations of our SMD simulations (41-68 ns), relatively long for system of this size [193],
the time lengths of the simulations, t0 ⇠ 40 ns, and the typical membrane binding distances (here referred
to as extensions), d0 ⇠ 50 A˚, permitted only pulling velocities of 1.25 A˚ / ns, which are a few orders of
magnitude higher than the velocities in a typical atomic force microscopy (AFM) experiment; as a result, the
pulling forces arising in our simulations are larger than experimentally measured ones [194]. Nevertheless,
as is typical in such cases, the qualitative force-extension profile gleaned from SMD simulations is consistent
with in AFM and optical tweezers pulling experiments [195, 196]. Given the consistent di↵erence of the force
extension curves shown in Figure 4.14, namely forces in SLA runs being higher than forces in SPC runs, our
simulations suggest that SP-A binds to lipid A more tightly than to DPPC as tighter binding implies larger
pulling forces.
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Figure 4.14: A larger force is required to pull SP-A o↵ a lipid A than o↵ a DPPC membrane. The force-
extension curves for simulations SLA (black) show that the applied pulling forces are at least 60% larger
than that of simulations SPC (gray). See Table 4.4.
4.3.2 Discussion
The soluble surfactant protein SP-A undergoes binding to various membrane lipids, including phosphatidyl-
choline from host membranes and bacterial lipids such as lipid A. The binding of peripheral proteins to
such membrane lipids is as yet poorly described on a molecular level. While there are many examples of
peripheral membrane proteins binding to anionic phospholipids, little is known about those binding neutral
phospholipids such as phosphatidylcholine. Still less is known about peripheral binding to microbial lipids
such as lipid A. The techniques used in this present study, namely X-ray crystallography, mutagenesis, and
large-scale molecular dynamics, o↵er an atomic resolution glimpse into the less known interactions and allow
one to construct a detailed model of SP-A interactions for the cases of two key ligands, namely DPPC and
lipid A.
DPPC Binding by SP-A
The present studies reveal that peripheral membrane interactions between SP-A and DPPC rely significantly
upon two structural features of the protein surface: (1) surface tyrosine residues that facilitate cation-⇡
interactions between protein and phospholipid and (2) basic residues, primarily arginines, which stabilize
binding to lipid phosphoryl groups. Cation-⇡ interactions occur frequently in proteins, where they o↵er
structural stability and often participate in ligand binding [197]. Opportunities for cation-⇡ interactions
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are numerous at the membrane interface, an environment often rich in aromatic residues that can serve as
⇡ electron donors [192]. The crystal structure of a phosphatidylcholine transfer protein complex described
an unusual structural motif in which the tetramethylammonium (choline) group of the PC lipid ligand is
held within a three-tyrosine cage via cation-⇡ interactions with the tyrosines [198]. More recently has such
a tyrosine box motif been found in B. thuringiensis phosphatidylinositol-specific phospholipase C (PI-PLC)
and has been identified as a phosphatidylcholine specific membrane targeting motif [191].
We propose that SP-A also contains a cation-⇡ box motif that promotes selective binding of phos-
phatidylcholine. In initial crystallographic studies of a construct based on the SP-A NCRD [28], a belt of
surface-exposed tyrosine residues had been identified, three of which are arranged as an open box. In SP-A
sequences, the three box tyrosines (Y164, Y192, and Y208) are conserved whereas a fourth belt tyrosine is
conserved at position 220 or 221. The invariance of these residues suggest that they play key functional
roles in SP-A, and indeed it has been previously proposed that the site is important for binding to PC [28].
Unfortunately, the earlier studies could not confirm this proposal crystallographically using soaked crystals
since critical crystal contacts occluded the entrance of lipid to the box. However, the initial crystal structure
suggested that there exists another PC binding site adjacent to the box and involving one of the three box
tyrosines, Y164 [28]. In this structure, which contained a MES molecule, the positively charged morpholino
group, analogous to a PC choline, bound to Y164 via an apparent cation-⇡ interaction. To follow up on this
observation, a crystal structure of a complex with POC was obtained, as presented above (see Figure 4.15A).
The choline group also bound similarly to Y164 while the phosphoryl group was bound at a highly conserved
basic cluster consisting of R216, Q220, and R222. Mutagenesis results confirmed the critical importance of
the tyrosines and the basic cluster in binding to DPPC, where mutating R216, R222, Y164 and Y221 to
alanine severely abrogated DPPC binding [7].
To gain further structural and mechanistic information, largescale molecular dynamics simulations using
explicit DPPC membrane bilayer models were undertaken. The advantage of using MD simulations to study
SP-A binding is that multiple binding sites can be identified in a single simulation trajectory. Figure 4.15
demonstrates the accuracy of MD simulations in reproducing the PC binding site observed in the SP-A/POC
crystal structure. More importantly, the MD simulations of SP-A binding to the DPPC membrane revealed
that all four tyrosines participate in PC binding. The binding site that has been suggested by the POC
complex crystal structure (Figure 4.15A) and supported by the mutational analysis [7] was confirmed by
MD simulations. However, the tyrosine box itself also contained a choline group from DPPC, stabilized
by cation-⇡ interactions. Y221, while not part of the tyrosine box, also exhibits cation-⇡ interactions with
DPPC choline. Amplification of the cation-⇡ interaction by the box motif was clearly observed as the tyrosine
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residues that form the tyrosine box were observed to interact with choline for a much longer duration than
Y221, the latter side group not participating in any such structural motif. Such amplification of cation-⇡
interactions due to geometrical arrangement of aromatic residues was also observed in molecular dynamics
studies of PI-PLC [191]. In addition to the cation-⇡ interactions, tyrosines 164, 192 and 221 were also seen
to form hydrogen bonds with the phosphate groups of the lipid molecules.
Figure 4.15: Binding site of POC in SP-A (purple ribbon). The lectin site calcium (orange sphere), key
side chains (licorice), and POC and DPPC (ball and stick) are shown. (A) The final, refined model of
the complex between SP-A and POC obtained from X-ray crystallography. (B) The same binding site as
observed in the MD simulations.
Lipid A binding by SP-A
Lipopolysaccharide (LPS), the major component of the outer leaflet of the outer membrane of gram-negative
bacteria, is a major microbial lipid target for SP-A. Full-length LPS consists of three regions: lipid A, which
is the membrane component, a conserved core oligosaccharide region, and a highly variable O-antigen region.
Studies of LPS of various lengths indicate that SP-A binds specifically to the lipid A component [27], and
that the high saccharide content of the O-antigen region actually inhibits SP-A binding. Therefore, studies
of lipid A binding to SP-A [27, 199] additionally have utilized Re-LPS, a naturally occurring mutant form
of LPS containing only lipid A and two Kdo (3-Deoxy-D-manno-oct-2-ulosonic acid) saccharides from the
conserved core region. For the MD simulations, the pure lipid A bilayer was used because it is a simple and
well-established model [200], and because SP-A specifically targets lipid A.
The greater number of hydrogen bonds between SP-A and lipid A suggests that lipid A binds more
tightly to SP-A than does DPPC. Supporting this idea, experimental measurements have yielded Kd values
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of 5 µM [201] and 28 nM [202] for DPPC and Re-LPS, respectively. Although lipid A does not bind in the
tyrosine box, strong hydrogen bonds are made with the same tyrosine side chains (Table 4.5). Additionally,
the basic cluster which binds DPPC phosphoryl groups also form key electrostatic interactions with the
phosphoryl groups of lipid A. Accordingly, the R216A and R222A mutants show significant reduction in
lipid A binding [7].
Despite the observation from MD simulations that SP-A utilizes a similar group of residues for DPPC
and lipid A binding, SP-A was estimated to bind 60% more tightly to lipid A than to DPPC according to the
peak pulling forces obtained from SMD simulations. Such large discrepancy in pulling forces could largely
be attributed to the dynamic properties of the lipid membranes and the number of lipid molecules bound
to SP-A. Lipid A, approximately twice the size of DPPC, is therefore less mobile than DPPC as clearly
shown by the slower lateral di↵usion (Figure 4.16, refer equation 4.1 and Method to see the calculations)
and the lower vertical fluctuations (Figure 4.12) of the lipid A membrane bilayer. Therefore, the thermal
perturbation on the SP-A/lipid A interactions is e↵ectively damped. Additionally, the fact that SP-A binds
to more lipid A molecules results in further damping of the dynamics of SP-A when bound to lipid A
membrane. As a result, once bound, SP-A does not ‘scoot’ on the membrane surface of lipid A, and SP-A
forms more consistent hydrogen bonds with lipid A than with DPPC.
In their studies of mixed monolayers of DPPC and lipid A or LPS of varying lengths, including Re-
LPS, Casals and coworkers found that the highly miscible mixed monolayers interact strongly with SP-
A [199]. Such monolayers could appear in the lung as LPS from inhaled bacteria becomes incorporated into
DPPC-rich monolayers. Studies from the McCormack lab suggest that binding of SP-A to LPS initiates
membrane permeabilization and direct killing of the bacteria by SP-A [203, 204]. Other studies show that
SP-A destabilizes LPS membrane structure [205]. It is tempting to speculate on the basis of the present
MD simulations that SP-A remains bound to surfactant DPPC until close proximity of the bacterial cell
and bacterial lipids, at which point SP-A transfers to LPS due to its higher a nity binding and initiates
bactericidal activity. However, additional studies are needed to investigate this scenario.
In summary, the present studies utilized MD simulations and other complementary approaches to probe,
at atomic resolution, the interactions between SP-A and the lipid surfaces of DPPC or lipid A. The crystal
structure of a complex of SP-A with POC mimicked specific interactions with the PC polar head, thus
identifying two key components to the SP-A binding site, the choline box and the basic cluster. We further
tested hypotheses regarding the phosphocholine site using alanine mutagenesis and binding assays. We also
extended the present studies to investigate lipid A/SP-A complexes, for which there are no crystallographic
data. For this purpose we utilized large-scale molecular dynamics approaches to investigate DPPC and lipid
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Figure 4.16: Lipid A di↵uses seven time slower than DPPC. Implication of SP-A bound lipid to the mobility
of DPPC lipid as measured from simulations SPC (Table 4.4). The mobility of lipid A does not seem to be
a↵ected by the binding to SP-A. The determination of the lateral di↵usion constant is detailed in Method
below.
A binding in an explicit membrane milieu. The combined studies present a collective view of the molecular
interactions, on an atomic level, of SP-A binding to two of its major lipid ligands, suggesting furthermore a
molecular mechanism underlying the bactericidal activity of SP-A.
4.3.3 Method
System preparation for MD simulations
The SP-A trimer was obtained by using the three-fold symmetry properties of the monomer. Two cysteine
residues C135-C226 and C204-C218 were cross-linked using psfgen in VMD [38]. An equilibrated structure
of DPPC membrane was obtained from a previous study [206]. To accommodate a su ciently large binding
area for the SP-A, four identical membrane bilayers were merged into a DPPC membrane bilayer of area
142 A˚ ⇥ 142 A˚. The resulting membrane, with 648 DPPC lipid molecules in total, was further equilibrated
for 20 ns under NPT-  ensemble. The structure of the lipid A monomer was obtained from Wu et al [200];
288 lipid A monomers were arranged into a bilayer configuration of an area of 142 A˚ ⇥ 156 A˚ and the
membrane was equilibrated for a total of 30 ns under NPT-  ensemble. The phosphate group of the lipid A
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was protonated such that each lipid A had a -2 charge to mimic the physiological condition of the bacterial
membrane. The shape of the carbohydrates of lipid A were maintained in the chair conformation by imposing
additional restraints on the glucosamine rings.
MD simulations
All coordinated ligands of the calcium ion were restrained to maintain the expected lectin site structure. The
6 coordinated atoms of the calcium were constrained with a harmonic potential of the form U(x) = k(xxref )2,
where k was 1000 mol 1 A˚ 2 and xref was set to 2.41 A˚ [168] throughout minimization, heating, equili-
bration, and production simulations [1]. SP-A was placed ⇠15 A˚ above the membrane bilayer. The whole
system was minimized, heated up and equilibrated for 5 ns with the backbone of SP-A constrained. Simula-
tions were performed under NPT-  ensemble using the program NAMD 2.9 [37] assuming the CHARMM36
force field for the protein [99] and lipid [206], and assuming the TIP3P model for water molecules [100].
Periodic boundary conditions were assumed, and the particle-mesh-Ewald (PME) summation method was
employed for the evaluation of Coulomb forces. The van der Waals energy was calculated using a cuto↵ of
12 A˚. Temperature and pressure were maintained at 323 K and 1 atm using a Langevin thermostat with
a damping constant of 1 ps 1 and Nose´-Hoover Langevin piston methods [172]. The integration time step
was 2 fs with all bonds involving hydrogen atoms constrained using SHAKE algorithm [207].
Steered Molecular Dynamics (SMD) simulations
With SP-A bound to membranes after 200 ns of simulation, SMD was used to apply a force perpendicular
to the membrane to pull the SP-A o↵ the membranes. The phosphate atoms of the bottom layer of the
membrane bilayer were restrained such that the vertical motion is subjected to a harmonic potential with a
force constant of 1 mol 1 A˚ 2. Note that the lipids can di↵use freely in the lateral direction. The last 10
C↵ atoms of the N-terminus of SP-A trimer were pulled with a constant velocity of 1.25 A˚ /ns and a spring
constant of 0.1 Nm 1 for 41 – 68 ns.
Analysis of MD trajectory
PME electrostatic potential maps and the binding footprint of SP-A were calculated using the PME elec-
trostatics and Volmap plugins in VMD [38]. The number of hydrogen bonds formed between SP-A and lipid
molecules and their occupancies were calculated using the Hydrogen-Bonds plugin in VMD. Residue-based
interaction energies between SP-A and the lipid molecules were calculated using a modified generalized-Born
(GB) model [173, 1]. This model considers van der Waals interaction, electrostatics, and a solvation energy
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component that takes solvent-polarization into account. All the graphs were plotted using Matlab versions
R2015a.
Calculation of lipid lateral di↵usion
Lateral di↵usion constants of DPPC and lipid A can be calculated as follows [208],
D =
MSD
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h
yi(t)  yi(0)
i2 (4.1)
where MSD is the lateral mean square displacement of lipid, t is total simulation time, i is the individual
lipid molecule and N is the total number of lipids in the membrane.
E↵ect of SP-A binding on DPPC and lipid A.
Table 4.6: Lateral di↵usion constant of lipids at di↵erent conditions.
Condition of lipid Lateral di↵usion constant, D (10 7cm2s 1)
Bound DPPC lipids 1.8 ± 0.4
Freely-moving DPPC lipids 2.5 ± 0.4
Bound lipid A molecules 0.42 ± 0.19
Freely-moving lipid A molecules 0.35 ± 0.17
SP-A-bound lipid is defined by lipid molecules that are within 30 A˚ from SP-A. SP-A binding has a
noticeable e↵ect on the di↵usion of DPPC lipids, reducing the lipid mobility by 28%; whereas SP-A binding
has no statistically significant e↵ect on the mobility of lipid A. Additionally, judging from the freely-moving
lipids, DPPC lipids di↵use laterally about seven times faster than lipid A molecules.
4.4 Conclusion and future work
In summary, all-atom MD simulations of the trimeric structures of SP-D and SP-A have allowed us to
investigate the detailed molecular interactions of SP-D/influenza and SP-A/lipid, respectively.
Using modeling and MD approaches, SP-D was found to not only binds to the glycan chains on HA, but
more importantly blocks the sialic acid binding site upon binding to the glycan chains. In the future, HA
from other strains will be investigated to test the generality of our conclusions. For example, HA glycan 104,
a functionally important site found in most H1N1 strains, is also located near the SA site and may similarly
block it. We additionally have suggested means through which binding of HA glycans by D325A+R343V
could lead to increased viral neutralization. These studies will shed light on how factors associated with HA
binding correlate with antiviral activities of SP-D.
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Non-canonical lipid binding site of SP-A was studied via a combination of MD simulations and experi-
ments for two types of lipids: DPPC and lipid A. MD simulation is a unique tool to study the lipid binding
mechanism as it can investigate lipid membrane binding event in atomistic detail, obtaining information that
no experiments can provide. Together with X-ray crystallography data and ELISA binding experiments, this
study presents a collective view of the molecular interactions, on an atomic level, of SP-A binding to two of
its major lipid ligands, suggesting a molecular mechanism underlying the bactericidal activity of SP-A.
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Chapter 5
Computational Design of Antibodies
5.1 Background of antibody design and the role of MD
Computer-aided drug design has been widely used to invent novel small-molecule drugs [209, 210] and
studying antiviral drugs using MD and other computational methods are increasingly popular [5]. These
methods help to guide experiments in optimizing a nity and specificity for a target. Compared to drug
design, computational antibody design is relatively new and the tools are not as well developed and less
broadly used [211].
An antibody consists of two types of chains, the light and heavy chains. The antigen-binding site is
located in the ‘variable’ domains of each chain, VL andVH. The antigen-binding sites are called CDRs
(Complementarity Determining Regions) and are composed primarily of six ‘hypervariable’ loops, three on
the light chain (L1, L2 and L3) and three on the heavy chain (H1, H2 and H3). The remainder of the
variable domains is structurally well conserved at the backbone level, and aligning antibody sequences is
straightforward. An unexpected discovery in the 1980s revealed that most of the CDR loops (all but H3)
adopt a limited number of conformations called canonical structures [212, 213]. For these reasons, a primary
focus of antibody modeling is predicting the conformations of the CDR loops from their sequences.
There are several antibody design programs such as RosettaAntibody [30], ROSIE [31], OptCDR [32]
and OptMAVEn [33]. OptMAVEn [33] had been developed and employed in the past without use of MD
simulations. MD simulations have previously been applied to investigate antibody-antigen interactions [34,
35]. However, these simulations are often short (5 ns) and therefore insu cient to assess the binding stability
of the antibody. In this chapter, we will describe how long time-scale MD simulation was integrated into
OptMAVEn to improve the original design protocol and thereby developing antibodies with higher-a nity
binding.
The work presented in Section 5.2 was carried out for the purpose of developing new methodology [8]. To
establish solid test criteria, a 12-residue peptide (dodecapeptide) antigen chosen was one for which a native,
i.e., highly evolved, antibody existed already, namely 2D10. The new method, termed OptMAVEn-MD,
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is an extension of OptMAVEn with MD added to optimize and refine the antibody designs. Several novel
antibody designs were predicted computationally to bind strongly the antigen, and they were subsequently
validated experimentally to bind to the antigen with a nities comparable with that of 2D10 [8].
With the new method in hand, we are currently employing OptMAVEn-MD to design antibodies that
target the glycoprotein of Ebola (Section 5.3). Since the Ebola glycoprotein is almost a hundred times larger
in size than the dodecapeptide, it presents a new set of challenges for de novo antibody design where a
number of modeling and design methodologies have to be developed to overcome these challenges.
5.2 De novo design of peptide-binding antibodies
5.2.1 Introduction
Traditional therapeutic antibodies against a target antigen are often isolated from humans or raised in an
immunized animal. Although these traditional methods are e↵ective, they remain time-consuming, lack of
the ability to target a specific epitope and to tolerate rapid changes of antigens [214]. Hence, advances in
antibody design technology and a deeper understanding of the action of therapeutic antibodies are required
for improved therapeutic antibodies [215]. Computational methods for the de novo design of a fully human
antibody against any specific antigen provide a route to resolve these issues [33]. This strategy, if validated,
could o↵er a general route to therapeutic antibodies for many pathogens that have resisted traditional vaccine
development, including highly antigenically-variable viruses such as HIV, influenza and Ebola virus.
A computational framework named Optimal Method for Antibody Variable region Engineering (Opt-
MAVEn) [33] was previously developed for the de novo design of fully-human antibody variable domains
to bind any specified antigen by assembling the six best-scored modular antibody parts (MAPs) [216].
OptMAVEn, which performs antibody design in two phases: antibody generation (phase A) and antibody
maturation (phase B). Phase A involves generating antibodies from a library of antibody fragments [216],
docking the generated antibodies to the target antigen, and score the resulting antigen-antibody complexes
by their interaction energies. Phase B mimics the natural evolution of an antibody in vivo by mutating the
amino acid residues of the antibody to enhance the interaction of the antigen-antibody complexes generated
from phase A. The goal is to increase the binding constant between antibody and the given antigen by in-
troducing computationally mutations into the antibody. The resulting antigen-antibody complexes are then
scored computationally according to their antigen binding energies. Typically, around 5-10 complexes with
the lowest interaction energies are selected for experimental validation. At this point starts the costly ex-
perimental phase of the project. The computationally determined antibodies are manufactured and exposed
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to the antigen. Dissociation constants, Kd, of the antibodies are measured using biolayer interferometry;
smaller Kd corresponds to a higher binding a nity.
This idea is inspired by the natural evolution of an antibody in vivo, in that the gene of a germline
antibody variable domain is initially assembled by combining random variable (V), diversity (D), and joining
(J) germline genes to create an antibody variable domain [217]. We have created the MAPs database [216]
analogous to the naturally occurring human repertoire of V, D and J genes. The primary advantage of
using MAPs to de novo assemble an antibody model is that the computational overhead is manageable
as the need for de novo folding calculations is bypassed by assembling structural domains. In addition,
compared to traditional fragment-assembly-based approaches [218] for de novo protein structure prediction,
OptMAVEn e ciently samples both local and non-local contacts that are inherently present in the relatively
large structural fragments. The designed sequences therefore should have a higher probability of proper
folding. Although OptMAVEn is capable of generating novel computational antibody models with numerous
interactions with their target epitopes, the feasibility of this protocol has not been validated by experiments
until now.
The success rate of computationally-designed antibodies, unfortunately, is very low. The calamity can
partly be attributed to the lack of dynamic information during the design process as only static structures are
considered. To generate antibodies of high quality, MD simulation is incorporated in the present study into
the design workflow of OptMAVEn to account for the dynamic nature of the antigen-antibody interaction.
For this purpose the antigen-antibody complexes generated from phase A of OptMAVEn are subjected to MD
simulations. The antigen-antibody complexes are each simulated independently at physiological temperature
for 100 ns of equilibrium simulation. The outcomes of the MD simulations are the structures reached at the
ends of the equilibration runs. The outcomes are categorized into consistent binding, altered binding, partial
binding and unbinding cases depending on if the antigen remained, at the end of the 100 ns simulations,
completely bound to the same binding pocket, relocated to a new binding pocket, partially bound, or
completely unbound. The designs with the antibody unbound from the antigen were discarded from the
design workflow. The simulated structures of the designs with bound or partially-bound antibody are used
as input structures for phase B of OptMAVEn. The top antibody designs, ranked by their antigen-antibody
interaction energies, are then selected for experimental validation.
Using OptMAVEn, we de novo designed single-chain variable fragment (scFvs) antibodies against the
dodecapeptide antigen DVFYPYPYASGS. The dodecapeptide with its Tyr-Pro-Tyr motif mimics the carbo-
hydrate methyl ↵-D-mannopyranoside, which has been studied extensively since it is the recognition target
of lectin concanavalin A (con A) and mAb-2D10 [219, 220]. Association with the two antigens (dodecapep-
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tide and methyl ↵-D-mannopyranoside) occurs at di↵erent sites for con A; therefore, from crystallization
data [221], molecular recognition for both the antigens was not attributable to their structures [220]. Be-
cause 2D10-Fab (fragment antigen-binding) could not be crystallized, a shorter recombinant scFv-2D10 was
constructed, refolded [222], and crystallized with both antigens which revealed that 2D10 has a rigid binding
site that does not change upon antigen binding [220]. We chose scFv-2D10 to test the OptMAVEn designs
because it can be produced in Escherichia coli, activated by in vitro refolding [222], has a crystal structure
bound to the dodecapeptide (PDB ID 4H0H) [220] and has an antigen (dodecapeptide) that may be easily
synthesized.
We designed five de novo scFvs possessing distinct sequences compared to all existing natural antibody
sequences that can bind with the dodecapeptide antigen using OptMAVEn. Since the stability and activity
of a protein often depend not only on its static structure but also on its dynamic properties [223, 2], an
additional conformational sampling and stability evaluation using long-time MD was added to the standard
implementation of OptMAVEn.
In the present study, 31 top-performing antibody designs were generated in OptMAVEn. Each antigen-
antibody system was subjected 100 ns of equilibrium simulation. Out of the 31 antibody designs, 4 designs
completely unbound from the antigen. The 4 bad designs were removed from the design workflow; the
27 simulated structures of the antigen-antibody complexes underwent in silico a nity maturation where
mutations were computationally introduced to enhance binding. Finally, 5 top-ranked antibodies were
chosen for experimental validation, where the binding a nities between the antibody and antigen were
measured.
Notably, the sequences of the top 5 antibodies di↵er by 41-57% amino acids compared to scFv-2D10.
Furthermore, sequence comparisons between the five designed sequences reveal on average 49% amino acids
di↵erences between them. The lack of sequence similarity demonstrates that the OptMAVEn procedure
broadly samples the vast sequence space and arrives at designs unbiased by the original antibody residue
composition. All five scFvs were found to be actively folded and stable in solution, and three of the scFvs
showed high binding a nity to the dodecapeptide antigen (nanomolar level) while exhibiting diverse binding
modes to the antigen.
The MD simulations performed in the present study not only assessed the stability of the antigen-antibody
complexes, but also refined the binding interface of the antibodies that is instrumental to the accuracy of the
antibody maturation calculations. In short, OptMAVEn combined with MD simulation (OptMAVEn-MD)
has been demonstrated to have a great capability in generating thermally-stable and high-binding-a nity
antibodies via de novo design and in silico optimization.
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5.2.2 Computational workflow
OptMAVEn [33] was used to de novo design a complete antibody variable domain targeting any specific
epitope by expanding the concepts pioneered in OptCDR [32]. However, OptMAVEn does not directly
account for antibody dynamics. Protein design procedures as OptMAVEn often generate designs with
poor stability characteristics given that functional sequences are so close to the limit of thermodynamic
and colloidal stability [224, 225]. It was found that a pre-screening step using MD simulation prior to
experimental testing is indispensable for discarding designs that exhibit poor stability and other design
flaws that are inaccessible to static evaluations [226]. Therefore, we introduced all-atom MD simulation into
our design protocol for which we refer the updated program as OptMAVEn-MD. Figure 5.1 pictorially depicts
the design workflow of OptMAVEn-MD: (1) Sampling of dodecapeptide (DVFYPYPYASGS) (Figure 5.1A)
conformations in the antibody-binding site (Figure 5.1B); (2) Assembly of germline antibodies (variable
regions of heavy and light chains) by best V, D, J modular antibody parts (MAPs) (Figure 5.1C); (3)
Structural refinement and stability evaluation using MD (Figure 5.1D); and (4) Iterative sequence design
and structural relaxation to select a nity mature antibody sequences (Figure 5.1E).
5.2.3 Conformational refinement and stability evaluation using MD
simulations
Computational de novo design of “germline” antibodies binding the dodecapeptide.
Figure 5.1 shows steps 1 and 2 generated “germline” antibody models with favorable interactions with the
antigen. In step 1, over 200,000 dodecapeptide conformations were sampled within the antibody-binding
site which is represented with about 2,000 grid points. The top 2,000 best combinations of MAPs parts
were selected based on mixed-integer linear programming (MILP) [33]. In step 2, interaction energy (IE) or
root-mean-square deviation (RMSDs) between the docked and best-positioned antigen conformations filters
to select thirty-one best de novo designed “germline” antibody models assembled by six MAPs from the top
2,000 candidates for further evaluation using MD simulation [8]. In the 31 designs, V and CDR3s parts in
both VH and VL exhibit considerable diversity, in accordance with their critical roles in recognizing di↵erent
antigen poses.
MD simulation
In step 3, all-atom MD simulations were performed to evaluate the binding stability of the antibody and to
refine the binding interface between antibody and antigen. Each one of the 31 antigen-antibody designed
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Figure 5.1: Strategy employed by OptMAVEn-MD for de novo antibody design. (A) Antigen dodecapeptide
(PDB 4H0H) [220]. (B) Step 1: sample antigen positions in a predefined antibody binding site. The binding
site is represented by a rectangular box that covers all mean epitope coordinates by analyzing 750 antibody-
antigen structures which are superimposed onto a reference antibody structure whose coordinate center of
CDRs attachment points was placed at the origin. (C) Step 2: assign best V, D and J MAPs antibody
modular parts [216] to assemble the germline antibody models against the dodecapeptide. (D) Step 3: refine
the antibody-peptide conformation using MD simulations. (E) Step 4: select the favorable mutations in
the antibody to improve the stability and binding to the dodecapeptide. These images were created and
provided by Dr. Tong Li.
complexes generated under OptMAVEn-MD steps 1 and 2 were simulated for 100 ns. Based on the dynamic
characteristics of the antigen observed in the MD simulations (Figure 5.2A), we categorized our designs
into four groups: stably bound (MD SB), relocating/reorientation (MD RE), partially bound (MD PB) and
unbound (MD UB). Eight (group MD SB) of the 31 designs (Figure 5.2B) remained stably bound to the
antigen throughout the 100 ns-long MD simulations. Four out of the eight stable complexes remained bound
to the antigen with an average root-mean-square deviation (RMSD) of less than 5 A˚ from the original coor-
dinates. In all eight designs of group MD SB, MD simulations show some backbone flexibility of the CDRs
loops (Figure 5.2B). In addition, the side-chains of several residues in direct contact with the dodecapeptide
undergo reorganization in order to form more favorable contacts (Figure 5.2B). The ten designs in group
85
MD RE exhibited even more significant conformational changes with antigens relocating to new binding
pockets (Figure 5.2C) or re-positioning in the original pocket (Figure 5.2D). From the remaining thirteen
germline antibodies that did not show stable binding to the antigen, nine designs (group MD PB) dynami-
cally evolved to only partially bound antigens (Figure 5.2E) while four (group MD UB) became completely
unbound from the complex during the MD simulation (Figure 5.2F) and thus rejected. Finally, a total of 27
designs from groups MD SB, MD RE and MD PB (Figure 5.2G) with either MD-refined or initial geometries
were retained and submitted for in silico maturation for improved a nity.
A nity maturation
The assembled “germline” antibodies were expected to have only low or moderate binding a nity to the
antigen. To further enhance antibody a nity we performed in silico a nity maturation (step 4) to the
MD-refined “germline” antibodies by randomly selecting mutations that are predicted to improve binding
energy. 27 “germline” antibodies refined by MD were submitted for in silico a nity maturation. The
complex and IEs were used to evaluate the stability of the complex and the binding strength between the
antibody and antigen, respectively. Not surprisingly, we found that the best ten designs with the lowest IE
(ranging from -550 to -360 kcal/mol) were from groups MD SB (four) and MD RE (six) while none were
from group MD PB (Table 5.1). The results reflect the di culty in introducing favorable interactions to
designs with antigens partially bound.
Designs from group MD SB were preferred as the binding location and mode was fully retained after
MD simulation [227]. We selected four designs from group MD SB with the lowest complex and interaction
energies (Table 5.1) denoted as scFv-1 (120 6290 1), scFv-2 (120 15439 2), scFv-3 (140 10149 1) and scFv-4
(140 15899 5). In addition, we selected design scFv-5 (200 15222 5) that did not have one of the lowest
complex and interaction energies but possessed the same binding mode as the selected design 200 15222 2.
It is important to note that in the five selected designs the sequence distribution of mutations involved
in a nity maturation is very diverse, with no clearly preferred amino acids/positions. The five antibody
designs (scFv-1 to scFv-5) were chosen for experimental characterization.
Diversity of antibody binding sites
Three out of the five designs, namely scFv-1, scFv-2 and scFv-4, exhibited low nanomolar to the dode-
capeptide in the binding a nity range [8]. Their respective residue compositions were assessed to identify
structural determinants favorable for binding. Interestingly, there is a noticeable decrease of aromatic
residues especially tyrosine, which is consistent with the trend of in vivo somatic hypermutations of natural
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Figure 5.2: Binding stability assessed by MD simulations. (A) Time evolution of the RMSD values during
the 100 ns MD simulations of the 31 antibody designs complexed with the dodecapeptide. (B)-(F) Snapshots
of representative designed scFvs complexed with the dodecapeptide during simulations. (B) Antigen stably
bound. The scFv remains stably bound to the dodecapeptide in the same binding pose during 100 ns
of simulation with an accompanying rearrangement of a few residues (shown in sticks) surrounding the
dodecapeptide. (C) Antigen relocation. The dodecapeptide relocates to a new binding pocket. (D) Antigen
reorientation. The dodecapeptide remains in the same binding pocket but executes a significant orientation
change. (E) Antigen partially bound. Parts of the dodecapeptide become unbound. (F) Antigen unbound.
The dodecapeptide shifts out of the binding site. (G) Flowchart of the selections of ”germline” antibodies
using MD for further in silico a nity maturation. These images were created and provided by Dr. Tong Li.
antibodies [228]. Tyrosine, which can provide hydrogen bonding and substantial hydrophobic interaction, is
frequently found in the paratope of germline antibodies to promote low-a nity binding to new antigens [229].
Another apparent trend is that charged residues are favorable in high-a nity mature sequences. More polar
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and charged residue occurrences contribute to the improvement of binding a nity and complex stability
in the solvent. A comparison of mutations before and after a nity maturation demonstrates that the net
overall e↵ect is a migration from residue types that could provide nonspecific binding to new ones that
generally provide specific binding.
5.2.4 Discussion
Despite significant progress over the past few years, the success rate of computationally designed libraries
of antibodies to bind di cult-to-target epitopes is still very low [211]. This calamity is mostly due to
our limited understanding of the process of antibody a nity maturation in vivo. It is often unclear how
germline antibodies are assembled in the first response to antigens and how the mutations selected during
the a nity maturation process contribute to improving binding a nity or other properties such as selectivity
or stability. To overcome these challenges, an approach named OptCDR [32] was first developed to provide
the first formal computational workflow for optimally selecting the residue composition of the CDRs to
enhance binding for a given antigen. Moving beyond CDRs to the entire variable region, OptMAVEn [33]
was developed for de novo designing the entire variable region of antibodies by drawing structural parts from
the MAPs database [216]. The epitope-focused antibody design approach had been a conceptually-appealing
but unproven method. In the present study, we aimed to experimentally validate this approach by designing
antibodies against a small peptide.
Despite the challenges encountered in the de novo design of antibodies, simulating the in vivo steps of
antibody generation and evolution in silico was shown here to be successful for the de novo design of stable
and high-a nity antibodies targeting a 12-mer antigen. Five antibodies in the format of scFv emerged as
anti-peptide candidates for experimental characterization, on the basis of optimal binding energy to the
antigen and the MD-confirmed stability of the complex. Among them, three show experimentally-validated
binding to the dodecapeptide in the low nanomolar range without any directed-evolution e↵ort. To our
knowledge, the three scFvs are the first experimental validated high-a nity antibodies completely de novo
designed.
The successful rate (three successful in five designs, 60%) in de novo antibody design using OptMAVEn-
MD is much higher than those of de novo protein binder design against the steroid digoxigenin (2 successful
in 17 designs, 12%) [230] and stem region of influenza hemagglutinin (2 successful in 73 designs, 3%) [231].
The high success rate quantitatively demonstrates the e ciency of OptMAVEn-MD in capturing the critical
structural features of antibodies responsible for the tight binding to antigens. Due to the similarity of general
structures of the antibodies, de novo antibody design with our strategy could e ciently sample both local
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and non-local contacts that are inherently present in the antibody structures. All-atom explicit-solvent MD
simulations have previously proved to be e↵ective at discerning stable from unstable homology models of
spacer peptide in immature retrovirus [2], and aiding in the prediction of a novel paratope of lung surfactant
protein D against hemagglutinin of influenza A virus [1]. Inspired by these success cases, we carried out
MD simulations for all de novo designed “germline” antibodies with the dodecapeptide prior to in silico
a nity maturation and experimental validation. The high success rate by finding successful designs from
the MD-stable group demonstrates that MD simulation can serve as a good filter for removing undesirable
designs and suggests that MD-based assessments should be incorporated into computational protein design
as a routine approach for involving dynamic properties of proteins in the selection. Encouragingly, all three
of our designs exhibit high binding a nities to the antigen, suggesting the potential of completely bypassing
the laborious and time-consuming in vitro-directed evolution and directly obtaining high-a nity antibodies
against a specific antigen.
Furthermore, the di↵erences with our scFv designs and the naturally-occurring antibodies suggest that
computational de novo designs generate a variety of possible antibody solutions binding to the same antigen
alluding to a plethora of possible binding possibilities to achieve high a nity. Given that OptMAVEn-MD is
epitope-specific implies that a cocktail of antibodies, containing multiple antibodies that each target di↵erent
epitopes of the antigen, may be designed simultaneously. A cocktail of therapeutic monoclonal antibodies
might tolerate better the mutations of the antigens and show better e cacy than single monoclonal antibody.
For example, ZMAb, a combination of multiple-neutralizing monoclonal antibodies that recognize three
di↵erent areas of the Ebola envelope GP protein have been shown to be an e↵ective strategy to improve
survival of Ebola-infected patients [232].
In the present study, OptMAVEn-MD simulation successfully generated high-a nity antibodies against
a linear epitope consisting of residues that correspond to a single segment of the amino acid sequence of a
peptide/protein. The proposed methodology can be extended in a straightforward manner to account for
discontinuous epitopes that include most of B-cell epitopes [233]. The methodology holds also great promise
for streamlining and greatly facilitating the development of high-a nity antibodies for a variety of di↵erent
antigens such as virus envelope proteins (e.g. HIV GP120/GP41).
5.2.5 Methods
Computational generation of peptide-binding antibodies
A library of “germline” antibody models was constructed to target each antigen pose by assembling six
modular antibody parts (MAPs) [216]. Antibodies were previously constructed in the spirit of template-
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based modeling, with each part being a prototype structure of the random variable (V), diversity (D), and
joining (J) regions in the MAPs database [216].
The designs were initiated by sampling positions of the dodecapeptide antigen (DVFYPYPYASGS)
(PDB 4H0H, chain D) [220]. All dodecapeptide residues were identified as the epitope. Over 300,000 initial
positions of the antigen were generated. After a series of filtering, 31 antibodies were chosen for further
refinement and stability evaluation using MD simulations.
Molecular dynamics simulations of the designed antibodies with dodecapeptide
Each antibody-antigen complex was simulated for 100 ns to access its binding stability and dynamics.
Simulations were performed using NAMD 2.10 [37] with the CHARMM36 force field [99] for the protein and
the TIP3P model for water molecules. Each model was solvated in a su ciently large water box such that
the minimal distance between solute and box boundary was 15 A˚ along all three axes. The net charge of
the solvated systems was adjusted to zero; the salinity of the solvent was set to 150 mM NaCl. The ionized
systems were then minimized for 20,000 steps and subsequently thermalized to 298 K within 4 ps. All
equilibrium simulations were performed in the NPT ensemble. Periodic boundary conditions were assumed,
and the particle-mesh-Ewald summation method [234] was employed for the evaluation of Coulomb forces.
The van der Waals energy was calculated using a cuto↵ of 12 A˚. Temperature and pressure were maintained
at 310 K and 1 atm, respectively, using a Langevin thermostat with a damping constant of 1 ps 1 and
Nose´-Hoover Langevin piston methods. The integration time step was 2 fs. The non-bonded interactions
were evaluated for every 2 fs, and electrostatics for every 4 fs. The procedure was followed by 10 ns of
equilibrium simulation with the positions of protein backbone atoms restrained via a harmonic potential of
force constant set to 1 kcal mol 1 A˚ 2. Finally, the harmonic potential was removed and the systems were
equilibrated for 100 ns.
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Table 5.1: Summary of energies of the five de novo designed scFvs against peptide 2D10 after in silico a nity
maturation. The interaction energy (IE) between the antibody and antigen is calculated using CHARMM
force field.
Antibody MD Description Complex Energy
(kcal/mol)
IE (kcal/mol)
120 6290 1 (scFv-1)
antigens stably bind
-11939 -474
120 15439 2 (scFv-2) -11629 -428
140 10149 1 (scFv-3) -7168 -360
140 15899 5 (scFv-4) -11110 -550
160 15235 2 -9089 -342
160 8161 1 -8548 -281
200 15222 2 -7954 -282
200 15222 5 (scFv-5) -8704 -225
120 10148 1 -11057 -394
120 13234 5 -11047 -523
120 13389 2 -11278 -428
140 9977 4 antigens bind to a -9197 -462
140 16152 1 new binding pocket or -7441 -353
160 10175 1 adopt a new -8437 -370
160 14896 1 orientation -9595 -213
160 10162 1 -7827 -242
200 15729 2 -10077 -399
240 4115 2 -8007 -329
120 10148 2
antigen partially bind
-8680 -323
140 4402 1 -8825 -322
140 9976 2 -8335 -330
140 13234 5 -11432 -340
160 8161 2 -6427 -191
160 10005 1 -5576 -135
160 10005 2 -9177 -353
160 10162 2 -7827 -242
160 15235 1 -7781 -290
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5.3 De novo design of antibody targeting Ebola virus
5.3.1 Introduction
Over 28,000 cases of Ebola virus (EBOV) disease have been reported since the outbreak began in December
2013. Despite the preventive measures recommended by the World Health Organization (WHO), health o -
cials were struggling to contain the disease outbreak. One of the primary reasons is that reliable diagnostics
for Ebola virus were not available in the early stages of the outbreak. Early detection technology that could
detect EBOV in presymptomatic patients would allow for rapid screening of individuals who are at high risk
of being infected, thereby keeping the outbreak in control.
To develop a diagnostic tool for rapid and sensitive detection of EBOV in a responsive manner, we
propose a scheme that would computationally generate antibodies that would bind to the viral epitope and
will therefore be used in any standard diagnostic tools like lateral-flow assays [235]. The target viral epitope
chosen is the glycoprotein on the surface of EBOV.
EBOV uses the glycoproteins (GP) on the viral surface to mediate host cell entry. The EBOV GP is
a trimeric structure that comprises a 334-residue-long GP1 and a shorter 131-residue GP2 per monomer
(Figure 5.3). GP1 recognizes and attaches on the human cell surface; upon attachment, GP1 and GP2
undergo structural transformation where the transformed GP2 faciliates membrane fusion to complete the
cell entry. Targetting the attachment and membrane fusion processes using antibody is key to prevent
infection and neutralize the functions of EBOV.
The overall shape of the GP trimer is similar to a chalice. The upper half of the chalice, also referred as
the head region, is higly glycoslyated. Unfortunately, the current version of OptMAVEn could not design
antibodies targeting heavily-glycoslyated proteins. Interestingly, the chalice base, also known as the stalk
region, has little to no glycoslyation. The lack of glycoslyation in the stalk region makes that region an
attractive and feasible drug target. Furthermore, a native antibody termed KZ52, which was isolated from a
human survivor, was determined to target the stalk region of EBOV GP using X-ray crystallography [236].
The antibody binding site identified in the crystal structure will limit the epitope conformational search
space during the docking procedure in OptMAVEn-MD. KZ52 will serve as the reference antibody in which
our designed antibodies have to out-perform. Note that KZ52 protected mice and guinea pigs from lethal
EBOV infection [237], but failed to protect non-human primates as a single monoclonal antibody [238].
In the previous section, we have shown that combining MD simulation into the design protocol would
overcome the limitations of the current protocol of OptMAVEn. However, one disadvantage of incorporating
MD into OptMAVEn on larger systems like EBOV GP is the increase of the demand for computational
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Figure 5.3: The overall structure of the GP trimer and the targeted binding site of the designed antibodies.
(A) Ebolavirus GP resides on the viral membrane as a trimer assembled by GP1 and GP2 which are shown
as silver and cyan ribbons. The native antibody KZ52 binds primarily on the loop residues of GP2 labeled
as small red spheres. The mucin-like domain at GP1, which is a highly glycosylated domain, is represented
as a big beige sphere as the structure of that domain could not be resolved crystallographically. (B) The
19 antibody designs selected from Stage 2 are overlaid with each other. These antibodies share the same
binding site as KZ52, but they also target other regions that were previously unexplored. The heavy and
light chains of the antibodies are shown as red and orange ribbons, respectively.
resources to perform all-atom MD simulations. We would argue that large scale MD simulations are increas-
ingly routine to be performed [3] with the increasing size and speed of supercomputers. Additionally, the
higher computational cost of incorporating MD simulation is justified by the higher accuracy and quality of
the MD-optimized antibody designs [8].
In this section, we employ OptMAVEn-MD to design antibodies that specifically target the unglycosy-
lated, stalk region of the GP trimer. 1 antibody design is predicted to outperform native antibody, KZ52,
in terms of binding a nity, and 4 other designs are predicted to have similar binding a nities compared to
the native antibody.
5.3.2 Result
Stability assessment and optimization by MD simulations
Figure 5.4 shows the overall work flow of OptMAVEn-MD, which combines OptMAVEn and MD simulations.
After the initial antibody designs were generated by OptMAVEn in Stages 1 and 2 (Figure 5.3B), the
antibodies with large interaction energies are selected for MD simulations. Note that the original design
framework of OptMAVEn does not consider the dynamics of the antigen-antibody complex, and therefore
could not accurately assess the complex stability. In Stage 3, all-atom MD simulations were performed
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Define antibody binding site 
and identify antigen epitope
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Top-scoring antigen 
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Figure 5.4: The flow chart of an improved antibody-design protocol of OptMaven. The stages where MD
simulations were employed were labeled in blue boxes. Stage 1: Selecting antibody fragments based on
an initial guess of the initial antigen position. Stage 2: Constructing first-round antibody designs upon
refinement and a nity maturation by IPRO [239, 240]. Stage 3: Generating second-round antibody designs
by incorporating MD simulations to enhance conformational sampling. Stage 4: Second-round antibodies
are then simulated to evaluate the interaction energies of the complex. The binding energies were calculated
using MMPBSA [241].
for the 19 antibody designs that were selected based on the interaction energies of the antigen-antibody
complexes in the first round of a nity maturation.
To simulate the GP in its native environment, the GP trimer was modeled based on a crystal structure
(PDB 3CSY [242]), and was shown to be structurally intact after a 500 ns of MD simulation. Using the
equilibrated GP trimer model, an antibody was placed to each of the 3 GP monomers according to the relative
coordinate of the antibody on the antigen-antibody complex. In addition to the 19 antibody designs, the
native antibody, namely KZ52, was also simulated using the same simulation protocol to serve as a control.
By assuming the dynamics of the antibody on each monomer as independent, the conformational sampling
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during the simulations has e↵ectively tripled. As a result, a total of 60 antibody monomers (57 de novo
designed and 3 native) were analyzed in the first round MD simulations.
Poor antibody designs are easily identified by their large root mean square deviation (RMSD) values (Fig-
ure 5.5A). Among the 60 simulated antibody-bound GP monomers, 7 antibodies were completely detached
from the GP as shown in Figure 5.5A,B. 9 antibody monomers remain within 10 A˚RMSD (Figure 5.5C),
indicating they are bound to binding sites similar to that of the three KZ52 monomers, which have low
RMSD values of ⇠ 5 A˚.
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Figure 5.5: MD simulations evaluated the binding stability of the antibody-antigen complexes. (A) RMSD
of 72 antibody monomers were measured and the values are plotted since 20 antibody-bound GP trimers (19
designed and 1 native antibody) were simulated. Some antibody designs disengaged from the GP (gray and
black lines), while most antibodies remain bound to GP with slight displacement from their original positions
(blue line). (B) Complete separation of poor antibody designs from GP was observed in the MD simulation.
Poor antibody designs can be identified by their high RMSD values (> 30 A˚). (C) Antibody remained stably
bound to GP. Stable antibody bindings are characterized by their low RMSD values (<10 A˚). The antibodies
at simulation time, t = 0 ns and t = 100 ns, are shown as translucent and solid red/orange ribbons.
Performing MD simulations on the antigen-antibody complex allows the antibodies to explore alternative
binding sites. Unlike RMSD, center of mass (COM) displacement is used to measure the translational
displacement of the antibodies from their initial positions. Judging from the COM displacement of the
antibodies with respect to their initial positions and excluding the 7 antibodies that unbound from GP
(Figure 5.6), 47 antibodies have relocated to a binding site di↵erent from KZ52. Once relocated, the
antibodies remain stably bound, particularly in the last 10 ns (Figure 5.6A). Only 6 antibodies, three of
which belonged to KZ52, have their COM displaced for less than 5 A˚from the initial binding sites (Figure 5.6).
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Table 5.2: Ranking of the first-round antibody designs based on the interaction energies between the antibody
and EBOV GP. SD refers to standard deviation.
First Interaction energy (kcal/mol)
round Subunit A Subunit B Subunit C Average
designs Mean SD Mean SD Mean SD Mean SD
150 11547 -65.8 9.6 -68.9 13.0 -48.0 10.2 -60.9 11.0
KZ52 -74.2 11.8 -66.9 8.3 -41.6 7.8 -60.9 9.3
90 6007 -47.8 7.3 -41.0 6.7 -35.0 12.7 -41.3 9.3
150 11897 -36.6 8.7 -55.2 11.0 -30.1 12.5 -40.6 10.9
300 4220 -41.9 5.8 -50.0 9.4 -28.2 6.9 -40.0 7.5
120 5916 -38.9 9.1 -28.4 9.3 -49.8 8.7 -39.1 9.0
150 5600 -38.0 8.7 -25.8 4.8 -35.5 6.2 -33.1 6.8
0 1002 -27.7 9.1 -16.7 4.8 -49.1 9.0 -31.2 7.9
0 625 -60.8 13.8 -18.0 5.8 -8.1 8.3 -28.9 9.9
150 6090 -31.0 8.2 -25.3 5.5 -25.0 10.7 -27.1 8.4
120 5634 -30.8 7.4 -17.3 5.9 -33.1 9.4 -27.1 7.7
120 6098 -20.3 15.6 -22.5 4.4 -37.0 6.5 -26.6 10.1
120 5930 -28.2 5.9 -12.3 3.6 -31.7 7.2 -24.1 5.8
120 185 -41.0 13.0 -18.0 5.9 0.3 0.6 -19.6 8.3
240 2317 -29.6 10.3 -27.7 9.6 1.6 2.4 -18.6 8.2
120 3 -0.7 2.0 -20.2 9.2 -33.2 7.0 -18.0 6.7
120 29 -25.0 9.0 -18.0 7.1 4.4 12.4 -12.9 9.7
90 11259 -8.3 2.5 -15.9 6.5 -12.7 3.4 -12.3 4.5
0 833 1.4 4.1 -7.0 5.3 -28.5 7.2 -11.4 5.7
0 495 -9.0 7.9 -22.1 7.3 3.1 1.8 -9.3 6.3
KZ52 monomers stayed at the same binding site throughout the 100 ns MD simulation (Figure 5.6D).
The displacement of binding sites was accompanied by the formation of new intermolecular interactions
such as salt bridges while maintaining the original interactions (Figure 5.6B). The new interactions formed
during the simulations are likely to enhance the binding a nity of antibody designs. With the formation
of new interaction and the newly explored binding sites, it is necessary to perform a second round a nity
maturation to further optimize the binding between antibody and GP.
To systematically characterize the antibody designs, the binding a nities between the GP and the
antibodies presented in Table 5.2 were estimated using MM-PBSA interaction energies [241]. Additionally,
the number of hydrogen bonds and buried surfaced area formed between the GP and the antibody were also
calculated to describe the electrostatic and hydrophobic interactions (data not shown). These information
will determine which antibody designs are selected for second round a nity maturation. The detail of the
selection criteria is specified in the Methods section.
The validity of the assumption that the dynamics of the three antibody-antigen monomers are inde-
pendent is evident as shown by di↵erent binding energies (not shown) and di↵erent displacements among
three monomers for each antibody designs (refer Figure 5.6). As a result, each monomer is independently
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Figure 5.6: MD simulations increased the conformational sampling of the antibodies. (A) Most of the
antibody designs explored new binding sites that are di↵erent from the binding site of KZ52. The center of
mass displacements of 53 antibody monomers are plotted as 7 antibody monomers that unbound from the
GP during the simulations are not shown. (B) Antibody design 150 11547 (black line in A), which initially
forms two salt bridges with GP, forms an additional salt bridge (R85-E258) during the simulation, thereby
enhancing the interaction with GP. (C) Antibody design 150 11897 (red line in A) drifted away from the
initial binding site and did not retain any of the original interaciton. (D) As a reference, KZ52 (blue line
in A) remain stably bound to its original position. The antibodies at the starting and final (after 100 ns)
positions are shown as translucent and solid red/orange ribbons, respectively.
subjected to the selection criteria. A total of 32 antibody-bound GP monomers were chosen for second
round a nity maturation. Although only 1 antibody has a comparable interaction energy with the native
antibody, KZ52, the binding a nities of the selected designs are expected to increase after the second round
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a nity maturation.
The second round a nity maturation improves the binding a nity
After the second round a nity maturations, the antibody designs were equilibrated for another 100 ns with
the same protocol as described above. The last 10 ns equilibrated trajectories were used to calculate binding
energy using MM-PBSA method. As expected, the antibody designs exhibited enhanced binding a nities.
Antibody designs were ranked according to their average interaction energies in order to select the top
designs for experimental validation (Table 5.3).
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Figure 5.7: Representative mutations during the second round a nity maturation. The second round a nity
maturation improves the binding interface. Left: The antibody binding interfaces of the antibody design
150 11547 before and after the second round maturation. Residues identified with the highest decomposed
binding free energy di↵erence are shown in licorice. Right: Relative positions of the representative mutations.
The interacting residues on GP are shown as orange spehres. These images were produced by Muyun Lihan.
To illustrate the improvement for the binding interfaces from the second round a nity maturation, the
per residue decomposed binding energies of both designs were calculated before and after second round
refinement. The di↵erence in residue-based decomposed energy was used to identify key mutations in the
a nity maturation. To highlight the mutations in the a nity maturation, the binding interface of the
top-ranked antibody in Table 5.3 were investigated. In the case of antibody 150 11547, the representative
residues identified with the highest decomposed binding free energy di↵erence were found to have mutated
in the second round a nity maturation to form salt bridges in all three complexes, namely T29R in complex
A, N59R and E63R in complex B, and N82R in complex C (Figure 5.7). In particular, E63R in complex
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Table 5.3: Ranking of the second-round antibody designs based on the interaction energies between the
antibody and EBOV GP. SD refers to standard deviation.
Second Interaction energy (kcal/mol)
round Subunit A Subunit B Subunit C Average
designs Mean SD Mean SD Mean SD Mean SD
B-150 11547 -62.2 10.1 -86.7 11.8 -60.8 8.9 -69.9 10.4
KZ52 -74.2 11.8 -66.9 8.3 -41.6 7.8 -60.9 9.3
C-120 3 -30.8 8.0 -62.2 10.5 -68.8 12.6 -53.9 10.5
A-150 11547 -40.5 8.5 -50.4 8.5 -62.4 9.5 -51.1 8.9
A-0 625 -51.7 7.2 -32.7 9.4 -67.0 8.7 -50.5 8.5
C-150 11547 -46.2 6.2 -43.5 10.1 -60.5 11.5 -50.1 9.6
B-300 4220 -42.0 6.9 -54.9 12.6 -45.9 11.6 -47.6 10.7
B-90 6007 -41.4 8.1 -63.1 9.4 -37.9 8.1 -47.4 8.6
A-90 6007 -51.5 13.1 -45.1 6.7 -39.5 8.7 -45.4 9.9
C-120 6267 -50.9 10.1 -31.6 13.4 -45.5 7.2 -42.7 10.5
A-0 1002 -72.1 8.8 -30.1 9.8 -18.1 9.2 -40.1 9.3
B-150 11729 -56.6 7.6 -33.9 8.4 -27.5 16.3 -39.3 11.5
C-90 6007 -43.3 6.8 -10.0 4.1 -63.8 10.0 -39.0 7.4
C-150 6090 -23.3 4.2 -46.3 8.7 -41.5 6.6 -37.1 6.7
C-120 5930 -41.1 10.3 -33.8 7.5 -31.6 10.2 -35.5 9.5
B-150 11897 -19.1 13.6 -41.0 11.0 -44.9 12.9 -35.0 12.5
A-300 4220 -32.4 10.6 -27.5 9.6 -37.5 9.2 -32.4 9.8
B-0 820 -41.4 7.0 -22.7 6.6 -28.2 6.6 -30.8 6.7
C-150 5600 -32.6 8.0 -30.2 7.8 -28.0 5.3 -30.3 7.1
A-0 820 -39.4 14.6 -19.6 7.2 -31.6 9.1 -30.2 10.8
A-240 2317 -18.7 10.1 -48.1 8.5 -22.6 9.9 -29.8 9.6
A-150 11897 -39.7 8.1 -15.1 10.6 -29.4 11.8 -28.1 10.3
C-0 1002 0.9 2.4 -55.1 10.5 -28.6 6.7 -27.6 7.3
C-120 5916 -24.1 10.3 -59.4 9.6 0.8 3.0 -27.5 8.3
A-120 5634 -22.5 7.8 -41.7 8.8 -13.4 7.5 -25.9 8.0
A-120 185 -23.3 8.9 -19.7 9.2 -29.0 6.5 -24.0 8.3
C-120 6098 -37.3 8.1 -29.1 9.0 -5.3 4.5 -23.9 7.5
C-0 833 -23.4 9.4 -29.8 9.7 1.9 2.6 -17.1 7.9
A-150 5600 -0.7 0.6 -22.1 8.0 -28.0 6.0 -16.9 5.8
B-240 2317 -24.3 5.7 -19.7 7.9 -5.4 6.1 -16.5 6.6
B-0 495 4.3 2.3 -45.0 12.0 -3.2 8.1 -14.6 8.5
A-150 6090 -25.1 11.4 3.5 2.3 -19.1 5.1 -13.6 7.3
C-120 5634 -14.2 6.6 0.8 1.7 -21.2 6.3 -11.6 5.4
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B were mutated to eliminate the unfavorable repulsive interactions between E207 and E63. An interesting
finding is that the relative positions for the key mutations were di↵erent, as the three complexes explored
slightly di↵erent binding sites in the previous equilibrium simulation. The variation of mutations on the
designs and the di↵erence of relative positions of the binding interfaces indicates the pivotal roles of the
sampling step and the second round a nity maturation in improving the second round antibody designs.
5.3.3 Discussion
In de novo antibody design, conformational sampling is crucial to explore the possible configurations of
an antigen-antibody complex could adopt. Monte Carlo based sampling routines used in ROSETTA [243]
and various optimization methods [244] could quickly explore the possible conformations using static struc-
tures. The resulting complexes are then evaluated using scoring functions where favorable complex could
be identified. MD simulations are also commonly used to explore the conformational space. Unbiased
binding events of small molecule drugs were studied using microseconds-long MD simulations on special-
ized machines [245, 246]. The system size of these simulations is relatively small, containing about 50,000
atoms. However, when studying larger complexes like antibody binding to Ebola GP trimer (350,000 atoms
including protein and solvent), the conformational sampling is typically limited to localized regions.
In the present study, we described an improved antibody design protocol, namely OptMAVEn-MD,
which combines OptMAVEn and MD simulation. OptMAVEn-MD consists of 3 general stages: antibody
generation using OptMAVEn, a nity maturation using IPRO [239, 240], and binding interface assessment
and refinement using MD simulations. The protocol was subsequently being applied to develop high-a nity,
novel antibodies that targets the stalk region of the Ebola glycoprotein.
The incorporation of all-atom MD simulation in OptMAVEn has several advantages. First, MD simula-
tion can probe the stability of the antigen-antibody complex. Unstable complexes can be identified by the
observation of antigen detaching from its original binding site. There are two scenarios when an antigen
drifted away from its original binding site: one, the antigen could not bind with the antibody; two, the
antigen relocates to a new binding site. Previous MD simulations on antigen-antibody complexes [34, 35]
(5 ns per complex) were too short to discern these two scenarios. Therefore, long time scale simulations
(100 ns per complex) were performed in the present study to distinct the di↵erent dynamic behaviors of the
complexes. The second advantage of incorporating MD simulation in the design protocol is that MD simu-
lation can accurately account for the dynamic properties of the antibody, particularly the six CDR loops. In
an MD simulation, the flexible CDR loops could interact with the antigen as structurally-dynamic objects,
thereby refining the binding interface of the antibody. Additionally, any antigen-induced conformational
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changes on the antibody could be observed in MD simulations. As a result, the accuracy of the second
round a nity maturation calculations is increased when the antigen-antibody complex with refined binding
interface is used as the input structure.
Typical MD simulations on the antigen-antibody system investigate antigen of size smaller or comparable
with the antibody [34, 35]. However, the antigen of the present study, namely Ebola GP, exists as a trimer
with over 1,000 residues in total. The large size of the antigen presents a di↵erent challenge to de novo
antibody design. One prominent challenge is to locate the antibody binding site. Binding sites are typically
obtained via structural experiments like X-ray crystallography, or via computational docking softwares like
AutoDock [247]. For the case of Ebola GP, a crystal structure of GP in complex with a native antibody [236]
was used as the starting point for design the antibodies. These structures are particularly important for
locating the epitopes of large antigens such as GP of Ebola virus and hemagglutinin of Influenza A virus.
Using the crystallographic position of native antibody with respect to the Ebola GP [236], antibodies are
designed to target the viral epitope (Figure 5.3B). However the designed antibodies may not necessarily have
exactly the same binding site as the native antibody.
Interestingly, many of the top-ranked antibodies adopt new binding sites that are di↵erent from their
initial positions. They form new hydrogen bonds that are not observed in the native antibody while main-
taining the same contact area between antigen and antibody. Additionally, the native antibody KZ52 remain
stable at the same binding site as reflected by its low RMSD and COM displacements (Figure 5.5 and 5.6),
suggesting the force field and protocol employed in the simulations are correct. The antibodies designs will
be validated by measuring the binding a nity to Ebola GP experimentally. An e↵ort to quantify the binding
a nities of the antibodies via in vitro binding assay is currently underway.
During the MD simulations, many antibodies drifted away from the KZ52 binding site and some of them
came to close contact with the glycosylation sites and the mucin-like domain (Figure 5.3A). These antibodies
will not be selected for experimental validation since the glycan/carbohydrate chains are likely to interfere
with the antibody binding. The current protocol did not account for the presence of carbohydrate because
they are usually not fully resolved crystallographically due to the high flexibility. The discard of a number
of antibody design, although necessary, reduces the e ciency of OptMAVEn-MD. A feature that we aim
to add in OptMAVEn-MD is the incorporation of carbohydrate molecules and its force field in the design
protocol. Additionally, an accurate carbohydrate modeling tool is also required in modeling programs like
VMD [38] to generate the complete structure of a highly-glycosylated biomolecule.
Before the antibody designs are tested and validated experimentally, it remains unclear whether the al-
ternative binding sites explored by MD are physiologically relevant. The di↵erent binding site observed could
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lead to non-specific binding of the antibody. As specificity and binding a nity are two necessary criteria
of a good antibody, the antibodies that resulted in non-specific binding, despite of its high binding a nity,
will be considered as failed designs. There is no standard recipe of reliably designing antibodies that target
an antigen with high specificity. What OptMAVEn-MD does is to first generate thousands of antibodies
with a variety of possible docking positions and orientations. These designs with low interaction energies are
then discarded. The e ciency of such approach is not particularly e cient and flexibility of the antibody
or antigen is not considered during the design phase as the docking were performed using rigid molecules.
Therefore, it remains challenging to computationally design an antibody with high binding specificity and
a nity. With the introduction of MD, we have shown antibody design programs can now produce antibod-
ies with higher binding a nities [8]. Other antibody design methodologies that involve knowledge-based,
statistical approach or employ machine learning have recently shown to successfully engineer the binding
specificity of antibodies [248, 249, 30, 31]. Such advanced features will be implemented into OptMAVEn-MD
in the future.
5.3.4 Method
Optimizating antibody designs using all-atom molecular dynamics simulations
Initial antibody designs were generated using OptMaven [33]. They subsequently undergo in silico a nity
maturation using IPRO [239, 240]. The antigen-antibody complexes were prepared using VMD [38] and
MD simulations were performed using NAMD2.10 [37] with the CHARMM36 force field [99]. The trimeric
structure of the antigen (GP1-GP2) and the native antibody, KZ52, were obtained from a crystal structure
(PDB ID: 3CSY) [236]. The missing residues at the loop regions (residues 279 to 301 of GP1 and residues
523 to 524 of GP2) were modeled using modeller [82]. The GP1-GP2 trimer was equilibrated for 500 ns
with several restraints to maintain its structural integrity. The positions of the stalk region and N-terminal
of GP2 were restrained using a harmonic potential with force constant, k = 1 kcal mol 1 A˚ 2. Secondary
structure restraints were applied on the beta sheet near the C-terminal of the GP1 using the extrabond
feature in NAMD.
The 19 antibody designs and native antibody KZ52 were docked to the equilibrated GP1-GP2 trimer
based on the relative orientation of KZ52 with respect to GP1-GP2 as observed in the crystal structure of
the complex. The trimeric complexes were simulated in a su ciently large water box such that the minimal
distance between solute and box boundary is 15 A˚ along all three axes. The solvated systems were neutralized
and the salinity of the solvent being set to 150 mM NaCl. The ionized systems were then minimized for
10,000 steps and subsequently thermalized to 310 K within 4 ps. The systems were equilibrated for 10 ns with
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all backbone atoms harmonically restrained before they were subjected to 100 ns of production simulation
with the necessary structural restraints on GP1-GP2. After the MD simulations, a representative monomer
candidates was selected and minimized to undergo the second round a nity maturation. After second round
of a nity maturation, the optimized antibody designs were simulated for 100 ns to evaluate the binding
stability using the same protocol as described above.
Assessment of antibody binding energies
The antibody binding energies were calculated using the MM-PBSA methods with MMPBSA.py [241]. For
each monomer, the calulation of MM-PBSA interaction energy between the GP and the antibody was carried
out with 50 snapshots, every 200 ps from the last 10 ns of the MD simulations. Residue-based interaction
energy was decomposed to identify key residues on the antibody. Residues with the lowest interaction energy
were considered as key residues at the binding interfaces.
Selection of the antibody designs for second round a nity maturation
The antibody designs listed in Table 5.2 were selected for second round a nity maturation according to
the criteria outlined below. The antigen-antibody complex must either have a MM-PBSA energy less than
-30 kcal mol 1, or have an average buried surface area more than 1000 A˚2. Complexes with larger buried
surface area subjects more antibody residues for mutation during a nity maturation.
For each antibody design, the 50 snapshots in the last 10 ns of the MD simulation were clustered based on
RMSD using k-Medoids methods [2, 85, 103]. The representative structure in the largest cluster was chosed
for energy minimization. Following the above selection criteria, 32 monomer antibodies were identified for
the second round a nity maturation.
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5.4 Conclusion
In the present study, MD simulation was incorporated into the antibody design framework described in [33].
OptMAVEn-MD, which introduced MD simulations into the original design protocol, aims to include the
dynamics of the antigen-antibody interfaces for both the evaluation and the improvement of antibody designs.
Compared to the scoring function based on CHARMM force field in the previous framework, the MMPBSA
interaction energy calculated using the equilibrium ensembles provides a more accurate estimation for the
binding a nity [250]. The MD simulations also allow the antibodies to sample the interface space, to refine
binding interface, and to explore alternative conformations. As the first round a nity maturation improves
the binding at the initial antigen positioning, the sampling of both refined and alternative binding interfaces
necessitate us to perform second round a nity maturation. We have shown that the second round a nity
maturation upon MD could further improve the binding interface and thus increasing the antibody binding
a nity.
Although OptMAVEn-MD require more computational resources, we have shown that including MD
simulation in the optimization process is necessary to generate high-a nity antibodies through our antibody
design work on 12-residue peptide antigen [8] and Ebola glycoprotein. With the increasing size of the
computers and the fact that simulations of large systems are routinely performed with atomistic detail [3],
we foresee the present study will serve as a catalyst to prompt the incorporation of long time-scale all-atom
MD simulations into future design protocols for antibody and drugs.
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Chapter 6
Summary and Outlook
In this dissertation, we employed molecular dynamics simulations to investigate the structure and dynamics
of viruses and to guide interpretation of experiments in understanding the functional processes of viruses,
such as assembly and maturation [2, 4]. We also investigated the host-pathogen interactions with the studies
of lung surfactant proteins [1, 7] and expanded the studies to de novo antibody design [8].
The first atomistic model of the immature Rous sarcoma virus (RSV) capsid was constructed using a
combination of experimental data and computational molecular modeling. The immature RSV model was
proposed to have a similar quaternary arrangement as the immature capsid lattice of Mason-Pfizer monkey
virus (M-PMV) [2]. The construction of the model involved docking the X-ray and NMR structures of
mature RSV capsid proteins into their corresponding regions of the immature M-PMV cryo-EM density
map. Notably, the spacer peptide and part of nucleocapsid domain (SP-NC) was previously proposed to
oligomerize into a six-helix bundle (6HB) structure [61]. The 6HB model, originally generated using an
ion channel as a structural homolog [14], was refined by adjusting the packing between the helices, and its
stability was probed by MD simulation [2]. Microsecond-long REMD simulations revealed that the 6HB
adopts multiple orientations, accounting for the lower resolution seen in the corresponding domains of the
cryo-EM density maps [48, 2]. The final immature lattice, which was selected using a clustering method,
exhibits key interactions that are consistent with mutagenesis experiments [13, 69]. An immature RSV capsid
recently solved by cryo-EM experiment displays a consistent architecture with the computationally-derived
lattice model [79].
Upon obtaining the atomistic structure of immature RSV capsid, we characterized the roles of key charged
residues of RSV in virus assembly and infectivity through in vivo and in vitro biochemical experiments and
all-atom MD simulations. We discovered a novel allosteric pathway that could explain how a mutation could
suppress the detrimental e↵ect of another mutation despite being 20 A˚ apart [4]. In short, the atomistic
model of the immature virus capsids serve as a platform to characterize the e↵ect of mutation on the viral
functions [4] and to investigate the delicate interactions of the capsid with numerous assembly-inhibiting
and maturation-inhibiting molecules [91, 251, 252].
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Surfactant proteins A (SP-A) and D (SP-D) provide primary innate immune responses to any inhaled
pathogens. These C-type lectin proteins bind to the sugar molecules on pathogenic surfaces using calcium
ions. The molecular mechanism of inhibition of influenza A virus by SP-D has been investigated using
a combination of X-ray crystallography and MD simulations [149, 1]. A double mutant of human SP-D,
namely R343V/D325A, was found through site-directed mutagenesis experiments to enhance SP-D’s virus
neutralization activity. We performed MD simulations on the wild type and mutant SP-D to investigate the
e↵ect of the mutations on SP-D recognition and inhibition of the globular head of influenza hemagglutinin
(HA), which is responsible for host-cell entry. We found that the double mutant of SP-D to binds stronger
to HA by using a di↵erent binding loop than the wild type SP-D [1]. We proposed that in the double
mutant of SP-D, viral aggregation can be achieved by SP-D-mediated cross-linking of HA on neighboring
viral particles.
Like SP-D, SP-A plays an important role in pulmonary innate immunity by recognizing canonical patterns
on microbial surfaces. It protects the lungs from infection by recognizing the lipid component (lipid A) on
gram negative bacterial surfaces [27], and by helping to initiate various clearance mechanisms [141]. SP-A is
also known to aggregate dipalmitoylphosphatidylcholine (DPPC), the major constituent of lung pulmonary
surfactant, to form tubular myelin, a highly structured form of surfactant lipids and proteins [174]. It is
unclear how SP-A can bind to both DPPC and lipid A for two very di↵erent functions. To unravel the dual
role of SP-A, we performed crystallographic and mutational analyses as well as all-atom MD simulations.
We found a non-canonical lipid binding site with several critical binding features that involve cation-⇡
interactions and hydrogen bonds [7]. MD simulations also revealed that SP-A binds to lipid A more tightly
than to DPPC. These results suggest that SP-A may transfer from surfactant DPPC to pathogen membranes
to initiate its host defense functions.
Since the Ebola outbreak in West Africa in December 2013, there has been an urgent need of a rapid
diagnostic tool for early detection of Ebola virus. Targeting viral antigens with high-a nity antibodies is
a strategy used extensively in diagnostic and therapeutic development. To develop antibodies that target
Ebola virus glycoproteins (GP), we improved an existing de novo design procedure by incorporating MD
simulation [8]. The antibodies generated using the new method, called OptMAVEn-MD, were successfully
validated experimentally to bind a 12-residue-peptide antigen with high binding a nity and specificity [8].
For the Ebola project, initial antibody designs were performed using OptMAVEn [33] by targeting the stalk
region of Ebola GP. Nineteen selected ALB designs were then optimized using all-atom MD simulations for
binding interfaces sampling and refinement. The binding interfaces were assessed in terms of interaction
energies using MM-PBSA method [241]. Antibodies characterized with high thermal stability and high
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binding a nity were selected and optimized. We identified five antibodies with comparable binding a nity
to the native antibody (KZ52). These results suggest that our computational method could simulate the in
vivo antibody generation and evolution, and that OptMAVEn-MD can design antibody with high a nity
to the Ebola viral antigen, an approach that may also be applied to other antigens.
In summary, the demonstrated ability of MD simulations to reveal critical insights into the physical and
chemical nature of viruses and their detailed interactions with the human immune system. MD simulation is
an invaluable tool for continued application to study the biology of viruses, as well as strategies for pharma-
cological interventions going forward. Indeed, many exciting discoveries regarding virus functions and use as
drug and antibody targets lie just ahead on the horizon. MD simulations will drive such discoveries pending
a series of notable advancements, such as incorporating more experimental data as part of hybrid modeling
tools [6], developing reliable tools for carbohydrate and RNA modeling, the introduction of constant-pH
simulations, and the routine parameterization of ions and small-molecule drug compounds for polarizable
force fields. Ultimately, biomolecular structure and dynamics, accessible through all-atom MD simulation,
hold the key to exploration of novel drug/antibody targets that interfere with the viral life cycle through
allostery, altered protein-protein interactions, and global structural changes of viral protein assemblies.
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